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1. Cartilage  
During our life moving, walking, sport, etc., are essential for our health and quality of life. 
Both bones and cartilage enable us to do so. Bones support us, allow muscles to move 
them, and protect vital internal organs. At their ends, most bones are covered with articular 
cartilage and form joints. Cartilage is not only present in articulating joints, but also in the 
rib-cage, ear, nose, bronchial tubes and intervertebral discs. It is essential for functions as 
breathing, hearing, articulation and locomotion. Based on its ultra-structural morphology 
and composition cartilage can be divided into three subtypes: hyaline-, elastic- and fibro-
cartilage. The most abundant of these is hyaline cartilage, which is present in a 2-4 mm 
layer on the articulating surfaces of long bones (Figure 1.1A). This hyaline articular carti-
lage is a truly remarkable material both structurally and functionally1-4. Its principal func-
tion is to provide a smooth, lubricated surface for articulation and is able to withstand an 
enormous amount of intensive and repetitive forces combined with low friction. The extra-
cellular matrix (ECM) of hyaline articular cartilage determines these cartilage-specific 
properties. The hyaline cartilage ECM is mainly composed of water (65-80%), collagens 
(12-21%), proteoglycans (6-10%) and other glycoproteins (2-3.5%)5. Only 1-5% of the 
articular cartilage volume consists of chondrocytes, the main cell type found in articular 
cartilage6 (Figure 1.1B). Typically, cartilage is devoid of blood vessels, lymphatics and 
nerve fibers. This implicates that cartilage is mainly hypoxic and chondrocytes receive 
their nutrients and oxygen via diffusion from the synovial fluid, through the surrounding 
extracellular matrix and from the underlying subchondral bone7.  
A B 
Figure 1.1: Schematic representation of a kneejoint and articular cartilage 
(A). Knee articular cartilage with a cartilage lesion. (B). Magnified view of articular cartilage with specific zones 
indicated and a magnified view of the contents of the middle layer of articular cartilage. 
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1.1 Cartilage Extracellular Matrix  
The articular cartilage ECM consists of a collagen network which is comprised of primari-
ly Collagen type II (Col2a1), and additionally of collagens type IX (Col9a1) and XI 
(Col11a1) which help to form and stabilize the collagen type II fibril network8-11. Minor 
quantities of Col6a1, Col12a1, Col14a1 and Col27a1 are also found in cartilage12. The 
collagen network is surrounded by a highly hydrated aggregation of proteoglycans and 
other glycoproteins (Figure 1.2A). Glycoproteins and proteoglycans as COMP (cartilage 
oligomeric protein), Matrilin1 (Matn1/Crtm), perlecan (Hspg2), versican (Vcan), decorin 
(Dcn), biglycan (Bgn) and fibromodulin (Fmod) are characterized by their ability to inter-
act with and support the collagen fibril network and retention and transport of growth fac-
tors13,14. Aggrecan (Acan) is the main proteoglycan and forms macromolecular complexes 
by binding to hyaluronan via link proteins and binding of glycosaminoglycans (GAGs), 
such as chondroitin sulfate and keratan sulfate (Figure 1.2B). The glycosaminoglycan side 
chains of the proteoglycans are composed of repeating disaccharide units carrying nega-
tively charged sulphate and carboxyl groups. The resulting fixed negative charge density 
attracts mobile cations and water into the ECM and thus provides in the elastic properties 
of the tissue15,16. In addition to resisting compressive forces and providing lubrication dur-
ing movement, the high water retention capacity of hyaline cartilage also supports in dis-
tributing nutrients to chondrocytes. The proteoglycan aggregations, together with the quali-
ty of the collagen network determine the strength and flexibility of the cartilage tissue and 
ability to withstand repetitive compressive forces for which articular cartilage has been 
designed17-20. 
A B 
Figure 1.2: Composition of the cartilage extracellular matrix  
(A). Representation of different components of the ECM, including the collagen fibril network, proteo-glycans 
and chondrocytes. (B). Proteoglycans have the appearance of “bottle brush” structure. Typically they contain 
GAG sidechains of chondroitin and keratan sulfate and are linked to a hyaluronan backbone via link proteins.  
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1.2 Chondrocytes and Macromolecular Structure of the ECM 
Chondrocytes residing in the ECM provide maintenance of the articular cartilage tissue. 
Each chondrocyte is entrapped in its own excreted matrix and is responsible for the matrix-
turnover in its own vicinity and its viability depends on an optimal bio-chemical and    
mechanical environment. Based on collagen fibre orientation, chondrocyte shape and dis-
tribution and biochemical composition1,3,4, four zones can be distinguished in articular car-
tilage (Figure 1.3). In the superficial zone, chondrocytes are flattened and are surrounded 
by a thin layer of ECM, mainly composed of collagen type II -fibres. The fibres are orient-
ed parallel to the articular surface and have a relatively low content of proteoglycans, 
which results in high tensile stiffness and the ability to distribute load over the surface and 
protecting the deeper layers. In the transitional middle zone the cells and collagen fibres 
appear dispersed randomly21,22. Here, high concentrations of proteoglycans enable the tis-
sue to bear compressive forces. In the deep zone, chondrocytes are grouped radially in 
columns and thicker collagen fibres are arranged perpendicular to the articular surface, 
providing the greatest resistance to compressive forces. In the calcified zone, 
(hypertrophic) chondrocytes are distributed sparsely and are surrounded by a calcified  
matrix. The calcified layer plays an integral role in securing the cartilage layer to the sub-
chondral bone by anchoring the collagen fibrils to the subchondral bone tissue. The junc-
tion between uncalcified and calcified cartilage is called the “tidemark”. At the tidemark 
shear stresses are converted into compressive forces which are in turn transmitted to the 
subchondral bone23. 
Figure 1.3: Macromolecular structure of the cartilage extracellular matrix  
Schematic macroscopic view on the different layers of articular cartilage with the collagen fiber orientation is 
depicted. 
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2. Cartilage defects and treatment of damaged cartilage 
Cartilage defects can arise due to trauma or cartilage degeneration, but are generally      
difficult to diagnose24,25. Since cartilage has no nerve fibres, cartilage lesions often present 
with only (minor) effusion of the affected joint or without symptoms at all. Symptoms as 
joint pain, locking phenomena and reduced or disturbed joint-function may arise from  
other tissues structures likely to be damaged upon trauma (e.g. subchondral bone, liga-
ments or menisci). Although the occurrence of chondrocyte progenitor cells has been re-
ported in the superficial layer of articular cartilage26,27, cartilage has a limited ability for 
self-repair28,29. This was already recognized in 1743 when the British surgeon William 
Hunter made the statement: “From Hippocrates to the present age it is universally allowed 
that ulcerated cartilage is a troublesome thing and that once destroyed it is not re-
paired”30.  
Small focal lesions will gradually increase not only in girth but also in length, ultimately 
leading to deterioration of the entire thickness of the articular cartilage layer. This process 
is initiated by loss of extracellular matrix eventually followed by loss of the chondrocytes. 
When unnoticed and/or left untreated, this will lead to destabilization of the joint and ulti-
mately to the onset of osteoarthritis (OA) (Figure 1.4).  This consequence is one of the 
main reasons for clinicians and researchers to find ways for repairing cartilage defects  
before OA is able to develop. 
A B 
Figure 1.4: Healthy versus Osteoarthritic cartilage 
View on healthy articular cartilage of the knee (A) and of a knee with osteoarthritis (B).  
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Treatment of damaged cartilage can be grouped to four concepts of principle; the four 
R’s31. The joint surface can be; (i) replaced, (ii) relieved, (iii) resected or (iv) restored/
repaired. A joint prosthesis is an example of joint replacement, joint distraction and      
osteotomies can induce joint relieve. Osteotomies are used to re-align the axis of loading in 
patients with a malalignment of the leg. By transferring the load to the less affected carti-
lage (e.g. previously less loaded/damaged cartilage) the damaged part is relieved.         
Arthodesis is an example of joint resection. Cartilage restoration implies methods to heal 
or regenerate the joint surface, with or without the subchondral bone, into healthy hyaline 
articular cartilage to restore joint functioning. As such, the definition of cartilage restora-
tion resembles the definition of regenerative medicine (RM): “regenerative medicine re-
places or regenerates human cells, tissues or organs, to restore or establish normal func-
tion”32. Current cartilage regenerative medicine approaches can be subdivided into clinical 
approaches and laboratory based approaches (Figure 1.5).  
One of the main problems in cartilage regenerative medicine is unwanted mineralization 
(and formation of intralesional osteophytes) of the cartilage33,34. As described above, the 
properties of the hyaline cartilage matrix are essential to withstand the repetitive compres-
sive forces of movement. Hypertrophic cartilage or mineralized cartilage in the articular 
surface has inferior properties concerning resisting repetitive mechanical loading and will 
thereby result in the further deterioration of the joint cartilage and can act as a source of 
pain35. Hypertrophic differentiation of chondrocytes is thus of concern in cartilage repair 
techniques but also in the onset of osteoarthritis, as markers for hypertrophic differentia-
tion are specifically expressed at early stages of OA36-38.In addition to formation of hyper-
trophic cartilage, stimulating progenitor cells towards extracellular matrix producing chon-
drocytes and keeping them in their desired differentiation state is another important factor 
to consider in cartilage repair techniques33,34.     
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2.1 Clinical Approaches in Cartilage Regenerative Medicine   
Bone marrow stimulating techniques as microfracture, abrasion and subchondral drilling 
are relatively easy applicable, cheap and reliable methods to approach the functional repair 
of cartilage defects. These techniques are based on the penetration of the subchondral bone 
allowing ingress of bone marrow stem cells into the damaged cartilage (Figure 1.6A)39-43. 
These cells are thought to differentiate into the chondrogenic lineage and functional ECM-
producing chondrocytes, thereby resulting in repair of the cartilage defect. However, for-
mation of fibrocartilage and calcification of repaired tissue are hampering clinical outcome 
on the long term34,43. Another source of mesenchymal progenitor cells can be found in the 
cambium layer of the periosteum and in the perichondrium. These cells have been de-
scribed to have a chondrogenic potential as well44-48 Covering cartilage defects with     
periosteum derived grafts (periosteal arthroplasty) is therefore another explored strategy to 
treat cartilage defects (Figure 1.6B)49-54 On short term, results were found to be quite 
promising with regard to cartilage repair50-54. Unfortunately, on the long term results were 
poor and failure was related to calcification of the grafts49.   
Other techniques imply the transplantation of mature chondrocytes or cartilage such as 
mosaicplasty (Osteochondral Autograft Transfer System; OATS), allografts and Autolo-
gous Chondrocyte Transplantation (ACT). Mosaicplasty or OATS involves harvesting one 
or more osteochondral plugs from a relatively less weight-bearing region of the joint and 
subsequent implantation of these plugs into the articular cartilage defect (Figure 1.6C)55-58.  
Figure 1.5: Articular cartilage regenerative medicine 
Schematic representation of principles of different cartilage regenerative medicine approaches. 
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The use of allografts can overcome possible donor site morbidity57,59-61 or shortage of graft 
material. ACT refers to a cell based cartilage repair procedure where cartilage is harvested 
arthroscopically from a less weight-bearing region of the joint and transferred to a special-
ized laboratory where the chondrocytes are enzymatically released from their matrix and 
expanded in vitro. The patient then undergoes a second operation where the in vitro      
expanded chondrocytes are re-implanted at the damaged site of the articular cartilage, in 
combination with a membrane (periosteum or collagen-based membrane)62-64 or pre-seeded 
in a matrix (Matrix Assisted Chondrocyte Transplantation; MACT) (Figure 1.6D)65. Nev-
ertheless, the use of these techniques is restricted due to a limited availability of autolo-
gous cartilage (mosaicplasty) or donors, possible disease transfer (allografts), or expensive 
and time consuming logistics and culture methods (ACT). Furthermore, cartilage hyper- 
A B 
C D 
Figure 1.6: Current clinical cartilage repair approaches  
(A). Schematic representation of the microfracture procedure. (B). Schematic representation of the periosteal 
arthroplasty procedure. (C). Schematic representation of the mosaic plasty procedure. (D). Schematic representa-
tion of procedure of autologous chondrocyte transplantation (ACT) or chondrocyte transplantation with an engi-
neered carrier.  
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trophy is also seen after ACT, albeit more in the periosteum covered ACT than in matrix-
assisted ACT66,67.  
 
2.2 Cartilage Tissue Engineering / Laboratory-based Regenerative Medicine 
The science of combining cells with carrier materials to reproduce tissues is called Tissue 
Engineering (TE) (Figure 1.5). Carrier material or scaffold refers to a wide variety of artifi-
cial two-dimensional (2D) or three-dimensional (3D) structures that are designed for the 
purpose of tissue engineering. Carrier materials may be seeded with cells before implanta-
tion or are designed to recruit or retain cells at the desired place. Different variables are 
important parameters for carrier design: pore diameter, shape, kind of material, (bio)
degradability, implantation site, functionalization, mechanical stability and others. When 
applying carrier materials for cartilage regenerative purposes, some authors find enhanced 
cartilage healing, others conclude that scaffolds have a limited usefulness for chondrocyte 
grafting in large defects68-71. New generation experimental scaffolds are loaded with bio-
active factors (e.g. growth and differentiation factors) that directly influence the local im-
plantation environment72-74. Although it has already led to fruitful achievements, TE     
created cartilaginous tissues are not generated on a large scale63,75,76 and an ideal material 
for carrier material for cartilage regeneration has not been identified yet, as the biological 
processes involved are far more complex than anticipated. In addition, time consuming and 
expensive culture procedures and logistics, multiple operations and quality of the tissue 
repair initiated by tissue engineered constructs (e.g.: unwanted calcification and formation 
of fibrocartilage) remain important drawbacks. 
Recently a shift can be observed in the attempts to repair tissues in general. This shift in-
cludes more specific natural stimuli which trigger and enhance the regenerative capacity of 
the tissue itself. Examples are injection/stimulation of stem cells or progenitor cells (cell 
therapies) and the induction of local regeneration by biologically active molecules. Our 
group was recently successful in such an approach by injecting an agarose gel into the 
space between bone and periosteum, which initiated chondrogenic differentiation of the 
locally residing mesenchymal progenitor cells and resulted in cartilaginous tissue         
formation. The grown tissue was harvested during the chondrogenic phase and successful-
ly used to repair osteochondral defects (Figure 1.7)77.   
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A B 
C 
Figure 1.7: The in vivo bioreactor  
The in vivo bioreactor (IVB) is a strategy for de novo engineering of ectopical autologous cartilage within the 
subperiosteal space. (A). An agarose gel is injected in the subperiosteal space of the upper medial part of the 
rabbit tibia. (B). After two weeks callus formation becomes visible at the tibia. (C). The IVB-cartilage graft can 
be press-fit implanted in an osteochondral defect of the medial femur condyle of the same rabbit 28,77,78 
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3. Chondrogenic differentiation 
Chondrogenic differentiation encompasses the commitment and differentiation of chondro-
progenitor cells towards chondrocytes (see Figure 1.8). In vivo, chondrogenic differentia-
tion is almost exclusively initiated from local mesenchymal progenitor cells that reside in 
cartilaginous tissue (growth plate resting zone or the articular cartilage superficial         
layer79,80) or in surrounding fibrous tissues (e.g. periosteum47,81). Ex vivo however, 
chrondrogenic differentiation has been reported from various primary (mesenchymal)  
progenitor cell sources including synovial fluid/membrane, adipose tissue, induced plu-
ripotent stem cells (iPS82), bone marrow and many more83. 
In addition to providing articulating joint surfaces with functional cartilage and maintain-
ing cartilage integrity, chondrogenic differentiation also plays an essential role during  
endochondral ossification. Endochondral ossification underlies skeletogenesis and bone 
fracture healing and is a developmental process during which cartilaginous primordia are 
gradually replaced by bone tissue. Growth plate chondrocytes originating from the resting 
zone or fracture callus chondrocytes originating from mesenchymal progenitors gradually 
proliferate and produce a cartilaginous matrix. When exiting the cell cycle they differenti-
ate into mineralized hypertrophic chondrocytes which finally die by apoptosis. The       
remaining mineralized extracellular matrix provides a molecular scaffold for infiltrating 
osteoblasts and osteoclasts to adhere to and remodel, setting the stage for de novo bone 
deposition84,85. Notably, chondrocytes in articular cartilage retain their chondrocyte pheno-
type and, except for chondrocytes near the tidemark, normally do not further differentiate 
into hypertrophic chondrocytes, probably due to the local microenvironment. Unfortunate-
ly, as a natural result of this endochondral ossification process, in vitro chondrogenic    
differentiation of progenitor cells for cartilage regenerative purposes tends to progress into 
hypertrophic differentiating chondrocytes.  
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3.1 Transcriptional Regulators in Chondrogenic Differentiation 
Chondrogenic differentiation starts when mesenchymal progenitor cells are triggered to 
differentiate into the chondrogenic lineage (Figure 1.9). Chondrogenic progenitor cells 
express typical ECM and cell adhesion molecules like tenascin c (Tnc), syndecan 3 (Sdc3), 
N-cadherin (Ncad) and Ncam1 (neural cell adhesion molecule 1). One of the first key im-
portant chondrogenic differentiation regulatory events is activation of the Sox-trio tran-
scription factors; Sox9 (SRY-(sex determining region Y)-box9) in combination with         
L-Sox5 and Sox6 are responsible for commitment and differentiation in the chondrogenic 
lineage14,86,87. Sox9 was originally identified as the causative gene in Campomelic dyspla-
sia, a severe skeletal dysplasia associated with XY sex reversal and disproportionally short 
stature as well as general lack of cartilaginous tissue formation88,89. Sox9 was found to be 
essential for murine early chondrogenic lineage determination as well90. Upon nuclear  
occupation, Sox9 binds as a homodimer to its consensus recognition sequence (A/T)(A/T)
CAA(A/T)G, which includes the highly conserved AACAAT motif recognized by the high 
mobility group (HMG)-box domain shared amongst SOX and SRY proteins86,91-93. During 
chondrogenic differentiation Sox9 drives the transcription of and cooperates with L-Sox5 
and Sox6 for efficient transcription of the important ECM genes Col2a1 and Acan87,90,94-96.  
Figure 1.8: Chondrogenic differentiation 
Hematoxylin stained section of the growth plate near the articular joint from the proximal tibia of a six week old 
mouse. Different phases of chondrogenic differentiation are visible and the differnt layers of growth plate and 
articular cartilage are indicated.  
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Other ECM genes have also been shown to be under transcriptional control of Sox9, of 
which Col9a1, Col27a1 and Matn1 are important ones97-100. Another important transcrip-
tional regulator of early chondrogenic differentiation is Bapx1/Nkx3.2 (bagpipe homeobox 
homolog 1/NK3 homeobox 2). Interestingly, Bapx1/Nkx3.2 and Sox9 are able to induce 
each other’s expression which results in sustained chondrogenic differentiation101. Bapx1/
Nkx3.2 functions as a transcriptional repressor of the main hypertrophic transcription   
factor Runx2 (runt-related transcription factor 2) and is expressed during chondrogenic 
differentiation but lost upon chondrocyte hypertrophy102-104. Sox9 and Bapx1/Nkx3.2 are 
thus negative regulators of chondrocyte hypertrophy. The proliferative capacity of the  
differentiating chondrocytes is maintained by transcription factors, such as members of the 
activating transcription factor (Atf) and cyclic AMP response element binding protein 
(CREB) family105,106. Subsequently, the proliferative chondrocytes in growth plates exit the 
cell cycle and subsequently undergo a remodeling of their extracellular matrix and increase 
in cell volume up to ten times107 further differentiating into hypertrophic chondrocytes, 
which is in contrast to articular chondrocytes which will normally not progress into the 
hypertrophic phase. 
Hypertrophic differentiation is accompanied by increased expression of Runx2 and Mef2c 
(Myocyte-specific enhancer factor 2C), which are important transcription factors for colla-
gen type X (Col10a1), the main collagen found in hypertrophic chondrocytes108-111. Mice 
lacking Runx2 exhibit a disturbance of chondrocyte maturation as demonstrated by an ab-
sence of Col10a1 expression112-114. These abnormalities could be reversed by transgene-
driven expression of Runx2 in chondrocytes. Transgenic expression of Runx2 in wild-type 
mice not only accelerates hypertrophy in normal chondrocytes but even induced hypertro-
phy in cartilage that normally never undergoes hypertrophy, such as cartilage of tracheal 
rings115,116, further stressing on the key role of Runx2 in regulating chondrocyte hyper-
trophic development.  
In addition, hypertrophic chondrocytes also express vascular endothelial growth factor A 
(VEGF-A) to stimulate vascular ingrowth. The transcription of VEGF-A is regulated by 
Runx2 and Mef2c14,117. Also several MMPs (matrix metalloproteinases) and ADAMTSs (a 
disintegrin and metalloproteinase with thrombospondin motifs) for breakdown of the ECM 
are synthesized14,118. At the final stage of hypertrophic differentiation several mineraliza-
tion proteins are expressed, such as Alp (alkaline phosphatase) and osteopontin (Opn, also 
known as bone sialoprotein I (Bsp1)), which mineralize the extracellular matrix14,119. Final-
ly, the hypertrophic chondrocytes die by apoptosis, leaving their mineralized extracellular 
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matrix behind for osteoblasts to adhere, which will eventually remodel the matrix into 
bone tissue.  
 
 
3.2 Growth Factors and Paracrine Regulators in Chondrogenic Differentiation 
In growth plate development as well as in the development and homeostasis of articular 
cartilage several signaling pathways are interacting or shared between the different tissues. 
Indian hedgehog (Ihh) and parathyroid hormone related peptide (PTHrP) coordinate chon-
drocyte proliferation and differentiation in the paracrine PTHrP-Ihh feedback loop85. 
PTHrP is synthesized by proliferating chondrocytes and perichondrial cells85 and maintains 
chondrocyte proliferation by activating Cyclin D1120and prevents premature hypertrophy 
by inducing Cyclin D1-mediated degradation of Runx2121. Proliferating chondrocytes   
located at a sufficient distance from the PTHrP source stop proliferating and become    
hypertrophic, Ihh synthesizing cells122. Ihh is expressed by prehypertrophic chondrocytes 
and accelerates the (hypertrophic) differentiation of proliferative chondrocytes and addi-
tionally it increases the expression of PTHrP, resulting in a feedback loop that controls the 
pace of chondrocyte proliferation and maturation123-125. Next to the PTHrP-Ihh loop, fibro-
blast growth factors (FGFs) crucially regulate chondrocyte proliferation and differentiation 
possibly by stimulating Sox9 expression and inhibiting proliferation and Ihh expression85.  
Figure 1.9: Chondrogenic differentiation 
Successive steps of chondrogenic differentiation during endochondral ossification with schematic representation 
of the cells, major extracellular matrix genes, regulatory factors and growth and differentiation factors indicated at 
each step. (Adapted from:14) 
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FGF signaling is balanced by bone morphogenic protein (BMP)- signaling126. BMPs are 
described to have multiple roles during bone and cartilage formation, as well as growth 
plate development127. Interestingly; BMPs were initially discovered because of their     
remarkable ability to ectopically induce endochondral bone formation128. In a cartilage 
context, BMPs are involved in stimulating early chondrogenesis, cartilage maintenance 
and hypertrophic differentiation127. Especially BMP-2, BMP-4 and BMP-7 (OP-1) have 
been demonstrated to promote chondrogenic differentiation in vitro127. BMPs belong to the 
transforming growth factor beta (TGF-β) superfamily, which are important regulators of 
differentiation, proliferation, tissue homeostasis and -repair in general. TGF-β isoforms 
(TGF-β1, TGF-β2 and TGF-β3) support the differentiation of mesenchymal progenitor 
cells into the chondrogenic lineage129-134. The TGF-β isoforms mainly signal through  
phosporylated R-Smads, which in combination with co-(transcriptional) factors regulate 
specific target-gene expression135,136. Related to its chondrogenic properties, TGF-β      
signalling is also involved in the formation of osteophytes during OA137-140. Another     
important regulator of chondrogenic differentiation is the canonical Wnt (wingless-type 
MMTV integration site family)/β-catenin signalling pathway. Upon binding of a Wnt   
ligand to its receptor (Frizzled), cytosolic β-catenin translocates to the nucleus where it 
forms complexes with transcription factors such as the TCF/LEF (transcription factor/
lymphoid enhancer-binding factor) family and thereby regulates downstream target-gene 
expression. In absence of the Wnt signal cytosolic β-catenin is phosphorylated by GSK-3β 
(glycogen synthase kinase 3β) and subsequently degraded141-143. Members of the canonical 
Wnt/β-catenin signalling pathway are generally expressed during hypertrophy and        
accordingly also promote chondrocyte hypertrophy, presumably via the TCF/LEF binding 
site in the promoter region of the Runx2 gene144-146. In early chondrogenic differentiation 
Sox9 interacts with β-catenin and promotes its phosphorylation and thereby degradation 
thereby preventing osteoblastic or hypertrophic differentiation144,147-150.  
 
 
4. Tissue Repair Processes and Chondrogenic Differentiation 
 
Joint homeostasis is essential during cartilage repair, but methods for improving joint ho-
meostasis in cartilage repair techniques are hardly addressed151,152. Addressing the condi-
tion of the cartilage microenvironment may not only be the key to a new generation of 
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bone marrow-based techniques to regenerate hyaline cartilage153, but may also improve 
cartilage repair in general. While inflammatory processes are generally seen as a negative 
factor in cartilage and joint homeostasis and are contributing factors in OA and rheumatoid 
arthritis (RA), inflammation is also known to be the first and essential phase of tissue   
repair in general. This suggests that inflammatory processes could be relevant pathways 
for addressing cartilage tissue repair. Supporting data for this notion is found in bone   
fracture healing processes where haematoma formation and injury-induced inflammatory 
responses are essential for fracture healing and its accompanying chondrogenic                      
differentiation / endochondral ossification. (Figure 1.10)154-156. This essential inflammatory 
response induces local expression of extracellular signalling molecules like TGF-β1, 
BMPs, insulin-like growth factor (IGF)-1 and platelet derived growth factor (PDGF), 
which regulate chondrogenic differentiation processes157,158. In contrast to their well-
known catabolic effects in pathological conditions such as OA and RA, several inflamma-
tory cytokines and chemokines (e.g. interleukin-1 (Il-1), Il-6, tumor necrosis factor alpha 
(TNFα), prostaglandin E2 (PGE2) and nitric oxide (NO)) are essential for bone fracture 
repair155,158-160. TNFα signalling-deficient mice show impaired fracture healing due to   
delayed early chondrogenesis and chondrocyte apoptosis161,162. Il-6 knock-out (KO) mice 
show delayed cartilage callus maturation and impaired mineralization after inducing bone 
fracture163,164. Expression of the PGE2 synthesizing enzyme cyclooxygenase-2 (COX-2) 
has been observed during fracture callus formation as well as in the developing growth 
plate, pointing towards a role in endochondral ossification165-167. COX-2 knock-out mice 
exhibit impaired fracture healing due to lack of PGE2 synthesis
168. Similarly, inducible 
nitric oxide synthase (iNOS), responsible for NO synthesis during acute inflammation, is 
thought to have a pivotal role in bone fracture repair as well169. Expression of iNOS is  
observed in fracture callus and iNOS -/- mice display impaired fracture healing170-172.    
One of the key players in the transcriptional regulation of these inflammatory genes is nu-
clear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). NF-κB signalling 
can be activated via several receptors-pathways, amongst which classically the activation 
of Toll-like receptor (TLR)-2/-4 and the TNFα receptor173-176. In addition, also the TGF-β 
receptor and IGF receptor are described to induce NF-κB signalling177,178. Upon receptor 
activation, the cytoplasmically localized NF-κB complex translocates to the nucleus,  lead-
ing to NF-κB-mediated transcription of inflammatory target genes174,175. Besides its func-
tions in transcriptional regulation of catabolic inflammatory processes, NF-κB has been 
associated with skeletal development; double KO of NF-κB subunits p50 and p52 as well  
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as p65 -/- mice show retarded skeletal development179,180. Previous studies have established 
an important role for inflammatory mediators during endochondral bone formation,     
however mainly focused on the osteogenic phase or complete process of endochondral 
ossification. Thusfar a potential involvement of inflammatory signalling in chondrogenic 
differentiation remains poorly studied. The NF-κB subunit p65 was recently identified as a 
transcription factor for Sox9, the major chondrogenic transcription factor181. In addition to 
Sox9, expression of BMP-2 in chondrocytes is co-regulated by NF-κB182. Also, BMP-2 
expression is under control of pro-inflammatory cytokines TNFα and Il-1β183,184. 
Taken together there is a growing body of experimental evidence, showing that inflamma-
tory mediators and their down-stream pathways are not only associated with cartilage   
degeneration, but are also crucially involved in the chondrogenic differentiation process 
during endochondral ossification in vivo. These insights could be explored for cartilage 
repair technologies to increase the differentiation potential of progenitor cells toward     
cartilaginous tissue and establishing optimal joint homeostasis after cartilage repair to in-
crease the success of the treatment. 
Figure 1.10: Phases of endochondral fracture repair 
Schematic representation of different phases of bone 
fracture healing. First an inflammatory haematoma is 
formed and mesenchymal cell proliferation begins 
throughout the affected bone almost directly after 
injury. Secondly a cartilaginous callus is formed from 
this tissue which differentiates further along the endo-
chondral ossification pathway to woven bone. The 
woven bone is gradually replaced by lamellar bone 
and the fracture is united. The final phase is remodel-
ing, where the shape of the bone is gradually returned 
to the orginal bone. The latter process may take sever-
al years.  
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5. Aims and outline of this thesis  
Chondrogenic differentiation is a tightly regulated process in which many factors regulate 
the discrete stages of the differentiation program. Understanding the mechanisms of cell 
commitment and further differentiation into the chondrogenic lineage is of great           
importance to optimize (progenitor) cell-based cartilage repair techniques. The work     
described in this thesis aimed to investigate how chondrogenic differentiation capacity 
from progenitor cells can be influenced via pathways that were unprecedented to be in-
volved in determining the fate of the chondrogenic differentiation program.  
Chapter 2 focuses on the involvement of key inflammatory complex NF-κB/p65 in chon-
drogenic differentiation of progenitor cells. We questioned if NF-κB/p65 signalling is   
involved in early chondrogenic differentiation and if modulating the activity of NF-κB/p65 
alters the chondrogenic outcome via signalling through key chondrogenic transcription 
factor Sox9.  
NF-κB is a member of the Rel family of transcription factors, which also consists of     
Nuclear factor of activated T-cells 5 (Nfat5). Nfat5 was recently shown to be essential in 
the tonicity-responsiveness of human articular chondrocytes (HACs). HACs increase their 
matrix synthesis under increased tonicity of the culture medium via an Nfat5-dependent 
mechanism185. However, the effects of increased tonicity and the involvement of Nfat5 in 
chondrogenic differentiation of progenitor cells are largely unknown. We hypothesized in 
Chapter 3 that Nfat5 is involved in chondrogenic differentiation of progenitor cells in vitro 
and that the differentiation process can be enhanced by increasing the tonicity of the     
culture medium.  
Expression of several growth factors, including BMP-2, is co-regulated in differentiating 
chondrocytes by NF-κB/p65 and in turn BMP-2 is able to regulate NF-κB/p65 signalling 
which could, at least in part, explain the pro-chondrogenic effect of BMP-2182,186. The re-
combinant version of BMP-2 is clinically approved and used to promote osteogenesis at 
sites of poor fracture healing (non-unions) and as additional factors to enhance integration 
of bone grafts. Also, BMP-7 (OP-1) is clinically approved to promote bone healing. A 
comparison of the in vitro chondrogenic characteristics of BMP-2 versus BMP-7 on differ-
entiation of progenitor cells has not been reported and would warrant     evidence-based 
use of one or the other BMP for specific chondrogenic purposes (Chapter 4).                 
Cyclooxygenase-2 (COX-2) is a transcriptional target of the NF-κB/p65 complex and is 
involved in inflammatory processes. In line with a role for COX-2 in endochondral ossifi- 
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cation, mice lacking COX-2 show impaired fracture healing. However, the function of 
COX-2 in chondrogenic differentiation from progenitor cells in the context of endochon-
dral ossification remains unclear at present. In Chapter 5 we tested if  inhibition of COX-2 
activity by non steroidal anti-inflammatory drugs (NSAIDs) is able to decrease the level of 
chondrocyte hypertrophic differentiation in different endochondral differentiation models. 
Also, the effect of systemic inhibition of COX-2 activity in vivo on chondrocyte hyper-
trophic differentiation in rabbit growth plates was determined. Next to COX-2-specific 
NSAIDs, other NSAIDs specifically inhibit COX-1 or both COX-enzymes. To determine 
how COX-1-specific NSAIDs act in chondrogenic differentiation as compared to COX-2-
specific NSAIDs, we compared the effects of specific COX-1 and COX-2 inhibitors in 
chondrocyte ECM formation and studied if specific prostaglandins (PG) are involved in 
chondrogenic differentiation (Chapter 6).  
Equally important for obtaining an optimal chondrogenic phenotype is not only to stimu-
late progenitor cells towards chondrocytes but also prevent them from hypertrophy.    
Chondrocyte hypertrophy is not only an unwanted phenomenon in chondrogenic differenti-
ation from progenitor cells but is also a hallmark of early OA in mature chondrocytes and     
hampers the outcome of chondrocyte-based cartilage repair approaches. A cell culture  
system displaying a chondrocyte hypertrophic phenotype can be of importance when   
studying this process on a molecular basis. To hypertrophic marker expression and       
establish an human chondrocyte hypertrophic model we compared different redifferentia-
tion models for human articular chondrocytes (HACs) (Chapter 7). Potential chondrogenic
-stimulating and hypertrophic-suppressing factors identified in our previous studies can be 
further verified in such a model. 
In Chapter 8 the data described in this thesis are discussed with regard to fundamentally 
understanding chondrogenic differentiation and their relevance for optimizing progenitor 
cell-based cartilage regenerative medicine approaches.  
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Abstract 
 
Introduction: NF-κB/p65 has been reported to be involved in regulation of chondrogenic 
differentiation. However, its function in relation to key chondrogenic factor Sox9 and   
onset of chondrogenesis during endochondral ossification is poorly understood. We      
hypothesized that the early onset of chondrogenic differentiation is initiated by transient 
NF-κB/p65 signaling.  
Methodology: The role of NF-κB/p65 in early chondrogenesis was investigated in different 
in vitro, ex vivo and in vivo endochondral models: ATDC5 cells, hBMSCs, chicken      
periosteal explants and growth plates of six weeks old mice. NF-κB/p65 activation was 
manipulated using pharmacological inhibitors, RNAi and activating agents. Gene expres-
sion and protein expression analysis, and (immuno)histochemical stainings were employed 
to determine the role of NF-κB/p65 in the chondrogenic phase of endochondral             
development.  
Results: Our data show that chondrogenic differentiation is facilitated by early transient 
activation of NF-κB/p65. NF-κB/p65-mediated signaling determines early expression of 
Sox9 and facilitates the subsequent chondrogenic differentiation programming by         
signaling through key chondrogenic pathways.  
Conclusions: The presented data demonstrate that NF-ĸB/p65 signaling, as well as its  
intensity and timing, represents one of the transcriptional regulatory mechanisms of the 
chondrogenic developmental program of chondroprogenitor cells during endochondral 
ossification. Importantly, these results provide novel possibilities to improve the success of 
cartilage and bone regenerative techniques. 
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1. Introduction 
Chondrogenic differentiation encompasses the commitment and differentiation of chondro-
progenitor cells to chondrocytes. In addition to providing articulating joint surfaces with 
functional cartilage and maintaining cartilage integrity, chondrogenic differentiation plays 
an essential role during endochondral ossification. Skeletal growth and bone fracture heal-
ing depend on endochondral ossification; growth plate chondrocytes or fracture callus 
chondrocytes originating from mesenchymal progenitors gradually differentiate into    
mineralized hypertrophic chondrocytes and finally die by apoptosis. The remaining      
mineralized extracellular matrix provides a molecular scaffold for infiltrating osteoblasts 
and osteoclasts to adhere to and remodel, setting the stage for de novo bone deposition1-3.  
Transcriptional targets of NF-ĸB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) have been recognized as key developmental signaling mediators that regulate      
endochondral ossification. Early bone fracture healing by endochondral ossification de-
pends on a haematoma-induced inflammatory environment4 and several NF-ĸB-target 
genes (e.g. interleukin (Il)-6, tumor necrosis factor alpha (TNFα), cyclooxygenase (COX)2 
and inducible nitric oxide synthase (iNOS)) are involved in bone fracture repair5,6. Besides 
its functions in transcriptional regulation of general catabolic inflammatory processes,    
NF-κB has been linked to skeletal development7. Double knockout (KO) of NF-κB       
subunits p50 and p52 shows abnormal skeletal development in mice, which was attributed 
to impaired growth plate function8. Recently, NF-κB subunit RelA (V-rel reticuloendothe-
liosis viral oncogene homolog A or p65) was reported to be activated by Nkx3.2/Bapx1 
(NK3 homeobox 2/Bagpipe homeobox homolog1) to control chondrocyte viability9.   
Moreover, RelA was identified as a transcription factor for bone morphogenic protein 
(BMP) 28,10  and Sox9 (SRY (sex determining region Y)-box 9) in mature chondrocytes 
during         endochondral ossification11. Sox9 is expressed by chondroprogenitor cells and 
is indispensable for chondrogenic differentiation12-14. Sox9 drives the expression of carti-
lage matrix genes Collagen type II (Col2a1) and Aggrecan (Acan) cooperatively with        
L-Sox5 and Sox615-17 and as such maintains chondrocyte phenotype. The involvement    
NF-ĸB/p65 as indispensable factor during chondrogenic development has been studied in 
the context of mature chondrocytes. However, the mechanism by which NF-ĸB/p65 signal-
ing influences early differentiation of chondroprogenitors remains elusive. We hypothe-
sized that the   initiation of chondrogenic differentiation is regulated by transient NF-ĸB/
p65 signaling.  
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Our data show that during the very first hours of chondroprogenitor differentiation a  tran-
sient activation of NF-ĸB/p65 occurs which, in part, regulates the transient expression of 
key chondrogenic controller Sox9 at the early phase of chondrogenesis. This early        
transient Sox9 induction precedes the induction of Sox9 that is described to be related to 
late cartilage matrix synthesis15,16, revealing a novel bi-phasic induction for Sox9 during 
chondrogenic differentiation. We found indications that through the early Sox9 induction 
the transient NF-ĸB/p65 activation determines, at least in part, the late stage fate of the 
chondrogenic differentiation process. Inhibition of NF-κB/p65 mediated signaling is     
accompanied by inhibition of early Sox9 expression and subsequent inhibition of late stage 
chondrogenesis. In line with these findings, brief early NF-κB stimulation using different 
NF-κB activating molecules (lipopolysaccharide (LPS), tumor necrosis factor α (TNFα) or 
BMP-2), enhanced chondrogenesis in our in vitro and ex vivo endochondral models. Our 
findings demonstrate that NF-ĸB/p65 signaling, as well as its intensity and timing, is an 
important factor in the regulation of the early chondrogenic developmental program of 
chondroprogenitor cells and thereby in part determines endochondral ossification. 
 
 
2. Materials and Methods 
 
2.1 ATDC5 cell culture 
ATDC5 cells18 were cultured in proliferation medium (DMEM(Dulbecco’s modified eagle 
medium)/F12 (Invitrogen, Carlsbad, CA, USA), 5% fetal calf serum (FCS) (PAA, 
Pasching, Austria), 1% antibiotic/antimycotic (Invitrogen) and 1% NEAA (non-essential 
amino acids) (Invitrogen)). Differentiation medium comprised proliferation medium sup-
plemented with 10 µg/ml insulin (Sigma, St. Louis, MO, USA), 10 µg/ml transferrin 
(Roche Applied Science) and 30 nM sodium selenite (Sigma). Cells were plated at 6,400 
cells/cm2 and the following day chondrogenesis was initiated by changing the proliferation 
medium to differentiation medium (or proliferation medium in case of data presented in 
Figure 2.7). Medium was changed every two days and every day from day ten onwards. To 
inhibit NF-κB, TLCK (Acros), Parthenolide (Sigma) and Sulfasalazine (Sigma) were used. 
LPS (lipopolysaccharide) (Sigma) or TNFα (R&D) were used as NF-κB/p65 activators. 
BMP-2 was used at 30 ng/ml (Sigma). For RNAi-experiments a p65 small interfering RNA 
(siRNA) duplex (sense: 5’-AGAGGACAUUGAGGUGUAUTT-3’, anti-sense: 5’- 
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AUACACCUCAAUGUCCUCUTT-3’), a Sox9 siRNA duplex (sense: 5’- 
GACUCACAUCUCUCCUAAUTT-3’, anti-sense: 5’- AUUAGGAGAGAUGUG-
AGUCTT-3’) and a scrambled siRNA-duplex (indicated by “Control”) were used 
(Eurogentec, Seraing, Belgium). ATDC5 cells were seeded at 25,000 cells/cm2 and     
transfection with siRNAs (100 nM for p65 and 50 nM for Sox9) was performed using 
ICAfectin 442 (Eurogentec) according to manufacturers’ protocol. Cells were cultured for 
two days before chondrogenesis was initiated.  
 
2.2 hBMSC isolation and culture 
Human bone marrow stem cells (hBMSCs) were obtained from residual iliac crest bone 
marrow aspirate from young, genetically healthy individuals undergoing spinal surgery. 
The Maastricht University Medical Centre institutional policy on the use of residual human 
surgical material specifically states that no informed consent is needed in the case of    
residual surgical material. However an approval from the institutional Medical Ethical       
Committee (MEC) for the use of this material is required. The MEC approved this study 
and assigned approval ID: MEC 08-4-056. Human BMSCs were isolated from the aspirate 
using Ficoll Paque (Amersham Pharmacia, Diegem, Belgium). Proliferation medium    
consisted of DMEM high-glucose (Invitrogen,), 10% FCS (ES-grade), 1% antibiotic/
antimycotic and 1% NEAA. Passage 5 cells were plated at 30,000 cells/cm2 and chondro-
genesis was initiated the next day by changing to differentiation medium (proliferation 
medium supplemented with 1% ITS (insulin-transferrin-sodium selenite media             
supplement) (Invitrogen), 50 μg/ml L-ascorbic acid-2-phosphate (Sigma) and 1 ng/ml 
transforming growth factor β3 (TGF-β3) (R&D, Minneapolis, MN, USA))19. In              
experiments for Figure 2.7B the proliferation medium was changed with proliferation me-
dium. Medium was changed every two days. TLCK (Acros, Geel, Belgium) was used to 
inhibit NF-κB/p65 activation and LPS (Sigma) was used as NF-κB/p65 activator. 
 
2.3 Chicken periosteum agarose culture (cPAC) 
Fertilized eggs of Dekalb white chickens (‘t Anker, Ochten, the Netherlands) were placed 
in a polyhatch incubator (Brisnea, Sandford, UK) at 39.2°C and at relative humidity of 
40%. At embryonic day 16, embryos were removed and sacrificed by rapid decapitation. 
Incubation period corresponded to embyos at Hamburger and Hamilton stage 42.          
Periosteum was dissected from tibiae using aseptic techniques. Periostea were embedded 
in 1% low-melting agarose/0.9% NaCl using procedures described before20,21. Proliferation  
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medium (DMEM/F12, 10% FCS, 1% antibiotic/antimycotic, 1% NEAA) was added and 
incubated overnight at 37°C/5% CO2. The next day, medium was changed with prolifera-
tion medium supplemented with or without LPS (Sigma). For the differentiation control, 
medium was changed to differentiation medium (proliferation medium supplemented with 
1% ITS (Invitrogen), 50 µg/ml L-ascorbic acid-2-phosphate (Sigma), 10 ng/ml TGF-β3 
(R&D)). Medium was changed every two days. Ethical approval by the institutional animal 
ethical committee was waived for these experiments as institutional regulations state that 
no approval from an animal ethical committee is needed to perform embryonic chicken 
experiments. 
 
2.4 Mouse growth plates 
The growth plates were isolated from tibias of six weeks old C57BL/6 mice. These were 
surplus wildtype mice from another unrelated experiment. This experiment was approved 
by the Maastricht University animal ethical committee (DEC) and assigned approval ID: 
DEC 2008-042. The tibia’s were isolated and fixed in formalin. The growth plates were 
separated from the rest of the tibia and decalcified in 0.5 M EDTA pH 7.8 for two weeks. 
EDTA was refreshed every two days. Growth plates were dehydrated and embedded in 
paraffin. Five micrometer sections were cut and positioned on Superfrost Plus slides for 
immunohistochemistry (IHC). 
 
2.5 RT-qPCR 
Total RNA was extracted with TRIzol (Invitrogen). Quantity and purity of extracted RNA 
were determined by UV-spectrometry (Nanodrop, Thermo Scientific, the Netherlands). 
DNA-free total RNA was reverse transcribed to cDNA using standard procedures and  
random hexamer priming. Real time quantitative PCR (RT-qPCR) was performed using 
Mesagreen qPCR mastermix plus for SYBR Green (Eurogentec) and an Applied      Bio-
systems ABI PRISM 7300 Sequence Detection System for amplification with the follow-
ing profile: initial denaturation 10 minutes at 95oC, followed by 40 cycles of amplification 
(15 seconds at 95oC and 1 minute at 60oC), followed by a dissociation curve. Data were 
analyzed using the standard curve method and relative quantification of mRNA expression 
was normalized to a housekeeping mRNA. Primer sequences are depicted in Table 2.1. 
 
2.6 Immunoblotting 
Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Sodium deoxycho-
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late,0.1% SDS, 50 mM Tris pH 8.0, 5.0 mM EDTA pH 8.0, 0.5 mM dithiothreitol (DTT) 
and 1 mM phenylmethylsulfonylfluoride (PMSF). Nuclear extracts were prepared by    
lysing cells in a buffer containing 20 mM HEPES (pH 7.8), 20 mM KCl, 4 mM MgCl2, 0.2 
mM EDTA (pH 8.0), 1 mM DTT, 0.2 mM sodiumvanadate, 0.4 mM PMSF, 0.3 mg/ml 
leupeptin and 0.2 mM sodiumfluoride). Nuclei were separated from cytoplasm by centrifu-
gation (16.000 x g) and the nuclear pellet was lysed in RIPA buffer. Extracts were sonicat-
ed and protein concentrations were determined using the BCA method (Sigma).     Poly-
peptides were separated by SDS-PAGE and transferred to nitrocellulose membranes by 
electroblotting. Primary antibodies for immunodetection were anti-Col2a1 (Southern    
Biotech, Birmingham, AL, USA), anti-Col10a1 (Calbiochem, Darmstadt, Germany), anti-
Sox9 (Abcam, Cambridge, UK), anti-COX-2 (Cayman, Ann Arbor, US), anti-iNOS 
(Abcam), anti-p65 (Santa Cruz Biotechnologies, CA, USA), anti-Runx2 (MBL, Woburn, 
MA, USA) and anti-α-Tubulin (Sigma). Bound primary antibodies were detected with  
immunoglobulins conjugated with HRP (DakoCytomation, Glostrup, Denmark) and     
visualized by enhanced chemoluminescence (ECL). ECL signals were quantified using 
Biorad Quantity One 4.6.7 software and relative differences, corrected for background and 
housekeeper, were determined as compared to control conditions or t=0. 
 
2.7 (Immuno)histochemistry 
Chicken PAC samples were dehydrated following standard procedures and embedded in 
paraffin. Tissue sections were cut at 5 µm, deparaffinized and rehydrated using standard 
protocols. Proteoglycans were stained with Safranin-O (0.1%) (Sigma) and counterstained 
with Fast Green (0.1%) (Sigma). Stained sections were dehydrated and mounted in Histo-
mount (Thermo Shandon). For Sox9, p65, iNOS and COX-2 expression in 6-weeks old 
mouse growth plate and cPAC, sections were deparaffinized and antigen retrieval was  
performed by incubation in boiling citrate buffer (1.8 mM citric acid and 8.2 mM             
tri-sodium citrate) for 30 minutes. For Col2a1 detection in cPAC, sections were digested 
with 0.4% hyaluronidase (Sigma) for 30 minutes at 37°C. Endogenous peroxidase activity 
was inactivated and sections were blocked with 10% normal sheep serum. Primary anti-
bodies were: anti-Sox9 (sc-166505; Santa Cruz Biotechnology), anti-p65 (sc-372; Santa 
Cruz Biotechnology), anti-COX-2 (610203; BD Transduction Laboratories, the Nether-
lands), anti-iNOS (ab3523; Abcam) and anti-Col2a1 (II-II6B3; Developmental Studies 
Hybridoma Bank). Similar antibody concentrations were used for negative controls; mouse 
IgG1 (Dako) for COX-2 and Col2a1, mouse IgG2a (Dako) for Sox9, normal rabbit serum 
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for iNOS and anti-p65 blocking peptide (sc-372P; Santa Cruz Biotechnologies) for p65. 
After washing in PBS-T, bound antibodies were detected with HRP-labelled secondary 
antibodies (Dako, EnVision+ System-HRP labelled Polymer). For visualisation, DAB   
substrate (Dako) was used. Stained sections were counterstained with Mayer’s Hematoxy-
lin (Dako), dehydrated and mounted in Histomount as described above. 
 
Table 2.1. DNA oligo sequences for RT-qPCR.  
Forward and reverse oligo sequences (5’-3’) used for RT-qPCR are listed for mouse, human and chicken. 
 
2.8 Statistics 
In the Figures, bars represent average value of 3 individual experiments (performed in trip-
licate; 3x3 samples) and error bars represent mean ± s.e.m.. Statistical significance (p < 
0.05) was determined by unpaired two-tailed student t-tests using Graphpad PRISM 5.0 
(La Jolla, CA, USA).  
Oligo sets mouse Forward Reverse 
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCC-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
Col10a1 ‘5-CATGCCTGATGGCTTCATAAA-3’ ‘5-AAGCAGACACGGGCATACCT-3’ 
Runx2 ‘5-CGATGAAGACCCCAACCCTAA-3’ ‘5-ACTGGTAATGGCATCAAGGGATA-3’ 
Sox9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-TACTTGTAGTCCGGGTGGTCTTTC-3’ 
L-Sox5 ‘5-CCCAGCCACTGAACCTATCAG-3’ ‘5-TGTGAGGAGAGGTGGGTGATG-3’ 
Sox6 ‘5-AAATCCACCTAGAGAAGTACCCAAAC-3’ ‘5-CCCAATCCGGAGCTTCTTG-3’ 
COX-2 ‘5-GGCCATGGAGTGGACTTAAA-3’ ‘5-AAGTGGTAACCGCTCAGGTG-3’ 
iNOS ‘5-CAGCTGGGGCTGTACAACCCTT-3’ ‘5-CATTGGAAGTGAAGCGTTTCG-3’ 
Il-6 ‘5-GCTACCAAACTGGATATAATCAGGAAA-3’ ‘5-CTTGTTATCTTTTAAGTTGTTCTTCATGTACTC-3’ 
TNFα ‘5-CATCTTCTCAAAATTCGAGTGACAA-3’ ‘5-TGGGAGTAGACAAGGTACAACCC-3’ 
p65 ‘5-ACAGACCCAGGAGTGTTCACAGA-3’ ‘5-CATGGAACACACCCTGGTTCAG-3’ 
FGF-3 ‘5-AGCGGCCGCGTGAAC-3’ ‘5-CCACTTCCACCGCAGTAATCTC-3’ 
IGF-1 ‘5-AACAAGCCCACAGGCTATGG-3’ ‘5-AAGCAACACTCATCCACAATGC-3’ 
TGF-β3 ‘5-TCGACATGGAGCTGGTGAAA-3’ ‘5-GAGCCTTAGTTTGGACAGGATCTG-3’ 
BMP-2 ‘5-AGAAAAGCGTCAAGCGAAACA-3’ ‘5-GTCCACGTACAAAGGGTGTCTCT-3’ 
BMP-4 ‘5-ACCCGCAGCCTAGCAAGA-3’ ‘5-CTGACTGGAGCCGGTAAAGATC-3’ 
β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
Oligo sets human Forward Reverse 
COL2A1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
COL10A1 ‘5-ATGATGAATACACCAAAGGCTACCT-3’ ‘5-ACGCACACCTGGTCATTTTCTG-3’ 
SOX9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-CGCTTCTCGCTCTCGTTCAG-3’ 
COX-2 ‘5-ACCAACATGATGTTTGCATTCTTT-3’ ‘5-GGTCCCCGCTTAAGATCTGTCT-3’ 
IL-6 ‘5-GCTACCAAACTGGATATAATCAGGAAA-3’ ‘5-CTTGTTATCTTTTAAGTTGTTCTTCATGTACTC-3’ 
28S rRNA ‘5-GCCATGGTAATCCTGCTCAGTAC-3’ ‘5-GCTCCTCAGCCAAGCACATAC-3’ 
Oligo sets chicken Forward Reverse 
Col2a1 ‘5-AAGAAAGCCATCCTCATCCAG-3’ ‘5-CCATTTGCCAGTGTGTTTCG-3’ 
Aggrecan ‘5-AAGTGAAGATACCTGAGCAGTC-3’ ‘5-CAGCAGAGCATTGGTGTCC-3’ 
Sox9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-CGCTTCTCGCTCTCGTTCAG-3’ 
Cyclophillin A ‘5-CCTGCTTCCACCGGATCAT-3’ ‘5-CGTTGTGGCGCGTAAAGTC-3’ 
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3. Results 
 
3.1 Early ATDC5 differentiation is accompanied by a transient activation of NF-ĸB/p65 
and expression of Sox9 
As a model for endochondral ossification, the murine chondroprogenitor ATDC5 cell line 
was used18,22. Early involvement of NF-ĸB/p65 signaling was assessed by examining    
subcellular localization of the NF-κB subunit p6523 (Figure 2.1A). In proliferating cells 
(t=0) p65 was not detectable in the nucleus. However, upon initiation of chondrogenesis a 
fraction of cytoplasmically localized p65 translocated to the nucleus, which was readily 
detectable at 30 minutes post-induction of differentiation. The nuclear occupation of p65 
peaked between one half and four hours and was not detectable anymore after eight hours 
(Figure S2.1). To further verify overall activation of NF-κB/p65, expression of NF-ĸB-
target genes was measured (Figure 2.1B). Induction of COX-2, iNOS, Il-6 and TNFα 
mRNAs was detectable between one and four hours in differentiation and returned to   
baseline levels around eight hours. COX-2 and iNOS proteins showed a similar transient 
expression (Figure 2.1C).  To verify potential cross-talk between the differentiation      
program and the early NF-ĸB/p65 response, expression of Sox9 was determined. During 
ATDC5 differentiation Sox9 expression was transiently induced at one to four hours in 
differentiation and steadily increased again from day seven in differentiation (Figure 
2.1D). Remarkably, these data imply that the expression of Sox9 during chondrogenic  
differentiation in ATDC5 is bi-phasic. Confirming completion of the chondrogenic differ-
entiation program in the ATDC5 cells chondrogenic markers Col2a1, collagen type X 
(Col10a1), and runt-related transcription factor 2 (Runx2) increased in expression from 
day seven in differentiation (Figure 2.1E).  
Previously it was reported that an NF-κB/p65 transcription factor binding site is located in 
the Sox9 gene11. In silico screening of Sox9 promoter regions detected two other putative 
evolutionary conserved NF-κB/p65 transcription factor binding sites in various mammals 
(Figure 2.2).  
Post-natal growth plates contain a pool of dedicated chondroprogenitor cells in the           
so-called resting zone. During growth plate development, these resting zone cells differen-
tiate into proliferating chondrocytes and are thus responsible for cartilage generation in the 
growth plate24. To verify whether activation of NF-ĸB/p65 can also be detected in early 
chondrogenesis during endochondral ossification in vivo, the resting- and proliferative 
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zones of six week old mice growth plates were analyzed for expression of Sox9, p65 and 
NF-ĸB/p65-target genes (COX-2 and iNOS) (Figure 2.1F). As described previously25, 
Sox9 expression was detected in the resting zone (RZ) cells as well as in proliferative zone 
chondrocytes (PZ). Interestingly, Sox9 seems to be more abundantly expressed in the   
resting zone. Expression of p65 was found in the cytoplasm of RZ cells and was not de-
tectable in the PZ. Also, p65 was found to be localized in the nuclei of several RZ cells. 
Both the expression of the NF-ĸB/p65-target genes COX-2 and iNOS was found in the RZ. 
Overall, these results indicate that an NF-ĸB/p65 signaling response occurs very early in 
chondrogenic differentiation and correlates with a thusfar unknown early transient        
induction of Sox9 in ATDC5 cells.  
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Figure 2.1: Early chondrogenic differentiation is accompanied by NF-κB/p65 activation and transient Sox9 ex-
pression 
(A). Nuclear translocation of the NF-κB subunit p65. Total extract (T), cytoplasmic (C) and nuclear (N) fractions 
were isolated at 0, 0.5, 1 and 2 hours in ATDC5 differentiation. Cytoplasmic marker: α-Tubulin, nuclear marker: 
Histone H3. (B). COX-2, iNOS, Il-6 and TNFα mRNA expression at 0-24 hours in differentiation (relative to t=0 
and corrected for β-actin).* = p < 0.05. (C). Protein expression of COX-2, iNOS and Sox9 at 0-24 hours in differ-
entiation. Molecular weight markers (kDa) are depicted on the left of immunoblots and relative quantifications 
are depicted on top of immunoblots. (D). Sox9 mRNA expression during chondrogenic differentiation. (E). 
mRNA and protein expression of Col2a1, Col10a1, Runx2 and Sox9 (only protein) at day 0, 7, 10 and 14 in 
ATDC5 differentiation. (F). Sections from 6 weeks old mouse growth plates (resting (RZ) and proliferative (PZ) 
zones) stained for p65, COX-2, iNOS and Sox9. Lower panels show appropriate negative controls. Bars = 50 µm. 
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3.2 Inhibition of early NF-κB/p65 activation leads to impaired chondrogenic differentia-
tion 
To functionally determine the role of the early NF-ĸB/p65 activation in relation to initia-
tion of chondrogenic differentiation, nuclear translocation of NF-κB was inhibited by 
TLCK or Parthenolide. Dose-response experiments (data not shown) revealed optimal in-
hibitor concentrations: 100 μM TLCK or 10 μM Parthenolide efficiently inhibited NF-κB 
nuclear translocation during early ATDC5 chondrogenesis (Figure 2.3A). In agreement 
with efficient NF-κB inhibition, both TLCK and Parthenolide inhibited COX-2, iNOS and 
Il-6 mRNA expression at two hours in differentiation (Figure 2.3B). 
We next tested the functional relationship between the early NF-ĸB/p65 response and 
chondrogenic differentiation. Early Sox9 levels were reduced by both TLCK and          
Parthenolide (Figure 2.3B and Figure 2.5A). Inhibition of NF-κB activation by TLCK or 
Parthenolide resulted in a similar dose-dependent inhibition of late phase (day 14) Col2a1, 
Col10a1, Runx2 and Sox9 protein expression (Figure 2.3C). Results were confirmed using 
the clinically used NF-κB inhibitor Sulfasalazine (Figure 2.3C).  
To independently verify the effect of pharmacological NF-κB/p65 inhibition on Sox9   
expression during early chondrogenic differentiation, we genetically targeted NF-κB/p65 
by RNAi. Transient transfection of a p65 siRNA duplex in ATDC5 reduced p65 mRNA 
and protein expression at two hours in differentiation by ~50% (Figure 2.3D, upper left 
Figure 2.2: In silico scan for NF-κB/p65 transcription factor binding sites in the Sox9 promoter.  
Genomatix’s Gene2Promoter software (www.genomatix.de) was used to screen Sox9-promoters (-1000 bp  
region) from ten different vertebrates for putative NF-κB transcription factor binding sites, based on the consen-
sus binding sequence for NF-κB: GGGRNNYYCC (in which R = purine, N = any nucleotide and Y = pyrimi-
dine)26. A multiple nucleotide sequence alignment was generated by the T-Coffee multiple sequence alignment 
program (http://www.tcoffee.org/) and >50% nucleotide homology is depicted in black boxes generated by the 
Boxshade server v3.21 (http://www.ch.embnet.org/software/BOX_form.html). Evolutionary conserved putative 
NF-κB transcription factor binding sites are marked in grey boxes. In addition to the functional NF-κB transcrip-
tion factor binding sites found by Ushita and colleagues27, two other putative evolutionary conserved NF-κB 
transcription factor binding sites were detected. Ensembl references to used promoter sequences are Homo sapi-
ens: GRCh37:17:70116161:70117161:1, Macaca mulatta: MMUL_1:16:67356426:67357426:1, Gorilla gorilla: 
gorGor3:5:1129374:11298374:-1, Pan troglodytes: CHIMP2.1:17:71547493:71548493:1, Mus musculus: 
NCBIM37:11:112642524:112643524:1, Sus scrofa: Sscrofa9:12:6872241:6871241:-1, Cavia porcellus: cav-
Por3:scaffold_3:74364652:74365652:1, Tursiops truncates: turTru1:scaffold_92737:81033:82033:1, 
Oryctolagus caniculus: oryCun2:19:55819664:55820664:1, Canis familiaris: 
BROADD2:9:11347542:11348542:1 
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set). Expression of COX-2, iNOS and Il-6 were also reduced as compared to control    
transfection (data not shown). In good agreement with the results described above, early 
expression of Sox9 mRNA and protein was significantly reduced by p65 knock-down 
(Figure 2.3D, upper right set). To further validate how p65 knock-down affects long term 
chondrogenic differentiation, p65 mRNA expression was targeted for a longer timeframe 
by re-transfection of the siRNA duplex. We confirmed efficient knock-down of p65 
mRNA at ten days in differentiation (Figure 2.3D, upper left and lower left sets).         
Functionally the p65 knock-down resulted in impaired chondrogenic differentiation 
(Figure 2.3D, lower left and lower right). Finally, to test whether the early transient Sox9 
induction influences late chondrogenic differentiation we targeted the expression of Sox9 
only in the early phase of differentiation by one single Sox9 siRNA transfection, followed 
by seven days of differentiation follow-up under normal differentiation conditions.         
Efficient knock-down of Sox9 mRNA was confirmed at the start of differentiation. At two 
hours in differentiation the early induction of Sox9 was almost completely abolished 
(Figure 2.3E, upper panel). At day four, Sox9 siRNA treatment was not effective anymore, 
as no difference in Sox9   expression was detectable between conditions. To verify the 
consequence of this early Sox9 knock-down, the expression of Col2a1 was determined 
(Figure 2.3E, lower panel). Col2a1 expression was detectable from day four onwards. At 
day four a significant difference was found between control and the early Sox9 knock-
down. This difference was even bigger at day seven, where early Sox9 knock-down lead to 
an almost abolished expression of Col2a1.  
Taken together, these results indicate that inhibition of NF-κB/p65 nuclear translocation 
suppresses the initiation of chondrogenic differentiation, by inhibiting early Sox9          
induction and subsequent expression of late chondrogenic markers. This indicates that late 
phase chondrogenic development and endochondral ossification are, at least in part,       
regulated by early NF-ĸB/p65 and Sox9 signaling events. 
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3.3 Late phase ATDC5 differentiation is enhanced by stimulation of early NF-κB/p65 ac-
tivity 
The association between early NF-κB/p65 activation and initiation of chondrogenic differ-
entiation prompted us to test whether stimulation of NF-ĸB/p65 enhances chondrogenic 
differentiation. We enforced NF-κB/p65 signaling by supplementing differentiation      
medium with the NF-κB/p65-activating molecular tools LPS or TNFα. These activating 
agents were added to the differentiating culture during the first 24 hours of differentiation 
only (the timeframe in which the early NF-ĸB/p65 activation takes place). At low LPS 
concentrations (0.1 ng/ml) and TNFα (10 ng/ml), NF-κB/p65 nuclear translocation was 
slightly enhanced during early chondrogenic differentiation (Figure 2.4A) and resulted in 
increased early expression of COX-2, Il-6 and iNOS mRNAs (Figure 2.4B). Interestingly, 
increasing NF-κB/p65 activity enhanced the magnitude of transient Sox9 (as well as          
L-Sox5 and Sox6) expression early in chondrogenic differentiation (Figure 2.4B and     
Figure 2.5A). Interference with NF-ĸB-signaling by siRNA mediated p65 knock-down 
attenuated the LPS- and TNFα-induced increased Sox9 expression back to control-treated 
Figure 2.3: Inhibition of early NF-κB/p65-activation leads to impaired ATDC5 differentiation 
(A). Cells were differentiated in the absence (control) or presence of TLCK (100 μM) or Parthenolide (10 μM) 
and total (T) and nuclear (N) fractions were prepared. NF-κB was detected as p65. (B). Expression of COX-2, 
iNOS, Il-6 and Sox9 mRNAs at 2 hours in differentiation in the presence of TLCK or Parthenolide. * = p < 0.05. 
Sox9 protein expression was determined from similar samples (right panel set). (C). Protein expression at day 14 
in differentiation of Col2a1, Col10a1, Sox9 and Runx2 with TLCK (left panels), Parthenolide (right panels) or 
Sulfasalazine (lower left panels). (D). Knock-down (kd) of p65 mRNA and protein at 0, 2 hours and 10 days in 
differentiation (“Control” below figures indicates scrambled siRNA and “p65” below figures indicates p65 kd). 
Upper right set: expression of Sox9 mRNA and protein in p65 kd cells at 2 hours in differentiation. Lower sets: 
messenger RNA expression of Col2a1 and Col10a1 at 10 days in differentiation of p65 kd cells. (E). Sox9 mRNA 
expression at 0, 2 hours and 4 days in differentiation of cells transfected one day prior to differentiation with 
scrambled (indicated by “Control”) or Sox9 siRNA (indicated by “Sox9”) (upper panel). Col2a1 mRNA expres-
sion was determined at day 4 and 7 in differentiation (lower panel).  
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differentiation levels (Figure 2.4C). Moreover, increased Col2a1, Col10a1, Sox9 and 
Runx2 expression in 24 hour LPS- and TNFα-exposed cells was detected at day ten and 14 
in differentiation (Figure 2.4D and Figure 2.5B). These data show that early and short 
chondrogenic NF-κB/p65-activation positively responds to environmental stimulation of 
NF-κB/p65, resulting in overall increased  chondrogenic potential late in differentiation.  
 
Figure 2.4: Late phase ATDC5 differentiation is enhanced by stimulation of early NF-κB/p65 activity 
(A). Cells were differentiated in the absence (control) or presence of LPS (0.1 ng/ml) or TNFα (10 ng/ml) and 
total (T) and nuclear (N) fractions were prepared. NF-κB was detected as p65. (B). Expression of COX-2, iNOS, 
Il-6 and Sox9 mRNAs at 2 hours in differentiation in LPS or TNFα treated cells. Far right panel set: early Sox9 
protein expression in LPS or TNFα treated cells. (C). ATDC5 cells were transfected with a p65 siRNA duplex or 
scrambled (“Control”) siRNA duplex and differentiated in the absence or presence of LPS (0.1 ng/ml) or TNFα 
(10 ng/ml) for 2 hours. Knock-down of p65 mRNA was confirmed at 0 and 2 hours in differentiation (left panel). 
Right panel shows Sox9 mRNA expression. (D). Protein expression of Col2a1, Col10a1, Sox9 and Runx2 in 
differentiated ATDC5 cells (14 days) in the presence of LPS (left panel set) or TNFα (right panel set), only dur-
ing the first 24 hours of differentiation. * = p < 0.05. 
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3.4 Early transient NF-κB/p65 signaling during endochondral differentiation of primary 
mesenchymal progenitor cells  
To verify the results obtained with the ATDC5 system, similar endochondral differentia-
tion experiments were performed using human bone marrow stem cells (hBMSC). In 
hBMSCs, COL2A1 and COL10A1 mRNA and protein expression was evident from day 7-
21 in chondrogenic differentiation (Figure 2.6D). Expression of COL1A1 and PPARγ was 
Figure 2.5: Chondrogenic differentiation is enhanced by stimulation of NF-κB/p65 activity. 
(A). ATDC5 was cultured for 2 hours in the absence or presence of LPS (0.1 ng/ml), TNFα (10 ng/ml) or Par-
thenolide (10 µM) and mRNA expression of the “Sox-trio”; Sox9, L-Sox5 and Sox6 was determined. Although 
Sox6 expression was generally low, similar responsivity to NF-κB activation or inhibition were obtained for L-
Sox5 and Sox6 expression, supporting the suggestion that Sox9 might function in early chondrogenic differentia-
tion in conjunction with L-Sox5 and Sox6.  (B). Col2a1 and Col10a1 gene expression data from Figure 2.4D. * = 
p < 0.05. 
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not upregulated, ruling out osteogenic or adipogenic differentiation from this multipotent 
cell source during chondrogenic induction (data not shown).  
In concordance with ATDC5, p65 translocated to the nucleus at one hour in hBMSC    
differentiation and nuclear p65 levels further sustained up to four hours (Figure 2.6A). 
Analyses showed that hBMSC chondrogenic differentiation of three independent isolates is 
accompanied by transient expression of COX-2 and IL-6 early in differentiation (Figure 
2.6B). Furthermore, as in ATDC5, induction of SOX9 expression in hBMSC                
differentiation was also bi-phasic: from one and two hours onward, as well as late (day 14-
28) in differentiation (Figure 2.6C). In agreement with reduced NF-κB/p65 activity, COX-
2, SOX9 and IL-6 expression levels decreased in the presence of TLCK (Figure 2.6E; grey 
bars in graph). Conversely, brief stimulation of NF-κB/p65 activity by low LPS            
concentrations during the first 24 hours only, enhanced NF-κB/p65-target gene expression, 
as well as early SOX9 expression (Figure 2.6E; black bars in graph). Coherent with the 
murine model, human chondroprogenitor cells clearly showed increased expression of 
COL2A1 at day 21 when exposed to LPS during the first 24 hours in differentiation 
(Figure 2.6F; lanes 2) and lower COL2A1 levels in the presence of TLCK (Figure 2.6F; 
lanes 3). Taken together, these data show that hBMSC endochondral differentiation also 
integrates a transient NF-κB/p65 activation during the early initiation of differentiation, 
ultimately contributing to the outcome of the chondrogenic cell fate.  
 
3.5 NF-κB/p65 signaling induces chondrogenic marker gene expression in mesenchymal 
progenitor cells without the addition of chondrogenic growth factors 
The progenitor cell intrinsic NF-κB/p65 activation occurs as a result of environmental  
differentiation conditions, but positively responds to NF-κB stimulating agents (LPS and 
TNFα) early in chondrogenic differentiation. We therefore tested whether an NF-κB/p65-
activating stimulus alone would be able to facilitate chondrogenic signaling in              
mesenchymal progenitors, without the addition of other differentiation factors like insulin 
or TGF-β3. To this end, ATDC5 proliferation medium was supplemented with only LPS 
(first 24 hours alone) and subsequently cells were cultured in proliferation medium for ten 
or 14 days. A brief stimulation with LPS induced NF-κB/p65 activation (data not shown) 
and, in contrast to the control condition, resulted in a transient Sox9 expression at two 
hours after LPS exposure (Figure 2.7A, lower left panel) and equal Sox9, Col2a1 and 
Col10a1 mRNA expression levels (at day ten and 14) as normal differentiation conditions 
do in ATDC5 (Figure 2.7A). However Col10a1 expression in the proliferation condition at 
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Figure 2.6: Transient NF-κB/p65 signaling during early chondrogenic differentiation of human bone marrow 
stem cells 
Human bone marrow stem cells from three individuals (hBMSC1/2/3) were differentiated into the chondrocyte 
lineage using monolayer culture.  (A). Nuclear (N) and total (T) fractions were isolated from 0, 1, 2, 4 hours sam-
ples. NF-κB was detected as p65, cytoplasmic marker: α-tubulin. (B). Expression of COX-2 and IL-6 mRNAs at 0
-24 hours in hBMSC differentiation. (C). Left; SOX9 mRNA expression during hBMSC differentiation, SOX9 
protein expression during 0-24 hours in hBMSC differentiation (right) (D). COL2A1 and COL10A1 mRNA and 
protein expression during hBMSC differentiation. (E). Left; SOX9 and COX-2 protein expression at 0, 2, 4 hours 
in differentiation in the presence of LPS (0.1 ng/ml) or TLCK (100 μM). Right; SOX9 and IL-6 mRNA expres-
sion at 4 hours in differentiation in the presence of LPS (black bars) or TLCK (grey bars). (F). COL2A1 protein 
expression in day 21-samples of differentiated hBMSCs. Lanes 1: control condition, Lanes 2: 0.1 ng/ml LPS (only 
first 24 hours) and lanes 3: 100 μM TLCK. * = p < 0.05. 
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day 14 appeared unexpectedly high as compared to the LPS and differentiation conditions. 
Briefly, findings were verified in hBMSCs. After 21 days culture in proliferation medium 
(without insulin and TGF-β3), hBMSCs expressed SOX9 very lowly and COL2A1 and 
COL10A1 were not expressed (Figure 2.8B), whereas brief stimulation with LPS (0.1 and 
0.01 ng/ml) during the first 24 hours only, resulted in robust expression of SOX9, 
COL2A1 and COL10A1 protein at 21 days (Figure 2.7B).  
To further establish the relevance of our findings in tissue involved in endochondral      
ossification, we adopted an ex vivo periosteal tissue differentiation model for               
chondrogenesis using chicken embryonal periosteum20.  Importantly, as a source for mes-
enchymal   progenitor cells, periosteal tissue is directly relevant for endochondral ossifica-
tion processes and fracture healing. Harvested periosteal tissue from the chicken tibia was    
cultured between agarose layers (chicken periosteum agarose culture: cPAC). After one 
week of culturing in proliferation medium chicken periosteal explants did not acquire any 
chondrogenic properties (Figure 2.7C; black control bars and Figure 2.7D; left micro-
graphs). In contrast, supplementation of the culture medium with LPS for the first 48 hours 
only, resulted in the formation of cartilaginous tissue after one week, as determined by 
upregulation of Col2a1, Col10a1, Sox9 and aggrecan mRNA expression (Figure 2.7C; 
second black bars), as well as positive Safranin O staining, immunohistochemical detec-
tion of Sox9 and Col2a1 as well as typical chondrocyte morphology (Figure 2.7D). For 
comparative purposes, same chondrogenic markers were measured in cPACs that were 
differentiated in standard differentiation medium (containing insulin and TGF-β3) (Figure 
2.7C; grey bars). These data indicate that in mesenchymal progenitor cells a short         
exogenous NF-κB/p65-activating stimulus may result in cellular signaling through chon-
drogenic pathways which can explain the expression of chondrocyte marker molecules. 
 
3.6 BMP-2 activates NF-κB/p65 in early ATDC5 chondrogenic differentiation 
LPS and TNFα were used as tools to activate NF-κB/p65. Exceptions left alone (e.g. TNFα 
in osteoarthritis (OA) and rheumatoid arthritis (RA)), these activators are not known to be 
present in the cartilaginous environment. We therefore asked whether growth factors may 
support the initiation of an early NF-κB/p65 activation in the way described herein. BMP’s 
are known to play crucial roles in early mesenchymal condensation by regulating Sox9 
expression28 and contributing to other phases of the endochondral ossification processes. 
Also, BMP-2 has been described to be able to activate NF-κB/p65 in chondrocytes29. As 
shown in Figure 2.8A, 30 ng/ml BMP-2 resulted in increased expression of Col2a1 and 
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Col10a1 in differentiating ATDC5 cells. To verify whether a similar early NF-κB/p65  
activation might involve this BMP-2 action, we analyzed p65 nuclear translocation. We 
found that p65 nuclear translocation at two hours in differentiation was more increased in 
the presence of BMP-2 as compared to control (Figure 2.8B). Increased and more pro-
longed expression of Sox9, COX-2 and iNOS in the first 24 hours of differentiation      
confirmed downstream NF-κB/p65-activated pathways (Figure 2.8C).  
To further establish a role for p65 in this process, ATDC5 cells were transfected with a 
p65 siRNA duplex or scrambled siRNA duplex and differentiated in the absence or      
presence of BMP-2 (30 ng/ml) (Figure 2.8D). Knockdown of p65 mRNA was confirmed at 
start and two hours in differentiation (left panel). Middle and right panels show Sox9 and 
COX-2 mRNA expression, respectively. As described above, Sox9 and COX-2 mRNA 
expression increased at two hours in differentiation and increased further with BMP-2 
stimulation (see also Figure 2.8C). The BMP-2-initiated increased Sox9 and COX-2 
mRNA upregulation is inhibited to equal levels as the differentiated control p65 knock-
down condition without BMP-2 supplementation, supporting a role for p65 in this mecha-
nism.  
Finally we addressed whether BMP-2 might exert its pro-chondrogenic action early in   
differentiation through the NF-κB/p65 induced early Sox9 expression. The early Sox9 
mRNA expression was targeted by a single Sox9 siRNA transfection (see also Figure 
2.3E) and differentiation was initiated in the presence of BMP-2 (first 24 hours alone). As 
Figure 2.7: NF-κB/p65 activation induces chondrocyte marker gene expression without the addition of chondro-
genic growth factors 
(A). Col2a1, Col10a1 and Sox9 mRNA expression at 2 hours (Sox9 only), 10 and 14 days in ATDC5 cells, cul-
tured in proliferation medium in the absence (“control”) or presence (first 24 hours) of LPS (black bars). Col2a1, 
Col10a1 and Sox9 mRNA expression of standard differentiated ATDC5 is shown for comparative purposes (grey 
bars; “differentiation control”). (B). SOX9, COL2A1 and COL10A1 protein expression in a representative 
hBMSC sample cultured for 21 days in proliferation medium with 0.1 or 0.01 ng/ml LPS (first 24 hours). (C). 
Col2a1, Col10a1, Sox9 and aggrecan mRNA expression in cPACs (chicken Periosteum Agarose Culture) cul-
tured in proliferation medium for 7 days in the absence or presence of LPS during the first 48 hours (black bars). 
Col2a1, Col10a1, Sox9 and aggrecan mRNA expression of cPACs differentiated in standard differentiation medi-
um (containing TGF-β3 and insulin, see also Materials and Methods) is shown for comparative purposes (grey 
bars). * = p < 0.05. (D). In similar samples from (C) sections (5 μm) from cPACs were stained by Safranin O/
Fast green (upper set), for Col2a1 (middle set) and Sox9 (lower set). For Safranin O and Col2a1 stainings: bars = 
200 µm for first and third column micrographs and 100 µm for second and fourth column of micrographs. For 
Sox9 staining, bars = 150 µm for first and third column of micrographs and 100 µm for second and fourth col-
umn of micrographs. 
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shown in Figure 2.8E, in the presence of BMP-2, Sox9 siRNA transfection resulted in an 
efficient knock-down of Sox9 mRNA and protein expression at two hours in differentia-
tion. The early knock-down of Sox9 under BMP-2 treatment at two hours in differentiation 
resulted in impaired Col2a1 expression at seven days into differentiation.  
Overall, these results suggest that BMP-2 action in the early chondrogenic phase of endo-
chondral ossification may, in part, be explained via the herein described early transient    
NF-κB/p65 activation and Sox9 expression. These findings may provide a possible in vivo 
context for the herein described NF-κB/p65 pathway. 
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4. Discussion 
 
We here report that chondrogenic differentiation of chondroprogenitor cells is, at least in 
part, determined by early activation of NF-κB/p65 which subsequently contributes to the 
initiation of chondrogenic differentiation by regulating the early expression of key      
chondrogenic factor Sox9.  
Inflammatory mediators play crucial roles in cartilage degenerative conditions such as RA 
and OA30-32. Most, if not all of these inflammatory mediators are regulated via activated 
NF-κB pathways. However, recent studies reported that in chondrocytes NF-κB/p65-target 
genes are not exclusively associated with cartilage degenerative conditions33. TNFα was 
recently described to regulate expression of BMP-2 via an NF-κB/p65 dependent mecha-
nism8,34,35. Involvement of NF-κB was reported during development of the growth plate8,10, 
as well as in preventing apoptosis of maturating chondrocytes via interaction with Nkx3.29. 
NF-κB/p65 has been reported to function as a transcription factor for Sox9 in mature chon-
drocytes11 and finally, Aung and colleagues provided evidence that OA chondrocytes   
excrete soluble factors that initiate chondrogenic differentiation of human mesenchymal 
stem cells36. Except for the last study, most of these previous investigations were limited 
by the use of maturated chondrocytes, thereby leaving the question at which chondrogenic 
stage an imperative nuclear NF-κB/p65 presence would be required for differentiation. As 
we made use of cellular differentiation models that initiate chondrogenic differentiation 
Figure 2.8: BMP-2 activates NF-κB/p65 in early ATDC5 chondrogenic differentiation 
(A). ATDC5 was differentiated for 14 days in the absence or presence of BMP-2 (30 ng/ml). Relative mRNA 
expression of Col2a1 and Col10a1 was determined. (B). Cells were differentiated in the absence (control) or 
presence of BMP-2 (30 ng/ml) and total (T) and nuclear (N) fractions were prepared at 2 hours in differentiation. 
NF-κB was detected as p65. (C). Cells were differentiated for 0-24 hours in the absence or presence of BMP-2 
and expression of Sox9 (left) and NF-κB-targets COX-2 (middle) and iNOS (right) was determined. (D). ATDC5 
cells were transfected with a p65 siRNA duplex or control siRNA duplex and differentiated in the absence or 
presence of BMP-2 for 2 hours. Knock-down of p65 mRNA was confirmed at 0 and 2 hours in differentiation 
(left). Middle and right graphs show Sox9 and COX-2 mRNA expression, respectively. (E). Left panel set: Sox9 
KD at mRNA and protein level at 2 hours in differentiation in cells transfected with scrambled (indicated as 
“Control”) siRNAs, scrambled siRNAs in the presence of BMP-2, or Sox9 siRNAs (indicated as “Sox9”) in the 
presence of BMP-2. Transfection was done the day prior to differentiation and BMP-2 treatment was for the first 
24 hours only. Right panel: Col2a1 mRNA expression was determined in same experiment at day 7 in differenti-
ation. * = p < 0.05. 
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from a progenitor stage onward, our experiments provided the possibility to address the 
role of NF-κB/p65 activity in a specific chondrogenic phase, while at the same time      
determining the consequences of NF-κB/p65 activity during subsequent later chondrogenic 
phases. We found that Sox9 induction during chondrogenic differentiation of   chondro-
progenitor cells is bi-phasic and is evident during the first hours of differentiation and  
induced for a second time later on in differentiation. The late Sox9 induction follows  
chondrocyte matrix expression and is thereby expected to transcriptionally regulate the 
induction of cartilage matrix genes such as Col2a1 and aggrecan15,16. In addition to late 
Sox9 expression, upon early chondrogenic differentiation NF-κB/p65 transiently          
translocates to the nucleus, thereby enabling NF-κB/p65-driven early Sox9 transcription. 
Although the function of the novel short Sox9 pulse during the early start of chondrogene-
sis remains to be elucidated, our data indicate that it might function in the context of the 
Sox-trio13,17 and is important in determining the chondrogenic outcome, possibly by    
priming the early differentiating cell for chondrogenic commitment by yet unknown 
(epigenetic) mechanisms.  
Next to transcriptional induction of Sox9, the early chondrogenesis-associated NF-κB/p65 
activation results in additional transient expression of inflammatory target genes, such as 
COX-2, iNOS, Il-6 and TNFα. Expression of these inflammatory NF-κB/p65 target genes 
may be an aspecific result of the transient activation of NF-κB/p65. However ample exper-
imental evidence supports a critical role for these inflammatory mediators in cellular fate 
determination in the context of the endochondral ossification during fracture healing, as 
the respective knock-out mice display a severely impaired fracture healing capacity6,37-46. 
Human mesenchymal stem cells (MSCs) have been reported to excrete several chondro-
genic growth factors (e.g. insulin-like growth factor 1 (IGF-1) and fibroblast growth factor 
2 (FGF-2)) upon inflammatory LPS or TNFα stimulation47,48 and our data (Figure 2.9) 
show that treatment of differentiating ATDC5 cells with TNFα, for the first 24 hours only, 
also resulted in significantly higher expression of chondrogenic growth factors (IGF-1, 
TGF-β1, FGF-3, BMP-2, BMP-4) from seven days on in differentiation. It is therefore 
tempting to speculate that the expression of NF-κB/p65-targets during the onset of      
chondrogenic differentiation may have an additional function in the paracrine signaling for 
later stages during endochondral ossification. Also, despite the degenerative environment, 
the endochondral formation of cartilaginous osteophytes is a hall mark of OA49. An aspect 
of their formation may also be found in NF-κB/p65-driven chondrogenic differentiation of 
synovial or periosteal progenitors, initiated from the degenerating OA cartilage. As OA- 
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like conditions are absent in the developing growth plate, expression of NF-κB/p65-targets 
and growth factors by differentiating growth plate chondrocytes may maintain growth 
plate chondrogenic differentiation of local resting zone progenitor cells in a similar      
paracrine fashion. Although in early chondrogenic differentiation NF-κB/p65 is clearly 
activated during the first hours in the differentiation process, we do not yet fully under-
stand how the chondrogenic culture environment triggers this inflammatory response.  
Several chondrogenic growth factors are associated with NF-κB/p65 signaling. It is known 
that TGF-β-receptor (TGFR) and IGF-receptor (IGFR) signaling activate NF-κB and     
expression of chondrogenic markers in chondrocytes50,51. Key extracellular signaling    
molecules triggering chondrogenesis in vitro are insulin and TGF-β. Hence, insulin/IGFR- 
and TGF-β/TGFR-activation likely initiate signaling through NF-κB/p65, resulting in    
initiation of early transient Sox9 induction. Our observation that stimulation of NF-κB 
activity by LPS or TNFα under chondrogenic conditions or even under proliferation     
Figure 2.9: Connection between early NF-κB/p65 activation and growth factor expression in ATDC5 chondro-
genic differentiation. 
To investigate the connection between the early NF-κB/p65 activation and expression of chondrogenic differenti-
ation markers (see Figure 2.3D) at day 10 and 14, we determined the expression of multiple important chondro-
genic growth factors. Addition of NF-κB-activator TNFα (10ng/ml) for the first 24 hours resulted in increased 
expression of the chondrogenic growth factors at day 7 and/or 10 in differentiation (except for FGF3), consistent 
with the data from Figure 2.3. 
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conditions (in the absence of standard chondrogenic stimuli) enhances or triggers Sox9 
expression and eventually contributes to the chondrogenic potential, is well in line with 
this notion. Although mesenchymal progenitor cells express TNFR and TLR-2/452,53, the 
use of LPS and TNFα to activate NF-ĸB might be contradictory in the context of chondro-
genic differentiation. However, these agents were solely used as NF-ĸB-activating tools in 
the herein described work. More relevant to the in vivo context of early chondrogenic   
differentiation and endochondral ossification BMP-2 has previously been described to be 
able to translocate NF-ĸB/p65 to the nucleus29 and to be involved in Sox9 regulation    
during early mesenchymal condensation28. These previous findings may provide an in vivo 
context in which the herein described BMP-2 mediated NF-ĸB/p65 driven early Sox9 ex-
pression may function. In addition, other studies8,10 have shown that BMP-2 expression 
itself can be regulated by NF-ĸB/p65 during late chondrogenesis in maturated             
chondrocytes, thereby contributing to longitudinal bone growth and preventing apoptosis 
of these chondrocytes. Therefore, our and previous findings indicate that BMP-2 action 
and regulation might depend on the chondrogenic differentiation status34. 
In conclusion, our data indicate that initiation of chondrogenic differentiation during endo-
chondral development, at least in part, depends on an early activation of NF-κB/p65. The 
early NF-κB/p65 activation evokes a novel early and transient expression of Sox9, which, 
together with a late Sox9 induction, contributes to the outcome of the chondrogenic      
differentiation program of mesenchymal progenitor cells. Our findings complement      
previously reported NF-κB/p65 involvement in chondrogenic differentiation and provide 
novel insight into the origin, timing and dynamics of NF-κB/p65-induced gene expression 
in early chondrogenic differentiation. These data add to an emerging and growing concept7 
where differentiating chondrocytes and endochondral development are regulated by        
NF-κB/p65-mediated processes and may be used as new leads to modulate chondrogenic 
differentiation in cartilage and bone regenerative medicine approaches such as the ACT 
technique54 and the in vivo bioreactor technique55,56. 
 
 
 
 
Chapter 2 
68 
5. Acknowledgements 
 
This work is financially supported the Dutch Arthritis Association (grant LLP14) and the 
Dutch Stichting Annafonds|NOREF (grants 07/07 and 08/42). LPS and surplus mice were 
provided by Dr. M. Poeze and Drs. N. Wijnands (Dept. of General Surgery, MUMC, the 
Netherlands) and Parthenolide by Dr. R. Langen (Dept. of Pulmonology, MUMC, the 
Netherlands). P.T. Oostveen (Dept. of Orthopaedic Surgery, MUMC, the Netherlands) for 
performing cPAC experiments. Helpful suggestions about the cPAC model were provided 
by Dr. C.C. van Donkelaar (Dept. of Orthopaedic Biomechanics, Eindhoven University of 
Technology, Eindhoven, the Netherlands). 
 
 
 
6. Supplemental Figures 
 
 
Figure S2.1: NF-κB/p65 nuclear translocation during early ATDC5 differentiation. 
In addition to Figure 2.1A, nuclear translocation of p65 was besides at 0, 0.5, 1 and 2 hours in differentiation 
also determined at 4, 8, 12 and 24 hours in differentiation of ATDC5 cells. Total extract (T) and nuclear (N) 
fractions were isolated. Cytoplasmic marker: α-tubulin. NF-κB/p65 is transiently activated at 0.5 – 4 hours in 
differentiation.  
NF-κB/p65 Facilitates Chondrogenic Differentiation 
69 
7. References 
 
1 Kronenberg, H. M. Developmental regulation of the growth plate. Nature 423, 
332-336 (2003). 
2 Mackie, E. J., Ahmed, Y. A., Tatarczuch, L., Chen, K. S. & Mirams, M. Endo-
chondral ossification: how cartilage is converted into bone in the developing skel-
eton. Int J Biochem Cell Biol 40, 46-62 (2008). 
3 Zuscik, M. J., Hilton, M. J., Zhang, X., Chen, D. & O'Keefe, R. J. Regulation of 
chondrogenesis and chondrocyte differentiation by stress. J Clin Invest 118, 429-
438 (2008). 
4 Grundnes, O. & Reikeras, O. The importance of the hematoma for fracture heal-
ing in rats. Acta Orthop Scand 64, 340-342 (1993). 
5 Einhorn, T. A., Majeska, R. J., Rush, E. B., Levine, P. M. & Horowitz, M. C. The 
expression of cytokine activity by fracture callus. J Bone Miner Res 10, 1272-
1281, doi:10.1002/jbmr.5650100818 (1995). 
6 Mountziaris, P. M. & Mikos, A. G. Modulation of the Inflammatory Response for 
Enhanced Bone Tissue Regeneration. Tissue Eng Part B Rev (2008). 
7 Novack, D. V. Role of NF-kappaB in the skeleton. Cell Res 21, 169-182, 
doi:cr2010159 [pii] 
10.1038/cr.2010.159. 
8 Feng, J. Q. et al. NF-kappaB specifically activates BMP-2 gene expression in 
growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol 
Chem 278, 29130-29135 (2003). 
9 Park, M. et al. Constitutive RelA activation mediated by Nkx3.2 controls chon-
drocyte viability. Nat Cell Biol 9, 287-298 (2007). 
10 Wu, S., Flint, J. K., Rezvani, G. & De Luca, F. Nuclear factor-kappaB p65 facili-
tates longitudinal bone growth by inducing growth plate chondrocyte proliferation 
and differentiation and by preventing apoptosis. J Biol Chem 282, 33698-33706 
(2007). 
11 Ushita, M. et al. Transcriptional induction of SOX9 by NF-kappaB family mem-
ber RelA in chondrogenic cells. Osteoarthritis and cartilage / OARS, Osteoarthri-
tis Research Society 17, 1065-1075, doi:10.1016/j.joca.2009.02.003 (2009). 
12 Akiyama, H., Chaboissier, M. C., Martin, J. F., Schedl, A. & de Crombrugghe, B. 
The transcription factor Sox9 has essential roles in successive steps of the chon-
drocyte differentiation pathway and is required for expression of Sox5 and Sox6. 
Genes Dev 16, 2813-2828 (2002). 
13 Lefebvre, V., Behringer, R. R. & de Crombrugghe, B. L-Sox5, Sox6 and Sox9 
control essential steps of the chondrocyte differentiation pathway. Osteoarthritis 
Cartilage 9 Suppl A, S69-75 (2001). 
14 Lefebvre, V. & de Crombrugghe, B. Toward understanding SOX9 function in 
chondrocyte differentiation. Matrix Biol 16, 529-540 (1998). 
15 Han, Y. & Lefebvre, V. L-Sox5 and Sox6 drive expression of the aggrecan gene 
in cartilage by securing binding of Sox9 to a far-upstream enhancer. Mol Cell Biol 
28, 4999-5013, doi:MCB.00695-08 [pii] 
10.1128/MCB.00695-08 (2008). 
16 Lefebvre, V., Huang, W., Harley, V. R., Goodfellow, P. N. & de Crombrugghe, 
B. SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro 
alpha1(II) collagen gene. Mol Cell Biol 17, 2336-2346 (1997). 
Chapter 2 
70 
17 Lefebvre, V., Li, P. & de Crombrugghe, B. A new long form of Sox5 (L-Sox5), 
Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the 
type II collagen gene. Embo J 17, 5718-5733, doi:10.1093/emboj/17.19.5718 
(1998). 
18 Atsumi, T., Miwa, Y., Kimata, K. & Ikawa, Y. A chondrogenic cell line derived 
from a differentiating culture of AT805 teratocarcinoma cells. Cell Differ Dev 30, 
109-116 (1990). 
19 Schallmoser, K. et al. Rapid large-scale expansion of functional mesenchymal 
stem cells from unmanipulated bone marrow without animal serum. Tissue engi-
neering 14, 185-196 (2008). 
20 Kock, L. M. et al. Tuning the differentiation of periosteum-derived cartilage us-
ing biochemical and mechanical stimulations. Osteoarthritis Cartilage 18, 1528-
1535, doi:S1063-4584(10)00298-0 [pii] 
10.1016/j.joca.2010.09.001 (2010). 
21 O'Driscoll, S. W., Recklies, A. D. & Poole, A. R. Chondrogenesis in periosteal 
explants. An organ culture model for in vitro study. J Bone Joint Surg Am 76, 
1042-1051 (1994). 
22 Chen, L., Fink, T., Zhang, X. Y., Ebbesen, P. & Zachar, V. Quantitative transcrip-
tional profiling of ATDC5 mouse progenitor cells during chondrogenesis. Differ-
entiation 73, 350-363 (2005). 
23 Hayden, M. S. & Ghosh, S. Shared principles in NF-kappaB signaling. Cell 132, 
344-362 (2008). 
24 Abad, V. et al. The role of the resting zone in growth plate chondrogenesis. Endo-
crinology 143, 1851-1857 (2002). 
25 Huang, W., Zhou, X., Lefebvre, V. & de Crombrugghe, B. Phosphorylation of 
SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to 
transactivate a Col2a1 chondrocyte-specific enhancer. Mol Cell Biol 20, 4149-
4158 (2000). 
26 Quandt, K., Frech, K., Karas, H., Wingender, E. & Werner, T. MatInd and MatIn-
spector: new fast and versatile tools for detection of consensus matches in nucleo-
tide sequence data. Nucleic Acids Res 23, 4878-4884, doi:5s0483 [pii] (1995). 
27 Ushita, M. et al. Transcriptional induction of SOX9 by NF-kappaB family mem-
ber RelA in chondrogenic cells. Osteoarthritis Cartilage (2009). 
28 Yoon, B. S. & Lyons, K. M. Multiple functions of BMPs in chondrogenesis. 
Journal of cellular biochemistry 93, 93-103 (2004). 
29 Sugimori, K. et al. BMP-2 prevents apoptosis of the N1511 chondrocytic cell line 
through PI3K/Akt-mediated NF-kappaB activation. J Bone Miner Metab 23, 411-
419, doi:10.1007/s00774-005-0622-7 (2005). 
30 Glasson, S. S. et al. Deletion of active ADAMTS5 prevents cartilage degradation 
in a murine model of osteoarthritis. Nature 434, 644-648, doi:nature03369 [pii] 
10.1038/nature03369 (2005). 
31 Romas, E., Gillespie, M. T. & Martin, T. J. Involvement of receptor activator of 
NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheuma-
toid arthritis. Bone 30, 340-346, doi:S8756328201006822 [pii] (2002). 
32 Wehling, N. et al. Interleukin-1beta and tumor necrosis factor alpha inhibit chon-
drogenesis by human mesenchymal stem cells through NF-kappaB-dependent 
pathways. Arthritis Rheum 60, 801-812 (2009). 
33 Ulivi, V., Giannoni, P., Gentili, C., Cancedda, R. & Descalzi, F. p38/NF-kB-
dependent expression of COX-2 during differentiation and inflammatory response 
of chondrocytes. Journal of cellular biochemistry 104, 1393-1406 (2008). 
34 Fukui, N. et al. Pro-inflammatory cytokine tumor necrosis factor-alpha induces 
NF-κB/p65 Facilitates Chondrogenic Differentiation 
71 
bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and tran-
scriptional up-regulation. J Biol Chem 281, 27229-27241 (2006). 
35 Fukui, N., Zhu, Y., Maloney, W. J., Clohisy, J. & Sandell, L. J. Stimulation of 
BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal 
and osteoarthritic chondrocytes. J Bone Joint Surg Am 85-A Suppl 3, 59-66 
(2003). 
36 Aung, A., Gupta, G., Majid, G. & Varghese, S. Osteoarthritic chondrocyte-
secreted morphogens induce chondrogenic differentiation of human mesenchymal 
stem cells. Arthritis Rheum 63, 148-158, doi:10.1002/art.30086 (2011). 
37 Baldik, Y. et al. Deletion of iNOS gene impairs mouse fracture healing. Bone 37, 
32-36 (2005). 
38 Diwan, A. D., Wang, M. X., Jang, D., Zhu, W. & Murrell, G. A. Nitric oxide 
modulates fracture healing. J Bone Miner Res 15, 342-351 (2000). 
39 Franchimont, N., Durant, D. & Canalis, E. Interleukin-6 and its soluble receptor 
regulate the expression of insulin-like growth factor binding protein-5 in osteo-
blast cultures. Endocrinology 138, 3380-3386 (1997). 
40 Gerstenfeld, L. C. et al. Impaired intramembranous bone formation during bone 
repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Or-
gans 169, 285-294 (2001). 
41 Gerstenfeld, L. C. et al. Impaired fracture healing in the absence of TNF-alpha 
signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone 
Miner Res 18, 1584-1592 (2003). 
42 Naik, A. A. et al. Reduced COX-2 expression in aged mice is associated with 
impaired fracture healing. J Bone Miner Res 24, 251-264 (2009). 
43 Rundle, C. H. et al. Microarray analysis of gene expression during the inflamma-
tion and endochondral bone formation stages of rat femur fracture repair. Bone 
38, 521-529 (2006). 
44 Simon, A. M. & O'Connor, J. P. Dose and time-dependent effects of cyclooxy-
genase-2 inhibition on fracture-healing. J Bone Joint Surg Am 89, 500-511 
(2007). 
45 Zhang, X. et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation 
into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 
109, 1405-1415 (2002). 
46 Zhu, W., Murrell, G. A., Lin, J., Gardiner, E. M. & Diwan, A. D. Localization of 
nitric oxide synthases during fracture healing. J Bone Miner Res 17, 1470-1477 
(2002). 
47 Crisostomo, P. R. et al. Human mesenchymal stem cells stimulated by TNF-
alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-
dependent mechanism. American journal of physiology 294, C675-682 (2008). 
48 Wang, M., Crisostomo, P. R., Herring, C., Meldrum, K. K. & Meldrum, D. R. 
Human progenitor cells from bone marrow or adipose tissue produce VEGF, 
HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. 
American journal of physiology 291, R880-884 (2006). 
49 van der Kraan, P. M. & van den Berg, W. B. Osteophytes: relevance and biology. 
Osteoarthritis Cartilage 15, 237-244, doi:S1063-4584(06)00327-X [pii] 
10.1016/j.joca.2006.11.006 (2007). 
50 Grau, A. M., Datta, P. K., Zi, J., Halder, S. K. & Beauchamp, R. D. Role of Smad 
proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. Cell 
Signal 18, 1041-1050, doi:S0898-6568(05)00235-4 [pii] 
10.1016/j.cellsig.2005.08.021 (2006). 
51 Wu, S., Fadoju, D., Rezvani, G. & De Luca, F. Stimulatory effects of insulin-like 
Chapter 2 
72 
growth factor-I on growth plate chondrogenesis are mediated by nuclear factor-
kappaB p65. J Biol Chem 283, 34037-34044 (2008). 
52 Croitoru-Lamoury, J., Lamoury, F. M., Zaunders, J. J., Veas, L. A. & Brew, B. J. 
Human mesenchymal stem cells constitutively express chemokines and chemo-
kine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J 
Interferon Cytokine Res 27, 53-64, doi:10.1089/jir.2007.0037 (2007). 
53 Pevsner-Fischer, M. et al. Toll-like receptors and their ligands control mesenchy-
mal stem cell functions. Blood 109, 1422-1432, doi:10.1182/blood-2006-06-
028704 (2007). 
54 Brittberg, M. et al. Treatment of deep cartilage defects in the knee with autolo-
gous chondrocyte transplantation. N Engl J Med 331, 889-895 (1994). 
55 Emans, P. J. et al. Autologous engineering of cartilage. Proc Natl Acad Sci U S A 
107, 3418-3423, doi:0907774107 [pii]10.1073/pnas.0907774107 (2010). 
56 Stevens, M. M. et al. In vivo engineering of organs: the bone bioreactor. Proc 
Natl Acad Sci U S A 102, 11450-11455 (2005). 
 
 
 
 
  
Chapter 3  
Osmolarity Determines the in vitro Chondrogenic Differentiation 
Capacity of Progenitor Cells via Nuclear Factor of Activated  
T-cells 5 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
Osmolarity Determines the in vitro Chondrogenic Differentiation Capacity of Progenitor Cells via Nuclear Fac-
tor of Activated T-cells 5 
Marjolein M.J. Caron1, Anna E. van der Windt2, Pieter J.Emans1, Lodewijk W. van Rhijn1, Holger Jahr2# and Tim 
J. M. Welting1#  
1Department of Orthopaedic Surgery, Maastricht University Medical Center, Maastricht, the Netherlands 
2Department of Orthopaedics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands 
#Contributed equally 
Bone. (2013); 53(1): p.94-102 
Chapter 3 
74 
Abstract 
 
Introduction: Previous studies have shown that human articular chondrocytes in vitro are 
osmolarity-responsive and increase matrix synthesis under cartilage-specific physiological 
osmolarity. The effects of increased osmolarity on chondrogenesis of progenitor cells in 
vitro are largely unknown. We therefore aimed to elucidate whether hyperosmolarity    
facilitates their chondrogenic differentiation and whether Nfat5 is involved. 
Methodology: ATDC5 cells and human bone marrow stem cells (hBMSCs) were differen-
tiated in the chondrogenic lineage in control and increased osmolarity conditions.      
Chondrogenic outcome was measured by gene- and protein expression analysis. RNAi was 
used to determine the role of Nfat5 in chondrogenic differentiation under normal and    
increased osmolarity.  
Results: Increasing the osmolarity of differentiation medium with 100 mOsm resulted in 
significantly increased chondrogenic marker expression (Col2a1, Col10a1, Acan, Sox9, 
Runx2 and GAGs) during chondrogenic differentiation of the two chondroprogenitors, 
ATDC5 and hBMSCs. Nfat5 knockdown under both control and increased osmolarity  
affected chondrogenic differentiation and suppressed the osmolarity-induced chondrogenic 
induction. Knockdown of Nfat5 in early differentiation significantly decreased early Sox9 
expression, whereas knockdown of Sox9 in early differentiation did not affect early Nfat5 
expression.   
Conclusions: Increasing the osmolarity of chondrogenic culture media by 100 mOsm   
significantly increased chondrogenic gene expression during the course of chondrogenic 
differentiation of progenitor cells. Nfat5 may be involved in regulating chondrogenic   
differentiation of these cells under both normal and increased osmolarities and might regu-
late chondrogenic differentiation through influencing early Sox9 expression.     
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1. Introduction  
Chondrogenic differentiation of progenitor cells plays an essential role during endochon-
dral ossification for skeletal growth and bone fracture healing1,2. Moreover, progenitor cell
-based cartilage regeneration is a rapidly evolving field and methodologies promoting 
chondrogenic differentiation of mesenchymal progenitor and stem cells to chondrocytes 
are of interest to improve cartilage and endochondral bone regenerative medicine          
approaches. 
Chondrogenic differentiation during endochondral ossification is a multi-step developmen-
tal process during which mesenchymal progenitor cells condensate, differentiate into     
extracellular matrix (ECM) producing chondrocytes and ultimately terminally differentiate 
into hypertrophic chondrocytes1,3. This process is accompanied by a stage-dependent    
expression of chondrogenic makers: while for example Sox9 (SRY (sex determining    
region Y)-box 9) is a primary determinant of differentiation from early stages onwards 4,5, 
its transcriptional targets collagen type II (Col2a1) and aggrecan (Acan) are prominently 
expressed by more mature, ECM producing chondrocytes. Collagen type X (Col10a1) and 
its main transcription factor Runx2 (Runt-related transcription factor 2) are specifically 
expressed by hypertrophic differentiating chondrocytes4,5.  
The large amount of ECM produced by chondrocytes is mainly composed of proteoglycans 
(PG; like aggrecan) which are entangled in a network of collagens (mainly Col2a1) and 
further contains a lot of matrix-retained water6. The glycosaminoglycan (GAG) side chains 
of the PGs are sulphated and responsible for a high fixed negative charge density, which 
attracts mobile cations and water from the ECM-environment7,8. This, together with the 
quality of the collagen network, determines the osmolarity of the extracellular fluid and 
provides strength and flexibility to the tissue. The extracellular osmolarity of healthy    
articular cartilage ranges between 350 and 480 mOsm and is thus markedly higher than 
that of standard culture medium9,10, which ranges around plasma levels (280 mOsm)11,12.  
Several studies have shown that articular chondrocytes in vitro are osmolarity-responsive 
and increase their ECM synthesis under chondrocyte-physiological osmolarity10,13-15. The 
nuclear factor of activated T-cells 5 (Nfat5/TonEBP) plays an important role in this      
response14. Nfat5 is a member of the Rel family of transcription factors16 and mediates 
transcriptional activation of ion transporters like the sodium/myo-inositol transporter    
encoded by Slc5a317,18 and calcium binding proteins like S100a419,20 upon hypertonic 
stress in several cell types, including human articular chondrocytes14. Collectively, the 
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Nfat5-activated transporters exchange intracellular ions for compatible osmolytes and 
thereby regulate intracellular ionic strength and cell volume upon hypertonic stress21. 
However, a growing body of evidence indicates that Nfat5 can also be regulated            
independently of osmolarity22 and has diverse osmolarity-independent transcriptional   
functions in cell proliferation/survival23 , carcinogenesis24 and many others. To the best of 
our knowledge, no literature is available describing the effects of increased osmolarity on 
chondrogenic differentiation of progenitor cells in vitro. In addition, the expression and a 
potential (osmolarity-independent) function of Nfat5 during chondrogenic differentiation 
remains elusive. We therefore hypothesized that Nfat5 is involved in in vitro chondrogenic 
differentiation of progenitor cells during endochondral ossification and that the             
differentiation process can be enhanced by increasing the osmolarity of the culture medium 
possibly via an Nfat5 dependent mechanism.  
In the present study we used ATDC5 cells and human bone marrow stem cells (hBMSCs) 
as in vitro models for chondrogenic differentiation and provide evidence that Nfat5      
expression is indeed regulated during chondrogenic differentiation independently of osmo-
larity status, but also responds to increased osmolarity during chondrogenic differentiation. 
Furthermore, we show that increased osmolarity improves chondrogenic differentiation of 
progenitor cells in vitro and that, at least in part, this is regulated via Nfat5-mediated    
transcriptional regulation of Sox9.  
 
2. Materials and Methods 
 
2.1 ATDC5 cell culture 
ATDC5 cells were cultured in proliferation medium under a humidified atmosphere at 
37ºC, 5% CO2. Proliferation medium consisted of DMEM/F12 (Invitrogen, Carlsbad, CA, 
USA), 5% FCS (PAA, Pasching, Austria), 1% antibiotic/antimycotic (mixture of 10,000 U/
ml penicillin, 10,000 µg/ml streptomycin and 25 µg/ml amphotericin B; Invitrogen) and 
1% NEAA (non-essential amino acids; Invitrogen) and was changed every two days.    
Differentiation medium comprised proliferation medium supplemented with 10 µg/ml  
insulin (Sigma, St. Louis, MO, USA), 10 µg/ml transferrin (Roche Applied Science,     
Indianapolis, IN, USA) and 30 nM sodium selenite (Sigma, St. Louis, MO, USA). Cells 
were plated at approximately 6400 cells/cm2 in cell culture dishes, allowed to adhere over-
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night and the following day chondrogenesis was initiated by changing the proliferation 
medium to differentiation medium. Differentiation medium was changed every two days 
(day 0-10) and daily (from day 10 on). The osmolarity of the ATDC5 differentiation    
medium was determined to 310±5 mOsm using an Osmomat 030 (Gonotec GmbH, Ger-
many). The osmolarity of this medium was increased with 100 or 200 mOsm, respectively, 
by adding sterile NaCl from day 0 in differentiation. For RNAi-experiments an Nfat5 siR-
NA-duplex (sense: 5’-CCAGUUCCUACAAUGAUAACACU-3’, antisense: 5’-AGUGUU 
AUCAUUGUAGGAACUGG-3’), a Sox9 siRNA duplex (sense: 5’- GACUCACAUCU-
CUCCUAAUTT-3’, anti-sense: 5’- AUUAGGAGAGAUGUGAGUCTT-3’) and a scram-
bled siRNA-duplex (indicated by “Mock”) were used (Eurogentec). ATDC5 cells were 
seeded at approximately 25,000 cells/cm2 and transfection with siRNAs (30 nM) was   
performed using ICAfectin 442 (Eurogentec) according to manufacturers’ protocol. 
Knockdown was allowed for 1 day prior to the initiation of chondrogenic differentiation 
and knockdown for longer timeframes was accomplished by retransfection of the          
respective siRNA duplex.  
 
2.2 hBMSC isolation and culture 
Human bone marrow mesenchymal stem cells were obtained from iliac crest bone marrow 
aspirate from young, genetically healthy individuals (Medical ethical committee MUMC 
approval 08-4-056). BMSCs were isolated using Ficoll-Paque PLUS (Amersham Pharma-
cia, Diegem, Belgium) and plated on culture plates. Unbound cells were removed after 48 
hours, and bound fraction was expanded in culture medium to five passages under a     
humidified atmosphere at 37ºC, 5% CO2. Culture medium consisted of DMEM high     
glucose (Invitrogen), 10% FCS (PAA), 1% antibiotic/antimycotic and 1% NEAA. Chon-
drogenesis was performed in monolayer by plating the cells at approximately 30,000 cells/
cm2 one day prior to initiating chondrogenesis with differentiation medium (proliferation 
medium supplemented with 1% ITS (Invitrogen), 50 mg/ml L-ascorbic acid-2-phosphate 
(Sigma) and 1 ng/ml TGFβ3 (R&D))25. The osmolarity of the differentiation medium was 
determined using an Osmomat 030 (Gonotec GmbH, Germany) and was measured to be 
285±5 mOsm. When indicated, osmolarity of the differentiation medium was increased 
with 100 mOsm by adding sterile NaCl from day 0 in differentiation. Throughout the 
hBMSC differentiation, medium was changed every two days. 
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2.3 HAC isolation and culture 
Chondrocytes were obtained from the unaffected regions of osteoarthritic (OA) cartilage 
from total knee arthroplasty (MEC approval 08-4-028). Cartilage was separated from the 
subchondral bone and cut into small pieces using a sterile surgical blade. Cartilage pieces 
were digested overnight at 37°C in collagenase type II solution (300 U/ml in HEPES buff-
ered DMEM/F12 (Invitrogen, Carlsbad, CA, USA) supplemented with antibiotics) under 
continuous agitation. The preparation was rinsed with 0.9% NaCl over a 70 µm cell strain-
er and plated in culture flasks. Cells were cultured in a humidified atmosphere at 37ºC, 5% 
CO2 and after reaching confluency the cells were continuously passaged 1:2 until passage 
5. Culture medium consisted of DMEM/F12 (Invitrogen), 10% FCS (PAA; Pasching,  
Austria), 1% antibiotic/antimycotic (Invitrogen) and 1% non-essential amino acids 
(NEAA; Invitrogen). Chondrogenic redifferentiation was performed with passage five cells 
from six individuals and each isolate was redifferentiated in monolayer culture. The cells 
were plated 1 day prior to start of differentiation at a density close to confluency (30,000 
cells/cm2) to mimic the high cell density known from 3D cultures. Chondrogenic differen-
tiation was initiated by changing to differentiation medium (DMEM/F12, 1% antibiotic/
antimycotic and 1% NEAA supplemented with 1% ITS (insulin-transferrin-sodium sele-
nite media supplement, Invitrogen), 1% L-ascorbic acid-2-phosphate (Sigma Aldrich, St. 
Louis, MO, USA) and 10 ng/ml TGF-β3 (R&D, Minneapolis, MN, USA)).  Differentiation 
medium was changed every two days. Cells were harvested for RNA and protein analysis 
at day 7 in redifferentiation (see below). 
 
2.4 RT-qPCR 
For RNA isolation, cells were washed 3 times with 0.9% NaCl w/v and disrupted with 500 
µl Trizol (Invitrogen). RNA isolation, RNA quantification by UV-spectrometry 
(Nanodrop, Thermo Scientific), and cDNA synthesis were performed as described        
before26,27.  Real time quantitative PCR (RT-qPCR) was performed using Mesagreen 
qPCR mastermix plus for SYBR® Green (Eurogentec, Seraing, Belgium). An Applied 
Biosystems ABI PRISM 7700 Sequence Detection System was used for amplification  
using the following protocol: initial denaturation at 95ºC for 10 minutes, followed by 40   
cycles of DNA amplification (denaturing for 15 seconds at 95ºC and annealing for 1     
minute at 60ºC) followed by a dissociation curve. Data were analysed using the standard 
curve method, mRNA expression was normalized to a reference gene (β-actin for ATDC5 
and 28S rRNA for hBMSCs) and gene expression was calculated as fold change as com-
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pared to day 0 (t=0 in graphs). Primer sequences are depicted in Table 3.1.  
 
Table 3.1. Primer sequences for RTqPCR 
 
The 5’ to 3’ forward and reverse oligonucleotide sequences used for RT-qPCR are listed in the Table. 
 
2.5 Immunoblotting 
Cells were washed three times with 0.9% NaCl and lysed in RIPA buffer (150 mM NaCl, 
1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5.0 mM EDTA 
pH 8.0, 0.5 mM dithiothreitol and 1 mM phenylmethylsulfonylfluoride). Extracts were 
sonicated on ice using the Soniprep 150 (MSE, London, UK) at amplitude 10 for 14 cycles 
(1 second sonication and 1 second pause). Insoluble material was removed by                
centrifugation (13.000 x g, 4ºC). Protein concentration was determined using the BCA 
protein assay (Sigma). Polypeptides were separated by SDS-PAGE (samples were equally 
loaded) and subsequently transferred to nitrocellulose membranes by electroblotting.    
Primary antibodies for immunodetection were polyclonal goat anti-Col2a1 (Southern    
Biotech, Birmingham, AL, USA), polyclonal goat anti-Col1a1 (Southern Biotech,        
Birmingham, AL, USA), polyclonal rabbit anti-Col10a1 (Calbiochem, Darmstadt, Germa-
ny), polyclonal rabbit anti-Sox9 (Abcam), mouse monoclonal anti-α-Tubulin (Sigma, Saint 
Louis, MO, USA), polyclonal rabbit anti-Gapdh (Cell Signaling) and polyclonal rabbit anti
-Nfat516. Bound primary antibodies were detected with rabbit anti-goat, swine anti-rabbit 
or rabbit anti-mouse immunoglobulins conjugated with horseradish peroxidase 
(DakoCytomation, Glostrup, Denmark) and visualized by enhanced chemiluminescence 
Oligo sets mouse Forward Reverse 
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCC-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
Col10a1 ‘5-CATGCCTGATGGCTTCATAAA-3’ ‘5-AAGCAGACACGGGCATACCT-3’ 
Runx2 ‘5-CGATGAAGACCCCAACCCTAA-3’ ‘5-ACTGGTAATGGCATCAAGGGATA-3’ 
Sox9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-TACTTGTAGTCCGGGTGGTCTTTC-3’ 
Acan ‘5-CATGAGAGAGGCGAATGGAA-3 ‘5-TGATCTCGTAGCGATCTTTCTTCT-3’ 
Nfat5 ‘5-GGGTCAAACGACGAGATTGTG-3 ‘5-TTGTCCGTGGTAAGCTGAGAA-3’ 
Scl5a3 ‘5-CACTTCTGTCATTGGAGCGCT-3’ ‘5-ATGGCAATGTCTGCTGTGTCC-3’ 
S100a4 ‘5-GTCCACCTTCCACAAGTACTCG-3’ ‘5-TCATCTGTCCTTTTCCCCAAG-3’ 
β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
Oligo sets human Forward Reverse 
COL2A1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
COL10A1 ‘5-ATGATGAATACACCAAAGGCTACCT-3’ ‘5-ACGCACACCTGGTCATTTTCTG-3’ 
RUNX2 ‘5-TGATGACACTGCCACCTCTTGA-3’ ‘5-GCACCTGCCTGGCTCTTCT-3’ 
SOX9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-CGCTTCTCGCTCTCGTTCAG-3’ 
ACAN ‘5-GCAGCTGGGCGTTGTCA-3’ ‘5-TGAGTACAGGAGGCTTGAGGACT-3’ 
NFAT5 ‘5-GGGTCAAACGACGAGATTGTG-3’ ‘5-TTGTCCGTGGTAAGCTGAGAA-3’ 
28S rRNA ‘5-GCCATGGTAATCCTGCTCAGTAC-3’ ‘5-GCTCCTCAGCCAAGCACATAC-3’ 
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(ECL). ECL signals were quantified using ImageJ 1.46f software, and relative differences, 
corrected for background and housekeeper, were determined as compared to control condi-
tions. 
 
2.6 Cell proliferation 
Cell proliferation was assessed by crystal-violet (Sigma, Saint Louis, MO, USA) staining. 
Cells were washed two times with 0.9% NaCl and subsequently fixed with 4%               
paraformaldehyde in phosphate buffered saline for 10 minutes at room temperature. Fixed 
cells were washed 6 times with water and air dried for storage. Cells were incubated with 
0.1% crystal-violet for 30 minutes at room temperature. Cells were washed six times with 
water to remove excess crystal-violet and allowed to air-dry in the dark overnight. crystal-
violet was extracted from the cells by incubation with 10% acetic acid for 15 minutes   
under continuous agitation. Extracted crystal-violet was determined spectrophotometrically 
at 590 nm using a plate reader (Biorad, Hemel Hempstead, UK).  
 
2.7 Alcian blue staining 
GAG deposition was detected by Alcian blue staining. Cells were washed two times with 
0.9% NaCl and subsequently fixed with 4% paraformaldehyde in phosphate buffered    
saline for 10 minutes at room temperature. Fixed cells were washed 6 times with water and 
air dried for storage. Fixed cells were incubated overnight with 1% Alcian blue (Acros 
Organics, Geel, Belgium) in 0.1 M HCl at room temperature. Cells were washed six times 
with water to remove excess Alcian blue and allowed to air-dry in the dark overnight.   
Alcian blue was extracted from the cells by incubation with Guanidine-HCl (6 M) for 2 
hours under continuous agitation. Extracted Alcian blue was determined   spectrophoto-
metrically at 645 nm using a plate reader (Biorad, Hemel Hempstead, UK).  
 
2.8 Statistics 
Statistical significance was determined by two-way ANOVA (with Bonferroni post hoc 
test) for ATDC5 experiments and two-tailed student t-tests for hBMSC experiments using 
Graphpad PRISM 5.0 (La Jolla, CA, USA). To test for normal distribution of the input 
data, D’Agostino-Pearson omnibus normality tests were performed. All quantitative data 
sets presented passed the normality tests. 
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3. Results  
 
3.1 Increased osmolarity improves chondrogenic marker expression in differentiating pro-
genitor cells 
To determine whether increased osmolarity improves chondrogenic marker expression in 
differentiating progenitor cells14, the chondroprogenitor cell line ATDC528,29 was differen-
tiated under control conditions and increased osmolarity (+100 mOsm and +200 mOsm). 
Under control conditions ATDC5 cells acquired a chondrogenic phenotype from day 7 in 
differentiation as determined by increased expression of collagen type II (Col2a1),       
aggrecan (Acan) and Sox9 (Figure 3.1A). From day 14 in differentiation these cells also 
express increased levels of the hypertrophic markers collagen type X (Col10a1) and 
Runx2. Collagen type I (Col1a1) is only slightly induced during ATDC5 differentiation. 
Protein expression of the above collagens at day 14 in differentiation was confirmed by 
immunoblotting (Figure 3.1B). Increased osmolarity (+100 mOsm) significantly increased 
mRNA expression of Sox9 (1.9 fold, p=0.0005), Col2a1 (2 fold, p=0.0001), Acan (1.4 
fold, p=0.0018), Runx2 (1.5 fold, p=0.0061) and Col10a1 (2.5 fold, p=0.0001) during the 
course of differentiation when compared to the control condition (Figure 3.1A). Differenti-
ation in +100 mOsm conditions further clearly increased Col2a1 protein expression.     
Expression of Col10a1 did not increase as much at protein level as at mRNA level (Figure 
3.1B). The decreased Col1a1 mRNA (p=0.0035 at t=14 days) and protein expression 
(Figure 3.1B) is in line with our previous findings14. Chondrogenic differentiation was 
inhibited when osmolarity of the differentiation medium was further increased to +200 
mOsm, as the expression of all markers was significantly lower when compared to the con-
trol condition (at day 14 Sox9: p=0.0004, Col2a1: p=0.0184, Acan: p=0.0002), Runx2: 
p=0.0014 and Col10a1: p=0.0004) (Figure 3.1A/B). 
Besides mRNA and protein expression of important differentiation markers, glycosamino-
glycan (GAG) content is another hallmark of chondrogenic differentiation. At 14 days in 
differentiation, ATDC5 cells increased total GAG content by 3.2 fold (Figure 3.1C).    
Similar to mRNA and protein expression of chondrogenic marker genes, +100 mOsm  
significantly increased GAG content by another 2.7 fold (control versus +100 mOsm, 
p=0.0018), whereas +200 mOsm did not increase GAG content compared to t=0. As cell 
proliferation is another important element in chondrogenic differentiation of ATDC528 and 
e.g. in cartilage fracture callus development, differences in cell numbers between the con 
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Figure 3.1: Increased osmolarity improves chondrogenic differentiation of ATDC5 cells 
ADTC5 cells were differentiated under control osmolarity conditions (control, white bars), +100 mOsm (black 
bars) and +200 mOsm (grey bars). (A). Induction of Sox9, Col2a1, Aggrecan, Runx2, Col10a1 and Col1a1 
mRNA expression was determined by RT-qPCR at day 0, 7, 10 and 14 in differentiation. (B). Protein expression 
of Col2a1, Col10a1 and Col1a1 in day 14 samples, α-tubulin was used as loading control. Molecular weight 
markers (kDa) are depicted on the left of immunoblots. Quantifications of ECL signals (corrected for the comple-
mentary α-tubulin signals and set relatively to control condition) are depicted on top of all immunoblots. (C). 
Glycosaminoglycans (GAGs) were stained by Alcian Blue and fold change of t=14 samples was calculated as 
compared to t=0 samples. (D). Differences in proliferation speed between conditions were determined by crystal-
violet staining. Fold change (DNA) from samples from t=14 was calculated relatively to day 0. In graphs, error 
bars represent mean ±s.e.m.. * indicates p < 0.05, and is determined for control compared to +100 or +200 
mOsm. 
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ditions were determined. Increasing the osmolarity with 100 mOsm did not influence the 
increasing cell numbers during differentiation (Figure 3.1D), while culturing under +200 
mOsm conditions lead to significantly lower cell numbers (reduction by ± 50%, p=0.0001) 
compared to the control condition. Overall, increasing osmolarity with 100 mOsm resulted 
in an enhanced chondrogenic marker expression during differentiation of ATDC5 cells, 
while further increasing the osmolarity with another 100 mOsm inhibited overall ATDC5 
differentiation.  
To further substantiate the pro-chondrogenic effect of increased osmolarity during       
chondrogenic differentiation of progenitor cells, we differentiated human bone marrow 
derived mesenchymal stem cells (hBMSCs) from three individuals towards the chondro-
genic lineage in control medium and +100 mOsm conditions. As described earlier 26,  
chondrogenic/hypertrophic marker expression in these cells is detected around day 21 in 
differentiation. Increased osmolarity (+100 mOsm) resulted in increased COL2A1 
(p=0.0005), ACAN (p=0.0012) and COL10A1 (p=0.0001) mRNA and protein expression 
when compared to control conditions (Figure 3.2A/B). Gene expression of their respective 
transcription factors SOX9 and RUNX2 was also increased in +100 mOsm conditions: 
SOX9 1.5 fold (p=0.0449) and RUNX2 2.1 fold higher (p=0.0010) (Figure 3.2A). 
COL1A1 mRNA expression at day 21 in differentiation was only marginally induced in 
the control condition, but was found to be suppressed under increased osmolarity 
(p=0.0021) (Figure 3.2A). Decreased COL1A1 protein expression was also observed under 
increased osmolarity conditions (Figure 3.2B). Therefore, hBMSC responded similarly to 
increased osmolarity as ATDC5 cells.  
Taken together, we found that the magnitude of chondrogenic differentiation of chondro-
progenitor cells is sensitive for the osmolarity of the culture environment, providing the 
overall indication that chondrogenic marker expression by these cells benefits from      
osmolarity values in the range of that of articular cartilage.  
 
3.2 Nfat5 is involved in gene expression under normal and increased osmolarity  
Nfat5/TonEBP is a key regulator of the cellular response to hypertonic conditions and its 
expression increases during human articular chondrocyte expansion culture in 380 mOsm 
conditions14. We determined the expression of Nfat5 during chondrogenic differentiation 
of ATDC5 cells under control and +100 mOsm conditions. Nfat5 mRNA expression was 
found to be upregulated during normal differentiation under control conditions (3.4 fold at 
day 7 and 5 fold at day 10 and day 14, respectively) (Figure 3.3A). When differentiated in  
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Figure 3.2: Increased osmolarity improves chondrogenic differentiation of hBMSCs 
hBMSCs from 3 individual donors were differentiated in the chondrogenic lineage under increased osmolarity. 
(A). Induction of SOX9, RUNX2, COL2A1, COL10A1, ACAN and COL1A1 mRNA expression was determined 
by RT-qPCR at day 0 and 21 in differentiation (control, white bars and +100 mOsm black bars). (B). Protein 
expression of COL2A1, COL10A1 and COL1A1 in day 21 samples. α-Tubulin was used as loading control. 
Molecular weight markers (kDa) are depicted on the left of the immunoblots.Quantifications of ECL signals 
(corrected for the complementary α-tubulin signals and set relatively to control condition) are depicted on top of 
all immunoblots. In graphs, bars represent the average value of 3 individually averaged values of 3 individual 
samples per hBMSC isolate and error bars represent mean ±s.e.m.. * indicates p < 0.05, and is determined for 
control versus +100 mOsm. 
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+100 mOsm conditions, the expression of Nfat5 was significantly higher as compared to 
the control condition (p=0.0445 for t=7, p=0.0474 for t=10 and p=0.0195 for t=14 days) 
(Figure 3.3A), indicating the osmolarity-responsiveness of Nfat5 also during chondrogenic 
differentiation. Similarly, NFAT5 mRNA expression in hBMSCs was significantly in-
creased after 21 days of chondrogenic differentiation and also further enhanced under +100 
mOsm conditions at day 21 in differentiation (p=0.0100) as compared to control conditions 
(Figure 3.3B). Confirming Nfat5 activation upon hyperosmolarity in ATDC5, the           
expression of the established Nfat5 target genes Slc5a3 and S100a4 specifically increased 
in +100 mOsm cultures as compared to control cultures (p=0.0360 for Slc5a3 at t=14 days 
and p=0.0175 for S100a4 at day 14) (Figure 3.3C)14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Nfat5 expression during chondrogenic differentiation 
(A). In similar ATDC5 samples from Figure 3.1A, Nfat5 mRNA expression was determined under control (white 
bars) and +100 mOsm (black bars) conditions. (B). In similar hBMSC samples from Figure 3.2A, NFAT5 mRNA 
expression was determined under control (white bars) and +100 mOsm (black bars) conditions. In graphs, bars 
represent the average value of 3 individually averaged values of 3 individual samples per hBMSC isolate and 
error bars represent mean ±s.e.m.. (C). In samples from (A) expression of established Nfat5 target genes (Slc5a3 
and S100a4) was determined. In graphs, error bars represent mean ±s.e.m.* indicates p < 0.05, and is determined 
for control versus +100 mOsm. 
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To functionally study the involvement of Nfat5 in chondrogenic differentiation under   
control and +100 mOsm conditions, Nfat5 expression was targeted using RNAi.        
Transfection of a target-specific siRNA duplex (30 nM) resulted in a 50% knockdown of 
Nfat5 mRNA expression in both osmolarity conditions at day 0 (p=0.0287), 7 (p=0.0415 
for control and p=0.0252 for +100 mOsm) and 10 (p=0.0275 for control and p=0.0225 for 
+100 mOsm) in differentiation (Figure 3.4A; black versus white bars and dark grey versus 
light grey bars). Functional Nfat5 knockdown under +100 mOsm conditions was          
confirmed by immunoblotting (Figure 3.4B), as well as prevented the upregulation of 
Nfat5 target genes Slc5a3 (p=0.0334 at day 14) and S100a4 (p=0.0091 at day 14) under 
increased osmolarity (Figure 3.4C; dark grey versus light grey bars). Knockdown of Nfat5 
under control conditions resulted in a significantly suppressed upregulation of              
chondrogenic markers genes Sox9 (63%, p=0.0047), Col2a1 (59%, p=0.0038), Acan (51%, 
p=0.0033), Runx2 (36%, p=0.0132) and Col10a1 (53%, p=0.0350) as compared to Mock 
conditions (scrambled siRNA) during chondrogenic differentiation (Figure 3.4D; black 
versus white bars and Figure 3.4E). As increased osmolarity not only induced Nfat5     
expression (Figure 3.3A/B), but also correlated with increased chondrogenic marker     
expression (Figure 3.1), we further tested the possibility whether this osmolarity-induced 
chondrogenic induction may be mediated by Nfat5. Knocking down the expression of 
Nfat5 under +100 mOsm conditions indeed suppressed the osmolarity effect on chondro-
genic gene expression back to normal osmolarity conditions for most of the measured 
chondrogenic genes (at day 10 Sox9: p=0.0134, Col2a1: p=0.0056, Acan: p=0.0065, 
Runx2: p=0.0324 and Col10a1: p=0.0328) (Figure 3.4D; dark grey versus light grey bars 
and Figure 3.4F). The osmolarity-induced suppression of Col1a1 mRNA and protein    
expression was also abrogated by Nfat5 knockdown, where it was expressed even higher 
than in normal osmolarity conditions (Figure 3.4D; dark grey versus white bars and Figure 
3.4E/F). Together, these findings indicate that Nfat5 is involved in chondrogenic          
differentiation of ATDC5 cells and that the increased expression of chondrogenic markers 
during chondrogenic differentiation under +100 mOsm conditions is, at least in part,    
dependent on Nfat5.  
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3.3 Nfat5 is involved in Sox9 function during chondrogenic differentiation 
To further explore the possibility whether osmolarity induces the increased chondrogenic 
marker expression via the key chondrogenic transcription factor Sox9 and to explore    
potential cross-talk between Nfat5 and Sox9, we determined whether osmolarity-driven 
chondrogenic marker expression can be abolished by interfering with Sox9 expression. 
Expression of Sox9 was targeted by siRNA transfection (30 nM) in ATDC5 and resulted in 
a knockdown efficiency of 58% at mRNA level at day 0, 7 and 10 in differentiation under 
both control and +100 mOsm conditions (p=0.0398 at t=0, p=0.0025 at t=10 control and 
p=0.0123 at +100 mOsm) (Figure 3.5A/C; black versus white bars and dark grey versus 
Figure 3.4: Nfat5 may regulate chondrogenic differentiation under normal and increased osmolarity 
To determine how Nfat5 is involved in chondrogenic differentiation of ATDC5 cells, expression of Nfat5 was 
targeted during the course of differentiation by retransfection of an Nfat5 specific siRNA duplex. (A). Knock-
down of Nfat5 expression was confirmed at mRNA level at day 0, 7 and 10 in differentiation. White bars repre-
sent normal osmolarity conditions (control) transfected with a scrambled siRNA (“Mock”) and black bars normal 
osmolarity conditions transfected with the Nfat5 siRNA. Light grey bars represent increased osmolarity condi-
tions (+100 mOsm) transfected with a scrambled siRNA (“Mock”) and black bars increased osmolarity condi-
tions transfected with the Nfat5 siRNA. (B). Knockdown of Nfat5 expression was confirmed by immunoblotting 
of protein samples from +100 mOsm conditions at day 10. (C). Knockdown of Nfat5 expression was functionally 
confirmed by decreased Nfat5 target gene expression of Slc5a3 and S100a4. (D). In similar samples from (A) 
Sox9, Col2a1, Aggrecan, Runx2, Col10a1 and Col1a1 mRNA expression was determined. (E). Protein expression 
of Col2a1, Col10a1, Col1a1 and Sox9 from day 10 samples in Mock and Nfat5 knockdown cells under control 
conditions. (F). Protein expression of Col2a1, Col10a1, Col1a1 and Sox9 from day 10 samples in Mock and 
Nfat5 knockdown cells under +100 mOsm conditions. In graphs, error bars represent mean ±s.e.m.. * indicates p 
< 0.05, and is determined for Mock versus Nfat5 siRNA under control osmolarity and under +100 mOsm condi-
tions, respectively. 
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light grey bars). Upon Sox9 knockdown under control conditions, expression of the      
important Sox9 targets, Col2a1 and aggrecan, was significantly decreased (p=0.0046 for 
Col2a1 and p=0.0076 for Acan at t=10 days) (Figure3.5B; black versus white bars and 
Figure 3.5C; left panel), showing that expression of these genes under control culture    
conditions is regulated through Sox9. The osmolarity-induced chondrogenic marker     
expression under +100 mOsm was also significantly affected by the Sox9 knockdown 
(p=0.0023for Co2a1 and p=0.0092 for Acan at t=10 days) (Figure 3.5B; dark grey versus 
light grey bars and Figure 3.5C; right panel), showing that the osmolarity-induced      
chondrogenic marker expression functionally depends on Sox9.  
 
 
 
 
Figure 3.5: Osmolarity-enhanced chondrogenic differentiation is Sox9 dependent 
Sox9 siRNA duplexes were retransfected under control and +100 mOsm conditions to investigate whether the 
osmolarity effect on chondrogenic differentiation is depending on Sox9. (A). Knockdown of Sox9 was confirmed 
at mRNA level at day 0, 7 and 10 in differentiation. White bars represent normal osmolarity conditions (control) 
transfected with a scrambled siRNA (“Mock”) and black bars normal osmolarity conditions transfected with the 
Sox9 siRNA. Light grey bars represent increased osmolarity conditions (+100 mOsm) transfected with a scram-
bled siRNA (“Mock”) and black bars increased osmolarity conditions transfected with the Sox9 siRNA. (B). The 
effect of the Sox9 knockdown under control and +100 mOsm conditions on chondrogenic differentiation was 
established by measuring Col2a1 and Acan mRNA expression. (C). Protein expression of Sox9 and Col2a1 from 
day 10 samples in Mock and Sox9 knockdown cells under control and +100 mOsm. In graphs, error bars repre-
sent mean ±s.e.m.. * indicates p < 0.05, and is determined for Mock versus Sox9 siRNA under control osmolarity 
conditions and under +100 mOsm conditions, respectively. 
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We next aimed at elucidating potential cross-talk and pathway hierarchy between Nfat5 
and Sox9, which might explain how Nfat5 influences chondrogenic differentiation. We 
analyzed Sox9 expression early in ATDC5 differentiation26 at 24 hours after Nfat5 knock-
down and Nfat5 expression upon Sox9 knockdown at the same moment in ATDC5       
differentiation as well. Functional interference with Nfat5 expression was confirmed by 
decreased expression of the Nfat5 targets Slc5a3 and S100a4 (Figure 3.6A; 68% 
(p=0.0202) and 44% (p=0.0293), respectively). In addition, knockdown of Nfat5 efficient-
ly decreased Sox9 mRNA (p=0.0404) and protein expression (Figure 3.6A/C). In contrast, 
knockdown of Sox9 solely decreased Sox9 mRNA (p=0.0339) and protein expression, 
without further affecting Nfat5 mRNA levels or those of its target genes (Figure 3.6B/C). 
These data suggest that Nfat5 may determine the outcome of ATDC5 chondrogenic differ-
entiation by transcriptionally influencing early expression of Sox9.  
 
 
In conclusion, increasing culture medium osmolarity from control levels (i.e. 285-310 
mOsm) with 100 mOsm significantly increased chondrogenic marker expression during 
the course of chondrogenic differentiation of progenitor cells (ATDC5 and hBMSCs). We 
further found evidence that Nfat5 may play a regulatory role during (osmolarity-induced) 
chondrogenic differentiation of these cells, at least in part, through influencing Sox9 ex-
pression.    
Figure 3.6: Nfat5 influences Sox9 expression 
Signalling hierarchy between Nfat5 and Sox9 was determined early (24 hours) in ATDC5 differentiation by siR-
NA transfections. (A). Expression of Nfat5, Sox9, Slc5a3 and S100a4 mRNAs in differentiating ATDC5 trans-
fected with Mock or Nfat5 siRNAs in control osmolarity conditions. (B). Same as (A) but with Mock or Sox9 
siRNAs. Data is presented as percentage to control condition. (C). Sox9 protein expression at 24 hours in ATDC5 
differentiation after Mock, Nfat5 or Sox9 siRNA transfection. In graphs, error bars represent mean ±s.e.m.. * 
indicates p < 0.05, and is determined for Mock versus Nfat5 or Sox9 siRNA. 
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 4. Discussion 
 
Several studies have shown that human articular chondrocytes in vitro are osmolarity-
responsive and increase matrix synthesis under cartilage-physiological osmolarity with 
Nfat5 being involved in this response. The potentially beneficial effects of increased    
osmolarity on chondrogenic differentiation of progenitor cells are largely unknown. In 
addition, the expression and function of Nfat5 during this process have never been        
described. We here report that chondrogenic marker expression and chondrogenic  extra-
cellular matrix synthesis during differentiation of the chondroprogenitor cell line ATDC5 
and in human bone marrow stem cells (both sequentially expressing a chondrocyte and 
hypertrophic chondrocyte phenotype, respectively) positively respond to increased       
osmolarity. Expression of Nfat5 is upregulated during chondrogenic differentiation and its 
expression is further upregulated under increased osmolarity. Nfat5 is involved in          
regulating chondrogenic marker expression under normal and increased osmolarity and 
may regulate the osmolarity-induced beneficial effects on Col2a1 and Acan through key-
chondrogenic transcription factor Sox9.   
In human articular cartilage the extracellular osmolarity ranges between 350-480 
mOsm9,10, due to the high fixed negative charge density of the sulfated GAG side chains in 
the proteoglycan network. It may therefore not be surprising that chondrocyte phenotypic 
preservation during isolation and culturing of articular chondrocytes in vitro benefits from 
increased osmolarity in the culture medium14. Following up on these results we determined 
whether improved expression of chondrogenic marker genes under increased osmolarity 
could also be found when fully dedifferentiated human articular chondrocytes (HACs) are 
redifferentiated under increased osmolarity. In agreement with our previous findings12 and 
the data described above, COL2A1 and COL10A1 protein expression, as well as GAG 
content were increased in the +100 mOsm condition when compared to control condition 
(Figure 3.7A and B). Similar to above findings, increased osmolarity had no effect on the 
proliferation capacity of these redifferentiating cells (Figure 3.7C).  
However, the osmolarity levels in the direct environment of chondroprogenitor cells in 
vivo are poorly investigated. Amongst others, mesenchymal stem cells are found in the 
bone marrow, adipose tissue, muscle, blood and periosteum30 and most of these tissues 
have a normal plasma level osmolarity of around 280 mOsm. It is therefore likely that pro-
genitor cells residing in these tissues experience an environment that is close to plasma  
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osmolarity in vivo. Yet, progenitor cells express similar chondrogenic markers (e.g. Sox9, 
Col2a1, Acan etc.) during chondrogenic differentiation as found in mature articular chon-
drocytes and may create a local self-sustaining hypertonic microenvironment by excretion 
of ECM components during their differentiation process. It seems therefore likely that the 
response of mesenchymal progenitor cells to increased osmolarity may be regulated 
through similar molecular mechanisms that are also responsible for increased               
chondrogenic marker expression in mature chondrocytes. 
We used established culture protocols for ATDC5 and hBMSC differentiation and thus 
their corresponding differentiation media had slightly different baseline osmolarities (310 
and 285 mOsm, respectively), within the range of plasma level osmolarity11,12. The relative 
cell type-specific quantity of the osmotic challenge was, however, identical for both cell 
types. Noteworthy, for ATDC5 we found that, as opposed to +100 mOsm, an osmotic 
challenge of +200 mOsm had deleterious consequences for the chondrogenic                 
differentiation process. This suggests the existence of an optimal osmolarity-window for 
the outcome of ATDC5 differentiation. The +100 mOsm condition (i.e. ~410 mOsm) is 
within the range of physiological articular cartilage osmolarity9,10. Higher osmotic       
pressures, as in the +200 mOsm condition, are rather high end physiological and may   
exceed membrane transport capacities. 
Figure 3.7: Increased osmolarity improves chondrocyte re-differentiation 
HACs from 3 individual donors were redifferentiated in the chondrogenic lineage under control and increased 
osmolarity (+100 mOsm).  (A). Protein expression of COL2A1, COL10A1 and COL1A1 from day7 samples was 
determined by immunoblotting, α-tubulin was used as housekeeper. Molecular weight markers (kDa) are depict-
ed on the left. Quantifications of ECL signals (corrected for the complementary α-tubulin signals and set relative-
ly to control condition) are depicted on top of all immunoblots. (B). Proteoglycans were stained by alcian blue 
and fold increase of t=7 samples was calculated from t=0 samples. (C). Differences in proliferation speed be-
tween conditions were determined by crystal-violet staining. Fold increase (DNA) from samples from t=7 was 
calculated relatively to day 0. In graphs, bars represent the average value of 3 individually averaged values of 3 
individual samples per HAC isolate and error bars represent mean ±s.e.m.. * indicates p < 0.05. 
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The molecular mechanism by which osmolarity is sensed by mammalian cells is only    
partially understood. Nfat5 is accepted as key transcription factor participating in the    
response to the deleterious effects of increased osmolarity21,31. The hypertonic stress-
induced increase in intracellular ionic strength is potentially genotoxic, inducing double-
strand DNA breaks, growth arrest and apoptosis32,33. Nfat5 is activated by hypertonic stress 
to compensate for these deleterious effects through activation of compensatory mecha-
nisms like e.g. activating osmolyte transporter gene transcription (e.g. Slc5a3 and S100a4) 
in order to reduce the intracellular ionic strengths21,34. However, little is known about the 
osmolarity threshold required to activate Nfat5 in specific cell types and several            
observations suggest that Nfat5 is active already at plasma level osmolarity in tissues that 
normally are not exposed to a hypertonic environment16. In addition, in our experiments 
knockdown of Nfat5 under plasma level osmolarity resulted in downregulation of Nfat5 
target gene expression (Figure 3.4C), indicating that Nfat5 is functionally active under 
these conditions in the tested progenitor cells. Also, it is becoming increasingly evident 
that Nfat5 is involved in cellular processes unrelated to hypertonic stress, such as cell    
proliferation, differentiation or integrin-mediated cell migration31,35,36. Our present study 
shows that Nfat5 expression follows the course of normal chondrogenic differentiation and 
may play a regulating role during chondrogenic differentiation of progenitor cells. While 
osmolarity may enhance chondrogenic differentiation through Nfat5, its knockdown during 
chondrogenic differentiation under both plasma (control) osmolarity and increased       
osmolarity (+100 mOsm) resulted in suppressed expression of chondrogenic markers 
Col2a1, Acan, Sox9, Col10a1 and Runx2 (Figure 3.4D-F), suggesting a regulatory       
function of Nfat5 during chondrogenic differentiation under both control culture conditions 
and increased osmolarity conditions.  
The mode of action by which Nfat5 may regulate chondrogenic differentiation of           
progenitor cells remains to be elucidated. Our data suggest that Nfat5 might act in this   
context through influencing the expression of key chondrogenic transcription factor Sox9. 
Regulation of Sox9 expression by osmolarity has been shown before. Stimulation of     
human chondrocytes with supraphysiological osmolarity not only induced SOX9 mRNA 
levels, but also increased SOX9 mRNA half-life37. Posttranscriptional stabilization of 
SOX9 mRNA is activated by p38 MAPK signalling38, which is also known to be involved 
in the hypertonic activation and nuclear translocation of NFAT539-41. Alternatively, we 
previously found that Sox9 expression during chondrogenic differentiation of progenitor 
cells in vitro is bi-phasic, with a first induction during the first hours of differentiation and 
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a second peak expression later on in differentiation. Next to the well documented crucial 
role of Sox9 during ECM synthesis (late expression peak), we showed that the early and 
transient induction of Sox9 crucially determines the chondrogenic outcome of mesenchy-
mal progenitor cell differentiation26. Knockdown of Nfat5 resulted in decreased Sox9 ex-
pression (Figure 3.4D) on the long term, which could explain the decreased Col2a1 and 
Acan expression seen in these cultures. In addition, and relevant to the early Sox9 induc-
tion, Nfat5 knockdown during early chondrogenic differentiation (24 hours) affected early 
Sox9 expression, as well as known Nfat5 target genes. Reciprocally, knockdown of early 
Sox9 expression did not influence the expression of Nfat5 or its target genes (Figure 3.6B/
C), suggesting that Nfat5 may act upstream of Sox9, through yet unknown (transcriptional) 
mechanisms.  
We have here shown that the magnitude of chondrogenic gene expression of differentiating 
chondroprogenitor cells in vitro can be enhanced by increasing the osmolarity levels of the 
culture medium. The osmolarity responsive gene Nfat5 seems to be part of the mechanism 
that underlies this effect and might influence chondrogenic differentiation via controlling 
the expression of key chondrogenic transcription factor Sox9. Future studies will focus on 
further elucidating the relation between Nfat5 and chondrogenic regulators. Increasing the 
osmolarity may be used as a relatively simple tool to modulate the formation of             
cartilaginous tissues for progenitor cell-based cartilage and endochondral bone regenera-
tive medicine approaches42.   
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Abstract 
 
Introduction: Bone morphogenic protein (BMP)-2 and BMP-7 are clinically approved and 
their recombinant proteins are used for bone tissue regenerative purposes and widely   
evaluated for cartilage regeneration. Previous comparison of the in vitro chondrogenic 
characteristics of BMP-2 versus BMP-7 did not address hypertrophic differentiation and 
characterizing their chondrogenic properties with a focus in on chondrocyte hypertrophy 
was topic of investigation in this study. 
Methodology: Equimolar concentrations of BMP-2 or BMP-7 were added to chondrogenic 
differentiating ATDC5, human bone marrow stem cells or rabbit periosteal explants.    
Expression of Col2a1, Sox9, Acan, Col10a1, Runx2, ALP, Mmp13, Mef2c and Bapx1/
Nkx3.2 was determined by RT-qPCR and immunoblotting. Glycosaminoglycan content, 
cell proliferation capacity and ALP activity were analysed by colorimetric analyses.     
Expression of Bapx1/Nkx3.2 and Sox9 was targeted by transfection of target specific   
siRNA duplexes. 
Results: BMP-2 dose-dependently increased chondrocyte hypertrophy during                
chondrogenic differentiation of progenitor cells, whereas BMP-7 acted hypertrophy      
suppressive and chondro-promotive. Both BMPs did not influence cell proliferation, but 
they did increase total glycosaminoglycan content. In a candidate approach Bapx1/Nkx3.2 
was found to be involved in the BMP-7 mediated suppression of chondrocyte hypertrophy 
in ATDC5 cells. 
Conclusions: BMP-2 and BMP-7 display opposing actions on the chondrogenic outcome 
of differentiating progenitor cells: BMP-2 acts a specific inducer of  chondrocyte  hyper-
trophy, while BMP-7 appears to increase or maintain chondrogenic potential and prevent 
chondrocyte hypertrophy. Our results pave the way for an application-dependent          
differential use of BMP-2 or BMP-7.  
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1. Introduction  
 
Methodologies controlling chondrogenic differentiation of mesenchymal progenitor cells 
towards chondrocytes are of interest to improve the outcome of skeletal regenerative    
medicine approaches. During chondrogenic differentiation mesenchymal progenitor cells 
condensate and differentiate into proliferating and extracellular matrix synthesizing    
chondrocytes which, in the case of endochondral ossification and different cartilage      
pathologies, ultimately terminally differentiate into hypertrophic mineralized chondro-
cytes1,2. For progenitor cell-based cartilage regeneration it is therefore crucial to find    
optimal strategies to stimulate progenitor cells to differentiate into chondrocytes and    
preventing them from hypertrophy and mineralization3,4. On the contrary, for bone tissue 
engineering, promoting terminal differentiation through endochondral ossification may be 
advantageous5.        
Growth factors are important soluble mediators for tuning a variety of cellular processes 
including cell proliferation and differentiation. In this respect, members of the transform-
ing growth factor (TGF)-β superfamily are frequently used to promote chondrogenic    
differentiation processes in vitro6,7. A separate class of TGF-β superfamily-members are 
the bone morphogenic proteins (BMPs). These proteins were discovered in extracts of   
demineralized bone and were demonstrated to induce de novo endochondral bone         
formation in vivo when administered ectopically8. Especially BMP-2 and BMP-7 (also 
known as osteogenic protein-1 (OP-1)) are clinically approved and their recombinant   
proteins are used to promote healing at sites of poor bone fracture healing (non-unions), as 
additional factors to enhance integration of bone grafts and are widely evaluated for     
cartilage and bone tissue regenerative purposes 9-11. BMPs are involved in all phases of 
chondrogenic differentiation and are able to directly regulate expression of several      
chondrocyte specific genes12,13. BMP-2 is described to promote cell proliferation and    
matrix synthesis in human articular chondrocytes, growth plate chondrocytes and develop-
ing mouse limbs14-16. Moreover, BMP-2 has been demonstrated to regulate the expression 
and activity of key-chondrogenic transcription factor Sox9 (SRY (sex determining region 
Y) box9)17,18. BMP-7 is described to promote in vitro chondrogenic extracellular matrix 
synthesis in normal and osteoarthritic human articular chondrocytes14,19-21 and can       
counteract retinoic acid-induced dedifferentiation of bovine chondrocytes22. In addition, 
BMP-7 also promotes chondrogenic differentiation of human and goat perichondrium 
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cells, developing mouse limbs and human chondrocytes23.  
Although these BMPs are clinically used and their potential is widely explored in cartilage/
bone regenerative approaches, the hypertrophic properties of BMP-2 versus BMP-7 are not 
well documented. We aimed to compare the action of BMP-2 and BMP-7 on chondrogenic 
differentiation of progenitor cells, focusing on hypertrophic differentiation, using ATDC5 
cells and human bone-marrow-derived mesenchymal stem cells. These both cell models 
are known to eventually show chondrocyte hypertrophy in vitro. Our results demonstrate 
that BMP-2 and BMP-7 display opposing effects on the chondrogenic outcome of          
differentiating progenitor cells: BMP-2 acts a specific inducer of chondrocyte hypertrophy, 
while BMP-7 appears to increase or maintain chondrogenic potential and suppress       
chondrocyte hypertrophy. Further focussing of BMP-7 we found that Bapx1/Nkx3.2 
(Bagpipe homeobox gene 1 homolog/NK3 homeobox 2) is involved in the hypertrophy-
suppressive action of this BMP. Together our results may provide a basis for differential 
use of BMP-2 or BMP-7, depending on a chondrogenic or endochondral/bone application 
purpose. 
 
 
2. Materials and Methods 
2.1 ATDC5 cell culture 
ATDC5 were cultured (as described before24) in proliferation medium consisting of 
DMEM/F12 (Invitrogen, Carlsbad, CA, USA), 5% FCS (PAA, Pasching, Austria), 1% 
antibiotic/antimycotic (Invitrogen) and 1% NEAA (non-essential amino acids; Invitrogen). 
ATDC5 were differentiated in differentiation medium comprising proliferation medium 
supplemented with 10 µg/ml insulin (Sigma, St. Louis, MO, USA), 10 µg/ml transferrin 
(Roche Applied Science) and 30 nM sodium selenite (Sigma). Cells were plated at 6400 
cells/cm2 and chondrogenic differentiation was initiated by adding differentiation medium. 
BMP-2 (Sigma) or BMP-7 (R&D Systems, Minneapolis, MN, USA) were used in   
equimolar concentrations. For calculation of equimolar concentrations, disulphide-linked 
homodimers of both BMPs were regarded as the functional ligands. For comparison, 1 nM 
BMP-2 corresponds to 31 ng/ml and 1 nM BMP-7 corresponds to 26 ng/ml). For RNAi-
experiments a Bapx1/Nkx3.2 siRNA duplex (sense: 5’-CAGAGACGCAAGUGAAGAUT 
T-3’, anti-sense: 5’-AUCUUCACUUGCGUCUCUGTT-3’), Sox9 siRNA duplex (sense: 
BMP-2 versus BMP-7 in Chondrogenic Differentiation 
103 
5’- GACUCACAUCUCUCCUAAUTT-3’, anti-sense: 5’- AUUAGGAGAGAUGUGAGU 
CTT-3’) and scrambled siRNA-duplex (indicated by “Mock”) were used (Eurogentec,  
Liège, Belgium). ATDC5 cells were seeded at 25,000 cells/cm2 and transfection (50 nM) 
was performed using ICAfectin 442 (Eurogentec) according to manufacturers’ protocol. 
This resulted in an average transfection efficiency of 75% in these experiments 
(determined by fluorescence microscopy of 5’ FITC labeled variants of the respective  
siRNAs). Transfected cells were cultured for 1 day before chondrogenic differentiation 
was initiated and retransfection of siRNAs was carried out at 2 and 5 days.  
 
2.2 hBMSC isolation and cell culture 
Human bone marrow stem cells (hBMSCs) were obtained from iliac crest bone marrow 
aspirate from young, genetically healthy individuals (MEC MUMC approval 08-4-056). 
hBMSCs were isolated using Ficoll-Paque PLUS (Amersham Pharmacia, Diegem,       
Belgium). Culture medium consisted of DMEM high glucose (Invitrogen), 10% FCS, 1% 
antibiotic/antimycotic and 1% NEAA. Chondrogenic differentiation was performed in 
monolayer by plating passage 5 cells at 30,000 cells/cm2. Differentiation medium         
consisted of proliferation medium supplemented with 1% ITS (Invitrogen), 50 mg/ml        
L-ascorbic acid-2-phosphate (Sigma) and 1 ng/ml TGFβ3 (R&D)24,25. BMP-2 or BMP-7 
were used in equimolar concentrations as described above.  
 
2.3 Periosteum Agarose Culture (PAC) chondrogenic differentiation 
As previously described26, periosteum was harvested from the proximal tibia of skeletally 
mature NZW-rabbits. Post-mortem animals were obtained from an unrelated study, no 
ethical approval was necessary. Periosteum was prepared as a 3 x 3 mm piece and        
embedded between a layer of high melting agarose (1%) and low melting agarose (1%) 
according to O’Driscoll et al.27, and proliferation medium (DMEM/F12, 10% FCS, 1% P/
S, 1% NEAA) was added. After overnight incubation, medium was changed to differentia-
tion medium (proliferation medium supplemented with 1% ITS, 50 mg/ml L-ascorbic acid-
2-phosphate, 10 ng/ml TGFb3) and PACs were differentiated for 20 days with medium 
changes every 3 days. BMP-2 or BMP-7 were used in equimolar concentrations as       
described above.  
 
2.4 RT-qPCR 
For RNA isolation, cells were washed 3 times with 0.9% NaCl and disrupted with 500 µl 
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Trizol (Invitrogen). To isolate total RNA from PAC cultures, tissue was cut in pieces and 
soaked overnight in 500 ml Trizol at 4oC. RNA isolation, RNA quantification by ultra-
violet (UV)-spectrometry (Nanodrop, Thermo Scientific), and cDNA synthesis were    
performed as described before24. Real time quantitative PCR (RT-qPCR) was performed 
using Mesagreen qPCR mastermix plus for SYBR® Green (Eurogentec). An Applied   
Biosystems ABI PRISM 7700 Sequence Detection System was used for amplification   
using the following protocol: initial denaturation at 95ºC for 10 min, followed by 40 cycles 
of DNA amplification (denaturing for 15 s at 95ºC and annealing for 1 min at 60ºC)     
followed by a dissociation curve. Data were analysed using the standard curve method, 
mRNA expression was normalized to a reference gene (β-actin (ATDC5, rPACs) and 28S 
rRNA (hBMSCs)) and gene expression was calculated as fold increase as compared to day 
0. Validated primer sequences are depicted in Table 4.1.  
 
Table 4.1: DNA oligo sequences for RT-qPCR.  
 
Forward and reverse oligo sequences (5’-3’) used for RT-qPCR are listed for mouse, rabbit and human. 
Oligo sets mouse Forward Reverse 
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCC-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
Col10a1 ‘5-CATGCCTGATGGCTTCATAAA-3’ ‘5-AAGCAGACACGGGCATACCT-3’ 
Runx2 ‘5-CGATGAAGACCCCAACCCTAA-3’ ‘5-ACTGGTAATGGCATCAAGGGATA-3’ 
Sox9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-TACTTGTAGTCCGGGTGGTCTTTC-3’ 
Acan ‘5-CATGAGAGAGGCGAATGGAA-3 ‘5-TGATCTCGTAGCGATCTTTCTTCT-3’ 
Mef2c ‘5-GGGCCTCAATGGCTGTGA-3’ ‘5-CTCAGACTCAGGGCTGTGACCTA-3’ 
Mmp13 ‘5-CGATGAAGACCCCAACCCTAA-3’ ‘5-ACTGGTAATGGCATCAAGGGATA-3’ 
Alp ‘5-CCGATGGCACACCTGCTT-3’ ‘5-GGAGGCATACGCCATCACAT-3’ 
Bapx1/Nkx3.2 ‘5-GCGTGACGACCAAAGACAGTTATTT-3’ ‘5-GGGAGACAGTAGTAAGGGTAGTAGTAGGA-3’ 
β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
Oligo sets human Forward Reverse 
COL2A1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
COL10A1 ‘5-ATGATGAATACACCAAAGGCTACCT-3’ ‘5-ACGCACACCTGGTCATTTTCTG-3’ 
RUNX2 ‘5-TGATGACACTGCCACCTCTTGA-3’ ‘5-GCACCTGCCTGGCTCTTCT-3’ 
28S rRNA ‘5-GCCATGGTAATCCTGCTCAGTAC-3’ ‘5-GCTCCTCAGCCAAGCACATAC-3’ 
Oligo sets rabbit Forward Reverse 
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
Col10a1 ‘5-AACCTGGACAACAGGGACTTACA-3’ ‘5-CCATATCCTGTTTCCCCTTTCTG-3’ 
Runx2 ‘5-TGATGACACTGCCACCTCTTGA-3’ ‘5-GCACCTGCCTGGCTCTTCT-3’ 
β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
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2.5 Immunoblotting 
Cells were washed with 0.9% NaCl and lysed in RIPA buffer. Extracts were sonicated on 
ice using the Soniprep 150 (MSE) at amplitude 10 for 14 cycles (1 second sonication and 1 
second pause). Insoluble material was removed by centrifugation (13.000 x g, 4ºC).      
Protein concentration was determined using the bicinchoninic acid (BCA) protein assay 
(Sigma). Polypeptides were separated by SDS-PAGE (samples were equally loaded) and 
transferred to nitrocellulose membranes by electroblotting. Primary antibodies for immu-
nodetection were polyclonal goat anti-Col2a1 (Southern Biotech, Birmingham, AL, USA), 
polyclonal rabbit anti-Col10a1 (Calbiochem, Darmstadt, Germany), polyclonal goat anti-
Sox9 (Abcam, Cambridge, UK), mouse monoclonal anti-Runx2 (MBL, Woburn, MA, 
USA), polyclonal rabbit anti-Bapx1 (Abcam, Cambridge, UK) and mouse monoclonal anti
-α-Tubulin (Sigma). Bound primary antibodies were detected with rabbit anti-goat, swine 
anti-rabbit or rabbit anti-mouse immunoglobulins conjugated with horseradish peroxidase 
(DakoCytomation, Glostrup, Denmark) and visualized by enhanced chemiluminescence 
(ECL). ECL signals were quantified using ImageJ 1.46f software. Relative differences, 
corrected for background and housekeeper, were determined as compared to control     
conditions. 
 
2.6 Alcian blue staining 
Glycosaminoglycan content was detected by Alcian blue staining. Cells were washed with 
0.9% NaCl and fixed with 4% paraformaldehyde (Merck) in phosphate buffered saline for 
10 min at room temperature, washed with water and air dried. After overnight incubation 
with 1% Alcian blue (Acros VWR, Belgium) in 0.1 M HCl at room temperature, cells were 
washed six times and allowed to air-dry in the dark overnight. Alcian blue was extracted 
from the cells by incubation with Guanidine-HCl (6 M) (Sigma) for 2 hours under        
continuous agitation. Extracted Alcian blue was determined spectrophotometrically at 645 
nm using a plate reader (Multiskan FC, Thermo Scientific). 
 
2.7 Alkaline Phosphatase activity 
Cells were lysed in freshly prepared collection buffer (1.5 M Tris-HCl pH 9.0; 2% (v/v) 
Triton X-100) and homogenized by sonication (Soniprep 150 MSE). Insoluble material 
was removed by centrifugation (5 minutes; 13,000 x g; 4oC). Total protein concentration 
was determined (see above). ALP activity was determined by in time measuring ALP-
depend enzymatic conversion of p-nitrophenyl phosphate to nitrophenyl phosphate in  
Chapter 4 
106 
buffer containing 1.5 M Tris-HCl; pH 9.0, 1 mM ZnCl2, 1mM MgCl2 and 7.5 mM             
p-nitrophenyl phosphate. Substrate conversion was spectrophotometrically quantified at 
405 nm. A calibration curve consisted of an increasing concentration of nitrophenyl     
phosphate to determine the absolute amount of ALP-generated nitrophenyl phosphate in 
time. Values were normalized to total protein and expressed as µmol nitrophenyl        
phosphate/minute/gram (=1U).  
 
2.8 Cell proliferation 
Cells were washed two times with 0.9% NaCl and fixated with 4% paraformaldehyde 
(Merck) in phosphate buffered saline for 10 min at room temperature, washed with water 
and air dried for storage. Cells were incubated with 0.1% X-violet (Sigma) for 30 min at 
room temperature and washed six times with water and allowed to air-dry in the dark  
overnight. X-violet was extracted from the cells by incubation with 10% acetic acid for 15 
min under continuous agitation. Extracted X-violet was determined spectrophotometrically 
at 590 nm using a plate reader (Multiskan FC, Thermo Scientific).  
 
2.9 Histochemistry 
PACs were decalcified in formalin/EDTA, dehydrated following standard procedures and 
embedded in paraffin. Before histochemistry, tissue sections (5 µm) were deparafinized 
and rehydrated using standard protocols. Proteoglycans were stained with Safranin-O 
(0.1%) and counterstained with Fast Green (0.1%). Stained sections were dehydrated and 
mounted in Histomount (Thermo Shandon) for microscopic analysis.  
 
2.10 Statistics 
In the Figures based on ATDC5, bars represent average value of 3 individual experiments 
(performed in triplicate; 3x3 samples) and error bars represent mean ± 95% confidence 
interval (CI). In the experiments using hBMSCs or rPACs, all experiments were performed 
in triplicate with hBMSCs from 3 independent donors (n=3) or rabbit periosteal explants 
from 5 independent donors (n=5). Statistical significance (p <0.05) was determined by 
unpaired two-tailed student t-tests (paired two-tailed student t-test for data derived from 
hBMSC experiments (Figure 4.3A)) using GraphPad PRISM 5.0 (La Jolla, CA, USA). To 
test for normal distribution of the input data, D’Agostino-Pearson omnibus normality tests 
were performed. All quantitative data sets presented here passed the normality tests. Using 
an F-test homogeneous variance of the input data was confirmed.  
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3. Results 
 
3.1 Differential effects of BMP-2 and BMP-7 on chondrogenic differentiation of progenitor 
cells  
To determine whether BMP-2 and BMP-7 differently influence the outcome of chondro-
genic differentiation of progenitor cells we performed dose-response experiments to      
establish the minimal BMP concentrations that lead to detectable changes in the chondro-
genic outcome. Throughout a 14 day differentiation time course, ATDC5 cells were     
exposed to increasing equimolar concentrations of either BMP-2 or BMP-7. As presented 
in Figure 4.1A, 0.01 and 0.1 nM of BMP-2 (grey bars) did not influence the mRNA      
expression of Collagen type II (Col2a1), although a slight increase was detected at 1.0 nM. 
On the other hand, BMP-7 (black bars) dose-dependently increased Col2a1 expression. 
Collagen type X (Col10a1) mRNA expression (Figure 4.1B) revealed a robust dose-
dependent increase upon BMP-2 exposure, whereas the presence of BMP-7 led to an oppo-
site, Col10a1 suppressing action. From these dose-response experiments we decided to use 
1 nM of both BMPs throughout the rest of our experiments, as this dose was the minimal 
concentration needed to detect BMP-induced changes in chondrogenic gene expression. 
 
Figure 4.1: Effects of increasing BMP-2 or BMP-7 concentrations on chondrogenic differentiation of ATDC5 
cells 
Equimolar concentrations (0, 0.01; 0.1 or 1 nM) of BMP-2 or BMP-7 were added from the start of chondrogenic 
differentiation of ATDC5. (A). Col2a1 mRNA expression at day 14 in differentiation, relatively to t=0. White 
bars represent control (0 nM) condition, grey bars the different BMP-2 concentrations and black bars the different 
BMP-7 concentrations. (B). Same as in (A) but for Col10a1. In graphs, error bars represent mean ± 95% CI. Sta-
tistics are calculated with respect to the control condition and * =  p < 0.05 (statistical significant), ns = not 
stastistical significant.  
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To obtain further insight into the action of the different BMPs during the course of chon-
drogenic differentiation we determined the expression of Col2a1 and Col10a1 at different 
time points (0, 7, 10 and 14 days) in ATDC5 differentiation. In the course of ATDC5 
chondrogenic differentiation a gradual increase was found in Col2a1 and Col10a1 mRNA 
levels throughout the 14 day timeframe (Figure 4.2A; white bars). Addition of 1 nM    
BMP-2 (grey bars) resulted in a slight increase in both Col2a1 mRNA and protein        
synthesis during chondrogenic differentiation (Figure 4.2A/C). Col10a1 mRNA and     
protein levels were higher increased in the BMP-2 condition, as compared to the control 
condition (Figure 4.2B/C). Addition of an equimolar concentration of BMP-7 (black bars) 
resulted in increased Col2a1 mRNA and protein levels (Figure 4.2A/C ), whereas Col10a1 
mRNA and protein levels were less upregulated under influence of BMP-7 from day 10 
on, as compared to control (Figure 4.2B/C) and as compared to the BMP-2 condition 
(Figure 4.2B/C; black versus grey bars). To further corroborate on the observed              
pro-chondrogenic / hypertrophy-suppressing action of BMP-7 and the pro-hypertrophic 
effect of BMP-2 we measured the expression of other important chondrogenic and      
chondrocyte hypertrophy associated genes. Expression of key chondrogenic transcription 
factor Sox9 reacted mildly to BMP-2 exposure, whereas challenging the cells with BMP-7 
led to higher upregulated Sox9 levels (Figure 4.2C/D). Aggrecan (Acan) gene expression 
also reacted very similar (to Sox9 and Col2a1) upon exposure to both individual BMPs.  
Analogous to our above findings on Col10a1 expression, the expression of other chondro-
cyte hypertrophy genes as Runx2 (Runt related transcription factor 2), ALP (Alkaline 
phosphatase) and Mmp13 (Matrix metalloproteinase 13) was found to be increased in the 
BMP-2 condition (grey bars) as compared to control differentiation conditions (white bars) 
and suppressed in the BMP-7 condition (black bars) (Figure 4.2C/E). Expression of these 
hypertrophy-associated genes was also found to be significantly different between the 
BMP-2 and the BMP-7 condition (Figure 4.2E). A hypertrophy-inducing action of BMP-2 
and hypertrophy-suppressive action by BMP-7 was further confirmed by measuring ALP 
enzymatic activity in these cultures (Figure 4.2F). As an overall indicator for glycosamino-
glycan content, alcian blue stainings revealed that both BMPs caused increased glycosa-
minoglycan content in differentiating ATDC5 cells at day 14, as compared to control   
differentiation conditions (Figure 4.2G). No differences were detected between the       
glycosaminoglycan contents of BMP-2 versus BMP-7 treated cells. Interestingly, no     
significant differences between control, BMP-2 and BMP-7 were found when cell prolifer-
ation capacity was determined (Figure 4.2H), indicating that both BMPs do not influence  
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the cell proliferation rate in the herein tested setting.  
Finally, to verify our ATDC5 findings in primary human mesenchymal progenitor cells, 
we supplemented the differentiation medium of hBMSCs with equimolar concentrations  
(1 nM) of either two BMPs. Chondrogenic differentiation of three individual hBMSC    
isolates led to upregulation of COL2A1, COL10A1 and RUNX2 mRNAs at day 14 and 21 
in differentiation (Figure 4.3A; white bars). The addition of 1 nM BMP-2 increased the 
mRNA expression of COL10A1 and RUNX2, while leaving COL2A1 mRNA levels    
almost unchanged (Figure 4.3A; grey bars). However, addition of 1 nM BMP-7 to the  
differentiation medium resulted in significantly increased COL2A1 mRNA expression, 
while COL10A1 and RUNX2 mRNA expression was suppressed at day 21 (Figure 4.3A; 
black bars). Immunoblot analysis of protein lysates from day 21 samples overall confirmed 
the above findings (Figure 4.3B). To establish the opposing actions of BMP-2 and BMP-7 
in cartilage tissue formation we used an ex vivo periosteal organ culture system able to 
differentiate into cartilaginous tissue26,27. The mesenchymal progenitor cell-containing 
periosteal tissue was differentiated in between agarose layers (periosteum agarose culture 
(PAC) under influence of TGFβ3 and generated cartilaginous tissue after 20 days in differ-
entiation, as visualized by safranin-O staining of tissue sections (Figure 4.3C). The        
cartilaginous tissue expressed Col2a1, Col10a1 and Runx2 mRNAs (Figure 4.3D). BMP-2 
supplementation showed an increased hypertrophic phenotype (Figure 4.3C) as well as 
increased Col2a1, Col10a1 and Runx2 gene expression (grey bars). On the contrary, BMP-
Figure 4.2: Differential effects of BMP-2 and BMP-7 on the chondrogenic outcome of ATDC5 cells 
Equimolar concentrations (1 nM) of BMP-2 or BMP-7 were added from the start of chondrogenic differentiation 
of ATDC5. (A). Col2a1 mRNA expression at day 7, 10 and 14 in differentiation, relatively to t=0. White bars 
represent control condition, grey bars the BMP-2 condition and black bars the BMP-7 condition. (B). Same as in 
(A) but for Col10a1. (C). Protein expression of Col2a1, Sox9, Col10a1 and Runx2 at day 14 in differentiation. α-
Tubulin is used as loading control. (D). Induction of Sox9 and Acan mRNA expression was determined at day 14 
in differentiation. (E). Same as (D) but for Runx2, ALP and Mmp13 mRNA expression. (F). ALP enzymatic 
activity ((U) µmol/g/min) of t=14 samples was determined and normalized to total protein content. (G). Glycosa-
minoglycan content was determined by Alcian Blue staining and fold increase of t=14 samples was calculated 
relatively from t=0 samples. (H). Differences in cell proliferation speed between control and BMP conditions in 
ATDC5 differentiation was determined by X-Violet staining. Fold increase (DNA) from samples from t=14 was 
calculated relatively to day 0. In graphs, error bars represent mean ± 95% CI. Statistics are calculated with respect 
to the control condition and between BMP-2 and BMP-7 conditions. Statistical significant p-values (p < 0.05) are 
indicated by an *, ns = not stastistical significant. Molecular weight markers (kDa) are depicted on the left of 
immunoblots and relative quantifications are depicted on top of blots. 
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7 specifically increased Col2a1 mRNA expression, but showed a decreased Col10a1 and 
Runx2 mRNA expression as opposed to the control and BMP-2 conditions (black bars). 
Together these data show that exposure to equimolar concentrations of BMP-2 or BMP-7 
evokes differential chondrogenic outcomes during differentiation of ATDC5 cells, hBM-
SCs and rabbit periosteal explants; BMP-2 stimulates chondrocyte hypertrophy, whereas 
BMP-7 suppresses chondrocyte hypertrophy in the herein tested equimolar concentrations. 
 
Figure 4.3: Differential effects of BMP-2 and BMP-7 on chondrogenic differentiation of hBMSCs and rabbit 
periosteal explants 
Equimolar concentrations (1 nM) of BMP-2 or BMP-7 were added from the start of chondrogenic differentiation 
of hBMSCs (n=3 individual donors) or rPACs (n=5 individual donors). (A). COL2A1, COL10A1 and RUNX2 
mRNA expression at day 14 and 21 in hBMSC chondrogenic differentiation, relatively to t=0. White bars repre-
sent control condition, grey bars the BMP-2 treated condition and black bars the BMP-7 condition. (B). Protein 
expression of COL2A1 and COL10A1 at day 21 in chondrogenic differentiation of hBMSCs. α-Tubulin is used 
as loading control and molecular weight markers (kDa) are depicted on the left. (C). rPAC’s were harvested after 
20 days of chondrogenic differentiation. The panel shows representative examples of rPAC tissue sections 
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3.2 Involvement of Bapx1/Nkx3.2 in mediating the hypertrophy suppressing action of BMP
-7  in ATDC5 cells 
As BMP-2 and BMP-7 display differential effects on the chondrogenic outcome of  pro-
genitor cells it is expected that both BMPs differently direct pathways that balance the 
chondrogenic/hypertrophic fate of these cells. An important regulator in determining the 
chondrogenic fate is Bapx1/Nkx3.228,29. This transcription factor has been linked to      
preventing chondrocyte hypertrophy and maintaining a chondrogenic phenotype28,30,31. To 
determine whether Bapx1/Nkx3.2 may play a role as a downstream effector in the differen-
tial actions of BMP-2 and BMP-7 during chondrogenic differentiation, we measured 
Bapx1/Nkx3.2 expression levels in similar samples from Figure 4.2. As previously       
reported30, upregulation of Bapx1/Nkx3.2 expression was inversely correlated with        
progression in chondrogenic differentiation (Figure 4.4A; white bars). Expression of 
Bapx1/Nkx3.2 hardly responded to the presence of 1 nM BMP-2 (Figure 4.4A; grey bars 
and immunoblot). In contrast, an equimolar concentration of BMP-7 caused a significantly 
increased expression of Bapx1/Nkx3.2 at every time point measured in chondrogenic    
differentiation (Figure 4.4A; black bars and immunoblot), indeed suggesting an involve-
ment in the hypertrophy-suppressing action of BMP-7. To further investigate a potential 
functional involvement of Bapx1/Nkx3.2 in the BMP-7 action, Bapx1/Nkx3.2 expression 
was targeted in ATDC5 cells by RNAi. Transfection of a Bapx1/Nkx3.2 siRNA duplex 
during the course of chondrogenic differentiation (in the absence of added BMP-7) showed 
knockdown of Bapx1/Nkx3.2 mRNA as well as its protein expression at ten days in 
ATDC5 chondrogenic differentiation (Figure 4.4B; black bar and immunoblot).            
Previously, transcription of Bapx1/Nkx3.2 was reported to be driven by Sox928. In        
accordance with this we found that Sox9 expression only slightly, but not significantly, 
responded to Bapx1/Nkx3.2 knockdown (Figure 4.4B; black bar and immunoblot), as did  
stained with Safranin-O/Fast Green. Magnification is 200x. (D). Col2a1, Col10a1 and Runx2 mRNA expression 
at day 20 in chondrogenic differentiation or rPACs, relatively to t=0. White bars represent control condition, 
grey bars the BMP-2 treated condition and black bars the BMP-7 condition. In graphs, bars represent the average 
value of triplicate samples of 3 individual BMSC donors (n=3) or triplicate samples of 5 individual rPAC donors 
(n=5) and error bars represent mean ± 95% CI. Statistics are calculated with respect to the control condition and 
between BMP-2 and BMP-7 conditions. Statistical significant p-values (p < 0.05) are indicated by an *, ns = not 
stastistical significant. 
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Figure 4.4: Bapx1/Nkx3.2 is involved in regulating the hypertrophic fate of ATDC5 cells 
(A)  Bapx1/Nkx3.2 mRNA expression was determined in similar samples as Figure 4.2A/B. Right panel shows 
protein expression of Bapx1/Nkx3.2 at day 14 in ATDC5 differentiation in the absence or presence of equimolar 
concentrations of BMP-2 or BMP-7 (1 nM). (B). RNAi mediated knockdown of Bapx1/Nkx3.2 (black bars) or 
Sox9 (grey bars) mRNA expression was confirmed at day 10 in differentiation. Protein expression in similar 
samples is shown in the right panel. (C). Expression of Col2a1 and Acan mRNAs was determined in Mock and 
Bapx1/Nkx3.2 knockdown cells (B) at day 10 in differentiation. (D). In samples from (C)  but for  Runx2, 
Col10a1, Mef2c and ALP mRNA. (E). Protein expression of Col2a1, Sox9, Col10a1 and Runx2 in Mock and 
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Sox9 transcriptional targets Col2a1 and Acan (Figure 4.4C/E). On the other hand, knock-
down of Sox9 (Figure 4.4B; grey bar) downregulated  the expression of Bapx1/Nkx3.2 to 
the same extend as the dedicated Bapx1/Nkx3.2 knockdown, confirming that Sox9 mainly 
acts upstream of Bapx1/Nkx3.2 expression. Messenger RNA and protein expression of the 
Bapx1/Nkx3.2 repressional target Runx2 was increased upon Bapx1/Nkx3.2 knockdown 
(Figure 4.4D/E). Along with Runx2 other important chondrocyte hypertrophy-associated 
genes Col10a1, Mef2c (Myocyte-specific enhancer factor 2c) and ALP expression were 
also upregulated when expression of Bapx1/Nkx3.2 was inhibited (Figure 4.4D/E). We 
subsequently determined if the hypertrophy-suppressing effect of BMP-7 during chondro-
genic differentiation is related to the above Bapx1/Nkx3.2 action. To address this question 
we now transfected differentiating ATDC5 cells with the Bapx1/Nkx3.2 siRNA duplex in 
the absence or presence of 1 nM BMP-7. The presence of BMP-7 faithfully increased 
Bapx1/Nkx3.2 mRNA expression (Figure 4.5A; black bar) and the Bapx1/Nkx3.2 siRNA 
duplex effectively downregulated the BMP-7-induced Bapx1/Nkx3.2 expression (Figure 
4.5A; grey bar versus black bar). In accordance with the results presented in Figure 4.4B, 
Bapx1/Nkx3.2 knockdown in the presence of BMP-7 did not significantly affect Sox9 
mRNA expression, and only a slight, but not significant, decrease in Col2a1 and Acan 
mRNA expression was observed (Figure 4.5B). In contrast, we did observe clear effects on 
expression of chondrocyte hypertrophic genes. Despite the presence of BMP-7, Bapx1/
Nkx3.2 knockdown completely abolished the hypertrophy-suppressing effect of BMP-7. 
Expression levels of Col10a1, Runx2, Mef2c and ALP returned back to control condition-
levels or even higher (Figure 4.5C/D), showing that Bapx1/Nkx3.2 is involved in the    
hypertrophy-suppressing action of BMP-7 during chondrogenic differentiation of ATDC5 
cells.    
In conclusion, we here show that BMP-2 and BMP-7 have differential effects on the    
chondrogenic outcome of differentiating chondroprogenitor cells: BMP-2 acts a specific 
inducer of chondrocyte hypertrophy, while BMP-7 appears to increase or maintain       
chondrogenic potential and is able to suppress the level of chondrocyte hypertrophy via 
Bapx1/Nkx3.2. 
Bapx1/Nkx3.2 knockdown cells at day 10 in differentiation. In graphs, error bars represent mean ± 95% CI. Sta-
tistics are calculated with respect to the control condition (* indicates p-values < 0.05, ns = not statistical signifi-
cant), between BMP-2 and BMP-7 conditions and between Bapx1/Nkx3.2 and Sox9 siRNA treated conditions. 
For immunoblots, α-Tubulin is used as loading control, molecular weight markers (kDa) are depicted on the left 
of immunoblots and relative quantifications are depicted on top of blots. 
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4. Discussion 
Although BMP-2 and BMP-7 are both clinically used in bone fracture repair and are      
potential targets in cartilage regenerative approaches, a comparison of the effects of    
BMP-2 versus BMP-7 on chondrogenic differentiation of progenitor cells in vitro is not 
well documented and not taking chondrocyte hypertrophy into account. We here report 
that BMP-2 and BMP-7 display opposing actions on the outcome of chondrogenic        
differentiation of progenitor cells; BMP-2 stimulates a hypertrophic chondrocyte           
phenotype, whereas BMP-7 appears to suppress chondrocyte hypertrophy during chondro-
genic differentiation, associated with an increased chondrogenic phenotype. A hypertrophy 
stimulating action was reported previously for BMP-226, whereas the hypertrophy-
suppressing action of BMP-7 is an exciting new finding. Chubinskaya and colleagues    
reported that BMP-2 but even more BMP-7 was able to increase proteoglycan synthesis in 
adult human articular chondrocytes cultured in alginate beads14. This indeed suggests that 
BMP-7 predominantly acts in favour of a chondrogenic phenotype. Data reported by   
Shintani et al., are supporting our findings. The authors reported on a more pronounced 
beneficial action of BMP-7 as opposed to BMP-2 on chondrogenic outcome of bovine  
synovial explants, but hardly addressed the effects on chondrocyte hypertrophy32.         
Similarly, Kurth and colleagues compared different TGFβ-superfamily members and other 
factors for their chondrogenic potential on human synovial mesenchymal stem cells, but 
also excluded hypertrophic genes from their analyses33. In addition, Knippenberg et al. 
Figure 4.5: Bapx1/Nkx3.2 is involved in the hypertrophy-suppressing action of BMP-7 in ATDC5 cells 
The involvement of Bapx1/Nkx3.2 in the hypertrophy-suppressing action of BMP-7 during chondrogenic differ-
entiation of ATDC5 cells was determined. (A). Knockdown of Bapx1/Nkx3.2 by siRNA transfections was con-
firmed at day 10 in differentiation of BMP-7 treated cells on mRNA (left panel, grey bars) and protein level (right 
panel). (B). Expression of Sox9, Col2a1 and Acan mRNAs was determined in Mock (white and black bars, with-
out/with BMP-7 respectively) and Bapx1/Nkx3.2 knockdown cells (grey bars) at day 10 in differentiation in BMP
-7 treated cells. (C). In samples from (B.) mRNA expression of Col10a1, Runx2, Mef2c and ALP was deter-
mined. (D). Protein expression of Col2a1, Sox9, Col10a1 and Runx2 in Mock and Bapx1/Nkx3.2 knockdown 
cells at day 10 in differentiation of BMP-7 treated cells. In graphs, error bars represent mean ± 95% CI. Statistics 
are calculated with respect to the control condition and BMP-7 control condition, as well as between the BMP-7 
control condition and the BMP-7/Bapx1 kd condition, Statistical significant p-values (p < 0.05) are shown by an 
*, ns = not statistical significant. For immunoblots, α-Tubulin is used as loading control, molecular weight mark-
ers (kDa) are depicted on the left of immunoblots and relative quantifications are depicted on top of blots. 
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showed that short-term treatment (15 minutes) of undifferentiated mesenchymal progenitor 
cells with BMP-2 resulted in differentiation towards the osteogenic lineage, whereas short-
term BMP-7 treatment increased chondrogenic marker expression34. The majority of the 
literature however reports on the individual effects of BMP-2 or BMP-7 on chondrogenic 
outcome of progenitor cell differentiation16,23,33,35-37. 
Studies reporting on the use of BMPs in in vitro and ex vivo cell/cartilage models used 
various concentrations of both BMPs ranging from 10 ng/ml34 to as high as 500 ng/ml38. 
The BMP concentrations that were tested in our dose response experiments (Figure 4.1) 
are relatively low as compared to the majority of the published studies. As our main aim 
was to investigate whether BMP-2 and BMP-7 may display differential actions, we      
hypothesized that an inverse limiting dilution approach would be the most sensitive way to 
compare both BMPs, while avoiding the risk of growth factor overload and potential 
aspecific use of BMP receptors39,40. It remains however to be determined how higher     
concentrations of both BMPs would compare in their chondrogenic actions on the herein 
tested chondrogenic models.      
In analogy to the process of chondrogenic differentiation, different BMPs are expressed in 
different zones of the growth plate and it is thus likely that these BMPs exert                 
differentiation-phase dedicated functions in regulating chondrogenic development. BMP-2 
is expressed by hypertrophic chondrocytes whereas BMP-7 is mainly expressed by       
proliferating chondrocytes41. Also the BMP type I receptors, which activate R-Smad     
signalling, display differential expression patterns in the developing growth plate. BMP 
receptor type IA (BMPRIA or ALK (activin receptor-like kinase) 3) is expressed by      
proliferating and hypertrophic chondrocytes, BMPR-IB (also known as ALK6) is found 
throughout the growth plate and ALK2 is detected in the resting zone and proliferating 
chondrocytes. These receptors do not bind all BMPs with similar affinity and can thus  
potentially induce different chondrogenic outcomes. BMP-2 preferentially binds to   
BMPR-IA and BMPR-IB, whereas BMP-7 binds with higher affinity to ALK2 and   
BMPR-IB39,41,42, which could suggest a more prominent function for BMP-2 in chondro-
cyte hypertrophy and for BMP-7 in chondrocyte maintenance and cartilaginous extra-
cellular matrix synthesis. Although previously specific Smad-signalling has been linked to 
the chondrogenic fate43, it remains elusive whether the herein found differential action of 
BMP-2 and BMP-7 can be explained by specific Smad activation. In addition BMPs can 
also induce signalling through MAP (mitogen activated protein) kinases and thereby influ-
ence the chondrogenic outcome 6. We are currently evaluating the above options.   
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As a link between BMP-2 and chondrocyte hypertrophy has been established                 
previously26,44 we here specifically further focussed on a possible mechanism which could 
explain the hypertrophy-suppressing action of BMP-7. Focussing on Sox9 and Runx2 as 
key factors in regulating the balance between chondrogenic maintenance and chondrocyte 
hypertrophy, it was reported previously that Sox9 is able to repress Runx2 expression via 
the Runx2 transcriptional repressor Bapx1/Nkx3.228,30,31. Bapx1/Nkx3.2 is a transcriptional 
target of Sox9 and thus the BMP-7 induced Sox9 levels may prevent Runx2 induction via 
upregulating Bapx1/Nkx3.228.  In addition to suppressing the transcription of Runx2, 
Bapx1/Nkx3.2 was recently found to be directly involved in driving the transcription of 
Col2a145, providing an potential alternative route via which the BMP-7-induced        
Bapx1/Nkx3.2 may balance the hypertrophic fate of a chondrocyte. However, knockdown 
of Bapx1/Nkx3.2 in ATDC5 showed only moderate/non-significant effects on Col2a1 
mRNA levels, making it conceivable that the hypertrophy suppressive action of BMP-7 via 
Bapx1/Nkx3.2 in ATDC5 is mainly via an active hypertrophy-suppressing route rather 
than an active pro-chondrogenic (Col2a1) mechanism. Another possible determinant in the 
Bapx1/Nkx3.2 depending BMP-7 action could be parathyroid hormone related peptide 
(PTHrP). Our unpublished data show that PTHrP expression is upregulated upon exposure 
to BMP-7. Previously it has been reported that maintenance of Bapx1/Nkx3.2 expression 
in growth plate proliferative chondrocytes depends on PTHrP signals31 and that BMP and 
PTHrP signalling interact16. Finally, sonic hedgehog (Shh) has been reported to induce 
Bapx1/Nkx3.2 expression to induce somitic chondrogenesis in avian progenitor cells46. It 
was found that Nkx3.2 (like Shh) can only induce somitic chondrogenesis in the presence 
of a BMP signal. These findings may provide alternative explanations through which BMP
-7 might execute its hypertrophy-suppressive action, although at this stage it is not clear 
what the potential relative contribution of these alternative pathways is to control          
expression of Bapx1/Nkx3.2. Furthermore, it is well known that Sox9 is regulated by BMP 
activity in vitro and in vivo17,47,48. This was confirmed in our study for BMP-2 and BMP-7. 
In view of a Sox9-dependent expression of Bapx1/Nkx3.2 it was therefore surprising that 
we did not measure induction of Bapx1/Nkx3.2 in both BMP conditions. This discrepancy 
may be explained by potential BMP-specific differential signalling pathways downstream 
of different BMP-receptors, allowing (Sox9-driven) Bapx1/Nkx3.2 expression in the   
BMP-7 conditions, while not supporting this upon signalling by BMP-2. This, however, 
remains speculation. 
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In conclusion, we here show that BMP-2 and BMP-7 have differential actions during  
chondrogenic differentiating of chondroprogenitor cells: BMP-2 acts a specific inducer of 
chondrocyte hypertrophy, while BMP-7 appears to increase or maintain chondrogenic  
potential and prevent chondrocyte hypertrophy. These results may provide a rationale for 
an application-dependent use of specific BMPs in endochondral-based cartilage and bone 
regenerative techniques49. 
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Abstract 
 
Introduction: Skeletogenesis and bone fracture healing involve endochondral ossification, 
a process during which cartilaginous primordia are gradually replaced by bone tissue. In 
line with a role for cyclooxygenase-2 (COX-2) in the endochondral ossification process, 
non-steroidal anti-inflammatory drugs (NSAIDs) were reported to negatively influence 
bone fracture healing due to impaired osteogenesis. However, the role of COX-2 activity 
in chondrogenesis has not been addressed before.  
Methodology: The role of COX-2 was studied during chondrogenic differentiation of 
ATDC5 cells and rabbit periosteal explants. BMP-2 was used to increase hypertrophic 
differentiation and the NSAIDs NS398 and Celecoxib were applied to specifically inhibit 
COX-2 activity. Chondrogenic outcome was measured by gene- and protein expression 
analysis, and (immuno)histochemical stainings. For in vivo evidence skeletally immature 
NZW rabbits were treated with Celecoxib (10mg/kg) for 21 days. Growth plate             
development was analyzed by histochemistry.   
Results: Here we show that COX-2 activity fulfils a regulatory role in chondrocyte hyper-
trophic differentiation. Our data reveal essential cross-talk between COX-2 and bone   
morphogenic protein-2 (BMP-2) during chondrocyte hypertrophic differentiation. BMP-2 
mediated chondrocyte hypertrophy is associated with increased COX-2 expression and 
pharmacological inhibition of COX-2 activity by NSAIDs (e.g. Celecoxib) decreases   
hypertrophic differentiation in various chondrogenic models in vitro and in vivo, while 
leaving early chondrogenic development unaltered. Our findings demonstrate that COX-2 
activity is a novel factor partaking in chondrocyte hypertrophy in the context of            
endochondral ossification.  
Conclusions: These observations provide a novel etiological perspective on the adverse 
effects of NSAIDs on bone fracture healing and may have important implications for the 
use of NSAIDs during endochondral skeletal development.  
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1. Introduction 
Endochondral ossification is a multistage process that determines the major part of     
mammalian skeletal development. This process takes place in growth plates of long bones 
which are populated by highly proliferative chondrocytes, vectorially dictated to           
differentiate into hypertrophic chondrocytes before dying from apoptosis. The remaining 
mineralized extra cellular matrix provides a scaffold for infiltrating osteoblasts and osteo-
clasts to adhere to and remodel, setting the stage for de novo bone deposition1,2.         
Chondrocyte hypertrophic differentiation also plays a role in bone fracture healing which 
reiterates the endochondral ossification process: initial cartilage callus formation by     
mesenchymal progenitor cells from the local periosteum and bone marrow, followed by 
chondrocyte hypertrophy and osteogenic mineralization and remodelling. 
Non steroidal anti-inflammatory drugs (NSAIDs) are widely used systemic inhibitors of 
inflammatory prostaglandin production by cyclooxygenases (COX-1 and COX-2)3. In  
orthopaedic surgery the use of NSAIDs is under debate, as systemic NSAID treatment 
delays spinal fusion in patients and animal models 4 and fracture healing of the long bones5
-8. This property of NSAIDs is, however, exploited in the clinic to prevent periprosthetic 
heterotopic calcification after hip surgery9. The action of NSAIDs has been studied in the 
context of osteogenesis, and several observations link prostaglandin E2 (PGE2) and COX-2 
to osteoblast differentiation10-13. Mice lacking the prostaglandin synthesizing enzymes 
COX-2 or microsomal prostaglandin E synthase-1 (mPGES-1) show impaired fracture 
healing caused by insufficient PGE2 synthesis
13,14. Expression of bone morphogenic     
protein-2 (BMP-2) is regulated by COX-2 activity10 and downstream signalling of BMP-2 
in osteogenesis involves formation of a runt-related transcription factor 2 (Runx2) - Smad 
transcription factor complex15. Combined these data provide insight into the role of COX-2 
activity during osteogenesis and suggest a plausible explanation for the adverse effects of 
NSAIDs on bone healing.  
Recently, prostaglandins were shown to influence chondrogenesis in vitro16,17. Prostaglan-
din receptors and COX-enzymes localize to the developing growth plate18,19 and BMP-2, 
whose expression depends on COX-2 activity10, is described to determine endochondral 
ossification by regulating chondrocyte differentiation20. Hypertrophic chondrocytes 
uniquely express the collagen type X alpha-1 chain (Col10a1)21 whose expression depends, 
amongst others, on (BMP-2 induced) Runx2/core-binding factor subunit alpha-1 (Cbfa1)22. 
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However, the exact description of a role for COX-2 in chondrogenesis is lacking, and the 
functional relation between BMP-2, COX-2 and chondrocyte hypertrophic differentiation 
in the context of endochondral ossification remains unclear at present. We therefore     
hypothesized that chondrocyte hypertrophic differentiation is determined by BMP-2 via a 
COX-2 dependent mechanism. The hypothesis was addressed using different models for 
endochondral ossification. Our results reveal that inhibition of COX-2 activity specifically 
decreases the level of BMP-2 induced hypertrophic differentiation in endochondral culture 
models, and systemic inhibition of COX-2 activity in vivo resulted in significantly        
impaired chondrocyte hypertrophic differentiation in rabbit growth plates. 
 
 
2. Materials and Methods 
 
2.1 ATDC5 cell culture and chondrogenic differentiation 
ATDC5 cells were cultured in proliferation medium (DMEM/F12 (Invitrogen, Carlsbad, 
CA, USA), 5% FCS (PAA, Pasching, Austria), 1% NEAA (Invitrogen) and 1% antibiotic/
antimycotic (Invitrogen))23. Cells were differentiated in differentiation medium 
(proliferation medium supplemented with 10 mg/ml Insulin (Sigma, St. Louis, MO, USA), 
10 mg/ml Transferrin (Roche Applied Science, Woerden, the Netherlands) and 30 nM  
Sodium Selenite (Sigma)). The day prior to differentiation, ATDC5 cells were plated at 
6400 cells/cm2 in culture dishes and allowed to adhere overnight in proliferation medium. 
Chondrogenesis was initiated by changing the medium to differentiation medium.         
Differentiation medium was strictly changed at day 2, 4, 6 and 8 and from day 8 every day. 
When indicated BMP-2 was used (Wyeth). COX-2 activity was inhibited by NS398 
(Cayman Chemicals, Ann Arbor, MI, USA) or Celecoxib (LC Laboratories, Woburn, MA, 
USA). Phosphorylation of Smad1/5/8 was inhibited by Dorsomorphin (Santa Cruz Bio-
technologies, CA, USA) 
 
2.2 Periosteum Agarose Culture (PAC) chondrogenic differentiation 
Periosteum was harvested from the proximal tibia of skeletally mature New Zealand white 
(NZW) rabbits. Post-mortem control animals were freshly obtained from an unrelated 
study, no ethical approval was necessary. Periosteum was harvested from these rabbits 
within 15 minutes after sacrifice. Presence of the cambium layer was checked by          
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histology. The periosteum was transported in HEPES buffered DMEM/F12 supplemented 
with antibiotics. Per rabbit the harvested Periosteum (generally 5 x 5 mm) was prepared as 
a 3 x 3 mm piece using a sterile surgical blade and embedded in 24-wells plates using the 
following procedure adapted from O’Driscoll et al.24: 250 ml 1% high melting              
agarose/0.9% NaCl (37oC) was applied on the bottom of the well and allowed to solidify. 
Periosteum pieces were put on top and allowed to float in 375 ml 1% low melting         
agarose/0.9% NaCl (37oC). After solidifying, an additional 375 ml 1% low melting      
agarose/0.9% NaCl was applied. The agarose was allowed to solidify for an additional ten 
minutes. One milliliter of PAC proliferation medium (DMEM/F12, 10% FCS, 1% P/S, 1% 
NEAA) was added and incubated overnight at 37oC/5% CO2. After overnight incubation, 
medium was changed to PAC differentiation medium (proliferation medium supplemented 
with 1% ITS (insulin-transferrin- sodium selenite media supplement, Invitrogen), 50 mg/
ml L-ascorbic acid-2-phosphate (Sigma), 10 ng/ml transforming growth factor β3 (TGF-b3) 
(R&D, Minneapolis, MN, USA)). PAC’s were maintained in differentiation medium by 
changing medium every three days. 
 
2.3 Immunoblotting 
After washing with 0.9% NaCl, ATDC5 cells were lysed in RIPA buffer (150 mM NaCl, 
1% NP-40, 0.5% sodium dexoycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.00, 5 mM 
EDTA, 0.5 mM dithiotreitol, 2 mM phenylmethylsulfonylfluoride) and homogenized on 
ice by sonication (Soniprep 150, MSE). Insoluble material was removed by centrifugation 
(5 minutes; 13,000 x g; 4oC). Total protein concentration was determined using a BCA 
(bicinchoninic acid) assay (Sigma). Polypeptides were separated by SDS-PAGE and    
transferred to nitrocellulose membranes by electroblotting. Immunodetection of Col2a1, 
Col10a1, GAPDH (glyceraldehyde 3-phosphate dehydrogenase), Runx2, pSmad1/5/8,       
β-catenin and COX-2 was performed using polyclonal goat and rabbit sera (Col2a1 
(SouthernBiotech, Birmingham, AL, USA), Col10a1 (Calbiochem, Darmstadt, Germany), 
COX-2 (Oxford Biomedical Research, Oxford, UK), pSmad1/5/8 (Cell Signaling        
Technology, Boston, MA, USA) and mouse monoclonal antibodies recognizing GAPDH 
(Fitzgerald, Acton, MA, USA), β-catenin (BD Biosciences, Breda, the Netherlands) and 
Runx2 (MBL, Woburn, MA, USA). Horseradish peroxidase (HRP)-conjugated immuno-
globulins were purchased from DakoCytomation (Glostrup, Denmark) and applied as    
secondary antibody. Bound antibodies were visualized by enhanced chemiluminescence 
detection procedures. Several housekeepers were used to verify total protein loading.  
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However, although equally loaded (quantitatively determined by BCA assay and visually 
by Ponseau-S (on membrane) and Coomassie Brilliant Blue staining (in gel)), GAPDH,     
α-tubulin and b-actin protein expression appeared to be regulated during the course of 
chondrogenesis. However, these protein housekeepers were stable amongst different     
samples from the same chondrogenic differentiation stage (e.g. day 14). 
 
2.4 Real time quantitative PCR (RT-qPCR) 
To isolate total RNA from PAC cultures, tissue was cut in pieces and soaked overnight in 
500 ml Trizol (Invitrogen, Breda) at 4oC. For RNA isolation from ATDC5 cells, cells were 
washed with 0.9% NaCl and disrupted with 500 ml Trizol. Total RNA from the aqueous 
phase was precipitated by using isopropanol and centrifugation (13.000 x g; 30 minutes; 
4oC). Pellets were washed with 80% ethanol, allowed to airdry and dissolved in DEPC-
treated water. Genomic DNA was removed by DNase I (Roche) treatment (20 U; 1 hour; 
37oC). RNA was precipitated with NaAc/ethanol and subsequent centrifugation. Pellets 
were washed with 80% ethanol and allowed to airdry. Purified RNA was dissolved in 20 
ml DEPC-treated water and analyzed spectrophotometrically (Nanodrop, Thermo         
Scientific, the Netherlands). For cDNA synthesis, 200 ng total RNA was used in a 25 ml 
standard RT-reaction containing 1x RT-buffer (Promega, Madison, MA, USA); 2 ng/ml 
random primer (Promega); 0.5 mM per dNTP (Eurogentec, Seraing, Belgium); 10 mM 
dithiotreitol; 0.4 U/ml RNasin (Promega); 4 U/ml M-MLV reverse transcriptase 
(Promega). 
Real time qPCR was performed in triplicate with Mesagreen qPCR mastermix plus for 
SYBR® Green (Eurogentec) in 96-well optical plates according to the manufacturer’s   
protocol. Forward and reverse primers were used at 300 nM each. Gene expression was 
determined using an ABI PRISM® 7700 Sequence Detection System (Applied              
Biosystems, Foster City, CA, USA). Serially diluted standard curves were included to 
quantify the samples. Samples were heated for 10 minutes at 95oC and DNA was amplified 
by 40 cycles of 15 seconds 95oC and 1 minute 60oC, followed by a melting curve. Data 
were analyzed using Sequence Detection Software version 1.7 (Applied Biosystems,    
Foster City, CA, USA) using the standard curve method. Values were normalized to          
β-actin (in contrast to β-actin protein levels, β-actin mRNA levels are stable during chon-
drogenesis). The primer sequences for detection of Col2a1, Col10a1, β-actin, BMP-2, 
Runx2, Mef2c, MMP13, VEGF-A, COX-2 and ALP were based on the coding sequences 
of the respective mRNAs. The sequences are listed in Table 5.1. Values were normalized 
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to β-actin mRNA levels and fold increase gene expression was calculated relatively to the 
mean expression value at day 0 in differentiation. 
 
2.5 PGE2 measurement 
Inhibition of COX-2 activity was determined by measuring prostaglandin E2 (PGE2) in 
culture medium or blood plasma. PGE2 concentration was determined by a standardized 
EIA according to the manufacturers’ protocol (Cayman Chemical). 
 
 
Table 5.1: Primer sequences for RTqPCR 
 
 
The 5’ to 3’ forward and reverse oligonucleotide sequences used for RT-qPCR are listed in the table.  
 
2.6 Alkaline Phosphatase activity 
Enzymatic activity of Alkaline Phosphatase (Alp) in ATDC5 cultures was determined us-
ing a colorimetric assay. Cells were lysed in freshly prepared collection buffer (1.5 M Tris-
HCl pH 9.0; 2% (v/v) Triton X-100) and homogenized on ice by sonication (Soniprep 150, 
MSE). Insoluble material was removed by centrifugation (5 minutes; 13,000 x g; 4oC). 
Total protein concentration was determined using a BCA assay (Sigma). In flat bottom 96 
wells plates, containing assay buffer (1.5 M Tris-HCl pH 9.0; 1 mM ZnCl2; 1mM MgCl2; 
7.5 mM p-nitrophenyl phosphate), Alp activity was determined by measuring Alp-depend 
enzymatic conversion of p-nitrophenyl phosphate to nitrophenyl phosphate by             
spectrophotometrical analyses at 405 nm. A calibration curve containing an increasing 
Oligo sets mouse Forward Reverse 
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
Col10a1 ‘5-CATGCCTGATGGCTTCATAAA-3’ ‘5-AAGCAGACACGGGCATACCT-3’ 
Runx2 ‘5-CGATGAAGACCCCAACCCTAA-3’ ‘5-ACTGGTAATGGCATCAAGGGATA-3’ 
COX-1 ‘5-TCCTCACAGTGCGGTCCAA-3’ ‘5-AAGGCCTCCCAGCTGATGTAG-3’ 
COX-2 ‘5-GGCCATGGAGTGGACTTAAA-3’ ‘5-AAGTGGTAACCGCTCAGGTG-3’ 
BMP-2 ‘5-AGAAAAGCGTCAAGCGAAACA-3’ ‘5- GTCCACGTACAAAGGGTGTCTCT-3’ 
Mef2c ‘5-GGGCCTCAATGGCTGTGA-3’ ‘5-CTCAGACTCAGGGCTGTGACCTA-3’ 
Mmp13 ‘5-CGATGAAGACCCCAACCCTAA-3’ ‘5-ACTGGTAATGGCATCAAGGGATA-3’ 
VEGF-A ‘5-GTCAGAGAGCAACATCACCA-3’ ‘5-CATCTGCTGTGCTGTAGGAA-3’ 
Alp ‘5-CCGATGGCACACCTGCTT-3’ ‘5-GGAGGCATACGCCATCACAT-3’ 
β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
Oligo sets rabbit Forward Reverse 
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
Col10a1 ‘5-AACCTGGACAACAGGGACTTACA-3’ ‘5-CCATATCCTGTTTCCCCTTTCTG-3’ 
COX-2 ‘5-GGCCATGGAGTGGACTTAAA-3’ ‘5-AAGTGGTAACCGCTCAGGTG-3’ 
β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
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concentration of nitrophenyl phosphate was used to determine the absolute amount of Alp-
generated nitrophenyl phosphate in time. Values were normalized to total protein          
concentration and expressed as Units Alp activity (1U = 1 µmol nitrophenyl phosphate/
minute/gram).  
 
2.7 Cell proliferation 
Growth curves for ATDC5 cells were generated by determining DNA content using crystal
-violet. Cells were fixed with 4% paraformaldehyde in phosphate buffered saline for ten 
minutes at room temperature. After washing, cells were air dried for further analysis. Fixed 
cells were incubated with 0.1% crystal-violet for 30 minutes at room temperature. Cells 
were washed with water to remove excess crystal-violet and allowed to air-dry in the dark 
overnight. Crystal-violet was extracted by incubation with 10% acetic acid for 15 minutes 
under continuous agitation. Extracted crystal-violet was determined spectrophotometrically 
at 590 nm using a plate reader (Biorad, the Netherlands). 
  
2.8 (Immuno)histochemistry 
PAC tissue samples or mouse growth plates were decalcified in formalin/EDTA,          
dehydrated following standard procedures and embedded in paraffin. Tissue sections were 
cut at 5 mm and positioned on Superfrost Plus slides (Menzel, Germany). Before          
histochemistry, tissue sections on slides were deparafinized and rehydrated using standard 
protocols. Proteoglycans were stained with Safranin-O (0.1%) and counterstained with 
Fast Green (0.1%). Stained sections were dehydrated and mounted in Histomount (Thermo 
Shandon) for microscopic analysis.  
For immunohistochemical analysis of Runx2, Col2a1, Col10a1 and Alp in PAC sections, 
rehydrated sections were treated with 0.4% hyaluronidase (Col2a1 and Col10a1 only). 
Endogenous peroxidase activity was inactivated by Peroxidase-Blocking solution (Dako, 
REAL) and samples were blocked with 5% skim milk (Runx2), 10% normal sheep serum 
(Col2a1 and Col10a1) or 10% normal rabbit serum (Alp) for 30 minutes. Anti-Cbfa1/
Runx2 monoclonal antibody (MBL) was used at 1:700. Mouse monoclonal anti-Col2a1   
(II-II6B3; Developmental Studies Hybridoma Bank) and mouse negative control IgG1 
(Dako) were used at 1:50 and same IgG1 concentration, respectively. Rabbit polyclonal 
anti-Col10a1 and negative control non-immune rabbit serum were used at 1:1000. Goat 
polyclonal affinity purified anti-Alp IgG (R&D systems) and negative control non-immune 
goat total IgG (protein-G purified) were used at 1:50 and same IgG concentration, respec-
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tively. Primary antibodies were incubated for one hour at room temperature. Unbound anti-
bodies were removed by washing with TBS-T. For Runx2 detection sheep-anti-mouse-
biotin (Amersham Biosciences) was used as secondary antibody at 1:200 and incubated for 
one hour at room temperature in TBS/BSA. Sections were washed with TBS-T and Biotin 
conjugate was detected with SA-HRP (Beckman Coulter) at 1:500 in TBS/BSA and DAB 
chromogen (Dako). For Col2a1 and Col10a1 bound antibodies were visualized with HRP 
labelled anti-rabbit or anti-mouse secondary antibodies (Dako, EnVision+ System-HRP 
labelled Polymer) by incubation for 30 minutes at room temperature. Unbound antibodies 
were removed by rinsing in PBS-T. For Alp detection bound primary antibodies were   
detected by 1:500 diluted HRP labelled rabbit-anti-goat secondary antibodies (Dako). For 
detection, DAB chromogen substrate (Dako) was used. Stained sections were mounted in 
Histomount as described above. In mouse growth plates from 6 week old mice (Maastricht 
University Medical Center animal ethical committee approval ID: DEC 2008-042) COX-2 
was detected using citrate-mediated antigen retrieval and 1:50 anti-COX-2 monoclonal 
antibody (BD Biosciences). Mouse negative control IgG1 (Dako) was used at same      
concentration. Detection of COL10A1 and ALP in these growth plates was carried out as   
described above for the PAC sections. Visualisation of anti-COX-2, anti-ol10a1 and anti-
Alp primary antibodies was performed as described above. 
 
2.9 Celecoxib treatment of rabbits and analysis of growth plates 
The experiment was approved by the Maastricht University animal ethical committee 
(DEC 2010-027-g). celecoxib (10 mg/kg) (Pfizer) was orally administered to skeletally 
immature New Zealand white rabbits (107 days old) for 21 days on a daily basis in 1 ml 
Critical Care-paste (Oxbow Animal Health). Control animals received 1 ml paste only. The 
groups consisted of six control animals and seven celecoxib-treated animals. Rabbits were 
euthanized after three weeks by an overdosis of pentobarbital. The left ulnas were isolated 
and fixed in formalin. Growth plates were decalcified in 0.5 M EDTA pH 7.8 for three 
weeks. After that growth plates were briefly (20 hours) incubated in 1:5 diluted TBD-1 
Rapid Decalcifier (Thermo Shandon). Growth plates were cut in two halfs perpendicular to 
the growth plate plane, dehydrated and embedded in paraffin. From the anterior half, 5 mm 
sections were cut. Sections where stained with Haematoxylin and further processed for 
microscopic analysis using a Zeiss Axioscope A.1 (with AxioVision 4.8 software). The 
anatomical middle of the growth plates was used as an internal reference point. From each 
growth plate three consecutive sections were measured at both sides at half the distance 
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from the anatomical reference point. At this point a standardized box with a width of 250 
mm was defined that fitted an average number of 10 chondrocyte columns. Within the box 
the lengths of the proliferative and hypertrophic zones were determined by three            
independent blinded observers.  
 
2.10 Statistics 
Statistical analyses on the rabbit growth plates were performed as follows. Measurements 
from consecutive sections and both sides of the same growth plate were averaged. Data of 
the control (six rabbits) and celecoxib (seven rabbits) groups were tested for statistical   
significance using SPSS 16.0 software. Normal distribution of the data was confirmed by a 
Shapiro-Wilk normality test and subsequently the significance of the total length of the 
growth plates, length of the proliferative zone, length of the hypertrophic zone and the 
ratio between the proliferative and hypertrophic zone were determined using Mann-
Whitney tests. A p < 0.05 was defined as significant. Next to the above statistics, other 
statistical calculations were determined by unpaired two-tailed Student’s t-tests using 
Graphpad PRISM 5.0. A p < 0.05 was defined as significant. To test for normal             
distribution of the input data, D’Agostino-Pearson omnibus normality tests were per-
formed. All herein presented quantitative data sets passed the normality tests. 
 
 
3. Results 
3.1 BMP-2 increases COX-2 expression during endochondral ossification 
COX-2 expression was determined in the ATDC5 model. ATDC5 differentiation follows a 
well-defined endochondral program from undifferentiated chondroprogenitor to             
hypertrophic chondrocyte. Differentiation was initiated as described previously23 and was 
evident after 7 days of differentiation as measured by Collagen type II (Col2a1) mRNA 
expression. Col2a1 expression stabilized 10 days after induction of differentiation (Figure 
5.1A). Hypertrophic differentiation is characterized by upregulation of Col10a1 mRNA 
from 10 days in differentiation (Figure 5.1A) and increased further at 14 days and later 
time points (see also below; Figure 5.5). As an additional hypertrophic marker, increased 
expression of alkaline phosphatase (Alp) mRNA was confirmed (Figure 5.1A). Similarly, 
increased mRNA expression was observed over time for other hypertrophic markers as  
COX-2 is Involved in Chondrocyte Hypertrophy 
135 
 
 
Chapter 5 
136 
Runx2, myocyte-specific enhancer 2c (Mef2c), matrix metalloproteinase 13 (Mmp13) and 
vascular endothelial growth factor a (VEGF-A) (see below; Figure 5.5). Col2a1 and 
Col10a1 protein expression followed similar expression patterns as their respective 
mRNAs (Figure 5.1B). COX-2 mRNA expression was almost 4-fold upregulated at 14 
days in differentiation (Figure 5.1A) and immunoblotting showed that COX-2 protein is 
expressed during chondrogenesis from day 7 onward (Figure 5.1B). We next determined 
whether in chondroprogenitor cells COX-2 expression is regulated by BMP-2. In a BMP-2 
dose-response experiment COX-2 mRNA expression responded significantly to a concen-
tration of 30 ng/ml BMP-2 and was accompanied by a significantly increased Col10a1 and 
Figure 5.1: COX-2 expression and BMP-2 responsiveness during chondrogenic differentiation  
Differentiated ATDC5 cells were harvested at day 0, 4, 7, 10 or 14. (A). Induction of Col2a1, Col10a1, Alp and 
COX-2 mRNA expression was determined by RT-qPCR. Error bars represent mean ± s.d.. (B). Col2a1, Col10a1 
and COX-2 protein expression at 0, 7 and 14 days after initiation of differentiation. GAPDH was used as house-
keeper. Molecular weight markers (kDa) are depicted on the right. (C). BMP-2 was added to differentiation me-
dium at 0 ng/ml (white bars), 0.3 ng/ml (light grey bars), 3.0 ng/ml (dark grey bars) or 30 ng/ml (black bars). 
Induction of Col2a1, Col10a1, Alp and COX-2 mRNA expression was determined at day 0, 4, 7 and 10 by RT-
qPCR. Sample size is 9 for every time point. (D). Protein samples from 0 and 30 ng/ml BMP-2 conditions (day 
14) were analyzed for Col2a1, Col10a1, COX-2, Runx2 and GAPDH by immunoblotting. (E). ATDC5 cells were 
differentiated in the presence of increasing BMP-2 concentrations and induction of COX-1 and COX-2 mRNAs 
at day 14 was determined by RT-qPCR. Sample size is 9 for every BMP-2 concentration. (F). Spatiotemporal 
expression of COX-2, Col10a1 and ALP in 6 weeks old mouse growth plates was determined by immunohisto-
chemistry (IHC). Left upper panel: anti-COX-2, left lower panel: IgG1-control; middle upper panel: anti-
Col10a1, middle lower panel: non-immune serum (NIS) control; right upper panel: anti-ALP, right lower panel: 
IgG control. PZ = proliferative zone, HZ = hypertrophic zone. Scale bars indicate 25 µm. * indicates p<0.05. 
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ALP mRNA expression (Figure 5.1C). Although Col2a1 mRNA expression was only    
marginally affected, 30 ng/ml BMP-2 did result in higher Col2a1 protein expression, as 
well as increased expression of Runx2 and Col10a1 14 days in differentiation (Figure 
5.1D). Also COX-2 protein expression responded positively to this BMP-2 condition 
(Figure 5.1D). BMP-2 specifically provoked COX-2 expression, as COX-1 expression 
remained unaltered under various BMP-2 concentrations (Figure 5.1E). To further        
corroborate the relation between COX-2 and chondrocyte hypertrophic differentiation, 
spatio-temporal expression of COX-2 was determined in the murine growth plate. COX-2 
is specifically expressed in hypertrophic chondrocytes that express Col10a1 and Alp 
(Figure 5.1F). Throughout hypertrophic differentiation (i.e. more distal to the proliferative 
zone), expression of COX-2 increased. These data demonstrate that expression of COX-2 
correlates with chondrocyte hypertrophic differentiation and suggest that BMP-2 plays a 
central role in this process. 
 
3.2 COX-2 activity is required for chondrocyte hypertrophic differentiation 
To examine COX-2 activity in the context of chondrocyte hypertrophic differentiation, we 
analyzed enzymatic activity of COX-2 by measuring PGE2 levels in culture supernatants. 
PGE2 was readily detectable at 10 days in differentiation and further increased at 14 days 
(Figure 5.2; white bars; (-) BMP-2), in good agreement with increased COX-2 expression 
(Figure 5.1A/B). In line with the observed BMP-2 responsiveness of COX-2 expression 
(Figure 5.1C-E), increased PGE2 synthesis in the presence of 30 ng/ml BMP-2 (Figure 5.2; 
white bars; (+) BMP-2) indicated enhanced levels of enzymatically active COX-2. To  
substantiate a functional link between COX-2 protein levels and prostaglandin synthesis, 
we pharmacologically inhibited COX-2 enzyme activity using NS398. Specificity of 
NS398 for COX-2 over COX-1 was confirmed (Figure 5.3). Addition of NS398 almost 
completely abolished PGE2 synthesis to near-background levels (Figure 5.2; grey and 
black bars), confirming a role for COX-2-mediated prostaglandin synthesis during chon-
drogenic differentiation.  
Next we analysed whether COX-2 inhibition influences chondrogenic differentiation in the 
absence or presence of exogenous BMP-2. Differentiation medium was supplemented with 
increasing NS398 concentrations and chondrogenic marker expression was analyzed at 14 
days into differentiation. In the absence of BMP-2, 20 µM NS398 reduced Col10a1 protein 
and mRNA expression (Figure 5.4A/B). In line with reduced Col10a1 expression, Runx2 
protein expression was reduced by 20 µM NS398 (Figure 5.4A), whereas under all NS398  
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Figure 5.2: Inhibition of COX-2 activity during ATDC5 differentiation 
ATDC5 cells were differentiated in the absence or presence of 30 ng/ml BMP-2 and with increasing amounts of 
NS398 (black bars). COX-2 activity was determined by measuring PGE2 synthesis (pg/ml) using an EIA. Abso-
lute values are shown. Bars represent the mean PGE2-values of independent triplicate samples of 3 individual 
experiments (9 independent supernatant samples) and error bars represent mean ± s.d.. * indicates p<0.05. 
Figure 5.3: Selectivity of NS398 for COX-2 
The selectivity of NS398 for COX-2 over COX-1 was determined using a COX-1/COX-2 colorimetric inhibition 
assay. NS398 was tested at 0, 0.1, 0.2, 1.0, 2.0, 10.0 and 20.0 µM. The inhibitory capacity was determined as 
“percent inhibition” compared to a maximum activity control condition. Bars represent average inhibition per-
centages of COX-1 (black bars) and COX-2 (white bars). Measurements were done in triplicate and error bars 
represent the variances in inhibitory activity. 
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conditions Col2a1 protein and mRNA levels remained unaltered (Figure 5.4A/B). In the 
presence of exogenous BMP-2 (30 ng/ml), overall Col2a1, Col10a1, Alp and Runx2 levels 
were increased, confirming its pro-chondrogenic action (Figure 5.4A/B). The exposure to 
BMP-2 evoked an increased NS398 responsiveness, as Col10a1, Alp and Runx2 expres-
sion are more efficiently downregulated by NS398 as compared to the condition without 
BMP-2 (Figure 5.4A/B), whereas Col2a1 protein and mRNA expression remained un-
changed with increasing NS398 concentrations under BMP-2 conditions (Figure 5.4A/B).  
Reduced endogenous BMP-2 mRNA levels under BMP-2 supplemented conditions point 
to a negative auto-feedback mechanism (Figure 5.4C). In addition, the sharp NS398 dose-
dependent decline of BMP-2 mRNA levels suggests a crucial COX-2 activity-dependent 
positive effect on endogenous BMP-2 regulation (Figure 5.4C). The negative effect of 
COX-2 inhibition on chondrocyte hypertrophic differentiation was further established by 
measuring Alp enzymatic activity (Figure 5.4D). Following ATDC5 differentiation, Alp  
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activity increased and consistent with above findings the presence of 30 ng/ml BMP-2 
evoked significantly higher Alp activity at 7 and 14 days in differentiation. In agreement 
with the anti-hypertrophic action of COX-2 inhibition, Alp activity was significantly    
decreased in NS398 conditions. Consistent with a positive feedback mechanism, BMP-2 
supplementation increased COX-2 expression (Figure 5.1C-E and Figure 5.4C). Canonical 
Wnt- and Smad-signalling are important regulators of chondrocyte hypertrophic            
differentiation25,26. Involvement of these two pathways in the COX-2 mediated hyper-
trophic differentiation was determined by immunoblotting (Figure 5.4E). In keeping with 
involvement in chondrocyte hypertrophy, the level of active phospho-Smad1/5/8 increased 
in the BMP-2 condition (Figure 5.4E; lanes 1 vs. 3). However, inhibition of COX-2      
activity by NS398 did not influence the phosphorylation level of Smad1/5/8 (Figure 5.4E; 
lanes 1 vs. 2 and 3 vs. 4). Canonical Wnt-signalling transcriptionally regulates Runx2   
levels via b-catenin. Whereas BMP-2 only marginally enhanced b-catenin levels (Figure 
5.4E, short exposure; lanes 1 vs. 3), inhibition of COX-2 activity caused a sharp decline in 
b-catenin levels in both the absence as well as the presence of BMP-2 (Figure 5.4E; lane 1 
vs. 2 and 3 vs. 4), consistent with a possible regulatory role for COX-2 activity in        
chondrocyte hypertrophy via Wnt/b-catenin-signaling.  
In the above presented data COX-2 was inhibited from onset of differentiation (t=0)     
onward. However, COX-2 protein expression during ATDC5 differentiation is first detect-
able at day 7 onward (Figure 5.1B). To determine a possible window of action, we      
therefore asked whether inhibition of COX-2 at later differentiation stages would show the 
inhibitory effect on chondrocyte hypertrophy. Differentiation medium was supplemented 
with 20 mM NS398 from day 7 onward and chondrogenic differentiation was monitored 
Figure 5.4: Inhibition of COX-2 activity decreases chondrocyte hypertrophic differentiation  
(A). Increasing NS398 concentrations were added to differentiating ATDC5 cultures in the absence (left panel set) 
or presence of 30 ng/ml BMP-2 (right panel set). Protein expression of Col2a1, Col10a1 and Runx2 was analysed 
in day 14 cell extracts. (B). Induction of Col2a1, Col10a1 and Alp mRNA expression in day 14 samples from 
same experiment as (A). was determined. White bars: control, grey and black bars: NS398 conditions. (C). COX-
2 and BMP-2 mRNA induction was determined in similar samples as (B). In addition to shown statistical anal-
yses, for BMP-2 mRNA the statistical significance was also determined between the (-) BMP-2 and (+) BMP-2 
condition without NS398 (** indicates p<0.05). (D). ATDC5 cells were differentiated for 7 or 14 days in the 
absence or presence of BMP-2 (30 ng/ml) or NS398 (20 µM) and combinations thereof. Alp enzymatic activity 
(U) of triplicate samples was determined and normalized to total protein content. (E). In cell extracts from A., 
levels of p-Smad1/5/8 (upper panel set) and b-catenin (lower panel set; long and short refer to different ECL 
exposure times) were determined. * indicates p<0.05. 
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until day 21. Analyses of hypertrophic marker expression (Col10a1, Runx2, Mef2c, 
Mmp13, VEGF-A and Alp) revealed that inhibition of COX-2 caused significantly lower 
upregulation of all markers at 14 and or 21 days in differentiation (Figure 5.5). Of note, 
NS398 did not significantly influence Col2a1 mRNA expression at day 14, whereas it 
caused a significantly higher upregulation further in differentiation (day 21). Combined, 
these results clearly show that inhibition of COX-2 activity specifically affects late, hyper-
trophic chondrocyte differentiation, independently of early chondrogenic commitment. 
 
 
 
Figure 5.5: Inhibition of COX-2 activity decreases chondrocyte hypertrophic differentiation independent of the 
differentiation phase 
ATDC5 cultures were differentiated for 7 days. After 7 days COX-2 activity was continuously inhibited by addi-
tion of NS398 until day 21 into differentiation. In day 0, 7, 14 and 21 samples, gene expression of Col2a1, 
Col10a1, Runx2, Mef2c, Mmp13, VEGF-a and Alp was determined. For every condition and time point 8 indi-
vidual samples were measured. White bars indicate the control (DMSO) and black bars represent the 20 mM 
NS398 condition. * indicates p<0.05. 
Chapter 5 
142 
3.3 Inhibition of COX-2 activity does not affect chondrocyte cell proliferation 
As proliferation is a crucial aspect of ATDC5 chondrogenic differentiation23, we addressed 
a potential effect of COX-2 inhibition on cell proliferation under proliferation and      
chondrogenic conditions. To this end we generated growth curves with increasing NS398 
concentrations (0, 0.2, 2 and 20 mM). Under proliferation conditions, cell numbers       
increased approximately 15 fold over a 14 day time span (Figure 5.6A). None of the 
NS398 concentrations affected cell proliferation. Under chondrogenic conditions, cellular 
proliferation rate is significantly increased over normal proliferation conditions (Figure 
5.6B). Again, NS398 did not affect cell proliferation rate at any of the tested                  
concentrations under differentiation conditions. Overall these data show that specific inhi-
bition of COX-2 activity during ATDC5 proliferation and chondrogenic differentiation 
does not affect the proliferative capacity of ATDC5 and thus excludes an effect of NS398 
on hypertrophic differentiation through impaired proliferation capacity. 
 
 
3.4 Inhibition of chondrocyte hypertrophic differentiation in PAC 
To verify the anti-hypertrophic effect of COX-2 inhibition in vitro, we adopted an ex vivo 
periosteal organ culture system suitable to display chondrogenic potential24. Importantly, 
the use of periosteal tissue is directly relevant for endochondral ossification processes27. 
The mesenchymal progenitor cell-containing tissue is cultured in between agarose layers 
Figure 5.6: Influence of COX-2 inhibition on ATDC5 proliferation rate 
Proliferation speed of ATDC5 cells was determined under either proliferation (A) or differentiation (B) condi-
tions and in the presence of increasing concentrations of NS398. Crystal-violet staining was conducted collective-
ly on fixed day 0, 1, 2, 3, 4, 5, 7, 10 and 14 samples and absorbance of the eluates was determined spectrophoto-
metrically. Fold increase (DNA) from samples was calculated relatively to day 0. The data points represent the 
average of 6 independent samples and error bars represent mean ± s.d.. 
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(periosteum agarose culture: PAC), and induced to differentiate by transforming growth 
factor β3 (TGF-β3). Chondrogenic differentiation of PACs was evident after 20 days, as 
visualized by safranin-O staining of tissue sections. Increasing intensity of safranin-O 
staining after 40 culture days indicates increased proteoglycan deposition (Figure 5.7A). 
TGF-b is absolutely required for the PAC model, as in its absence mature chondrocytes are 
not formed and cartilage matrix deposition is not detectable at 20 days (24 and Figure 5.7B; 
left panel). In agreement with a prominent role for BMP-2 in chondrocyte hypertrophy, 
combined treatment with TGF-β3 and BMP-2 clearly resulted in a hypertrophic PAC    
morphology at 20 days (Figure 5.7B; right panel) as compared to single treatment with 
TGF-β3 (Figure 5.7B; middle panel) or BMP-2 alone (data not shown). Gene expression 
analyses confirmed that chondrocyte hypertrophy in the PAC system completely           
dependents on BMP-2: Col10a1 mRNA (Figure 5.7C; middle panel) and Runx2 protein 
(Figure 5.7D) are only induced when TGF-β3 is combined with BMP-2. Consistent with 
its requirement for chondrogenesis, TGF-β3-only treated PACs show moderate Col2a1 
mRNA induction, which is more than 3-fold enhanced by combination treatment with 
BMP-2 (Figure 5.7C; upper panel).  
To analyze the relationship between COX-2 and chondrocyte hypertrophy in PACs,     
COX-2 gene expression was determined: TGF-β3 induced COX-2 expression, which is 
increased almost 2-fold by BMP-2 (Figure 5.7C; lower panel), confirming that chondro-
cyte hypertrophic differentiation also correlates to COX-2 levels in an independent ex vivo 
model. To further substantiate the requirement of COX-2 activity for hypertrophic differ-
entiation, the effect of NS398 on the PAC model (with BMP-2 treatment) was evaluated. 
Two micromolar NS398 did not alter proteoglycan deposition (Figure 5.7E, upper right 
panel) and correspondingly Col2a1 expression was not affected (Figure 5.7E, Col2a1 panel 
sets and Figure 5.7F, upper panel), consistent with our in vitro findings. In contrast, NS398 
treatment strongly reduced Col10a1 expression (Figure 5.7E, Col10a1 panel sets and    
Figure 7F, lower panel), Alp expression (Figure 5.7E, Alp panel sets) and prevented the 
hypertrophy-associated chondrocyte morphological changes in PACs (Figure 5.7E, upper 
right panel). COX-2 inhibition was confirmed by an almost complete lack of PGE2       
synthesis in the NS398 condition (Figure 5.7G).  
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Figure 5.7: BMP-2 mediated chondrocyte hypertrophy in PAC is decreased by COX-2 inhibition 
(A). Periosteum agarose cultures (PAC’s) were differentiated for 0, 10, 20 or 40 days as previously described 
previously 24. Five micrometer sections were stained with Safranin-O/Fast green (bars represent 100 mm). (B). 
PAC’s were differentiated in the absence of TGF-b3, in the presence of TGF-b3 (10 ng/ml) or in the presence of 
TGF-b3 (10 ng/ml) and BMP-2 (30 ng/ml). The panel shows representative examples of PAC tissue sections (20 
days) stained with Safranin-O/Fast (bars represent 1 mm). (C). Conditions mentioned in (B). were also analyzed 
quantitatively by RT-qPCR for induction of Col2a1, Col10a1 and COX2 mRNA expression. Bars represent the 
average of 6 individual PAC samples and error bars represent mean ± s.d.. (D). Hypertrophic differentiation of 
these samples was assessed by immunohistochemical staining of Runx2 (bars represent 100 mm). (E). PACs were 
differentiated (20 days) in the presence of TGF-b3 and BMP-2 with or without supplementation of NS398 (2 
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mM). Tissue sections (5 mm) were stained with Safranin-O/Fast green (top micrographs). Immunohistochemical 
stainings were performed to visualize Col2a1 (upper micrographs), Col10a1 (middle micrographs) and Alp 
(lower micrographs) (bars represent 100 mm). Negative controls are depicted for each immuno staining: negative 
IgG1 control for Col2a1; non-immune rabbit serum (NIS) for Col10a1 and non-immune goat IgG’s for Alp. (F). 
PACs were differentiated in conditions as used in (E). and induction of Col2a1 and Col10a1 expression was 
determined. Bars represent the average of 6 individual PAC samples and error bars indicate mean ± s.d.. (G). 
Inhibition of COX-2 activity was confirmed in samples from (F). by measuring PGE2 synthesis (pg/ml). Absolute 
values are shown. * indicates p<0.05. 
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3.5 Selective inhibition of COX-2 impairs chondrocyte hypertrophic differentiation in the 
growth plate  
To further corroborate our findings in a developmentally and pharmacologically relevant 
in vivo context, we determined whether treatment with a clinically relevant selective    
COX-2 inhibitor, celecoxib, affected growth plate development in vivo. Celecoxib         
selectively inhibited COX-2 over COX-1 (Figure 5.8A). A dose-response analysis con-
firmed a similar anti-hypertrophic action for celecoxib as for NS398: 10 mM celecoxib 
significantly decreased Col10a1 and ALP mRNA upregulation at day 14 in ATDC5      
differentiation, whereas it showed no negative effect on Col2a1 mRNA expression (Figure 
5.8B).  
 
 
 
Figure 5.8: Celecoxib properties 
(A). The selectivity of Celecoxib for COX-2 over COX-1 was determined using a COX-1/COX-2 colorimetric 
inhibition assay. Celecoxib was tested at 0, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0 and 50.0 µM. The inhibitory capacity 
was determined as “percent inhibition” compared to a maximum activity control condition. Bars represent aver-
age inhibition percentages of COX-1 (black bars) and COX-2 (white bars). Measurements were done in triplicate 
and error bars represent the variances in inhibitory activity. (B). Increasing concentrations of celecoxib were 
added to differentiating ATDC5 cultures. Messenger RNA expression of Col2a1, Col10a1 and Alp in day 14 
samples was determined. Bars represent mean ± s.d.. * indicates p<0.05. 
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To determine the consequences of selective COX-2 inhibition on growth plate              
development, skeletally immature New Zealand white rabbits were systemically treated 
with celecoxib for 3 weeks (six animals in control group and seven animals in celecoxib 
group). In blood plasma we confirmed that celecoxib efficiently inhibited in vivo PGE2 
synthesis and thus systemically inhibited COX-2 (Figure 5.9A). Growth plate sections of 
the ulnae were stained with Haematoxilin (Figure 5.9B). Analysis of the total growth plate 
thickness of control sections revealed an average thickness of 451.8 mm (Figure 5.9C). In 
contrast, the average thickness of the growth plates of the celecoxib-treated group was 
significantly reduced to 421.3 mm (Figure 5.9B/C). To discern a potential effect of 
celecoxib on early versus late chondrogenic differentiation stages, the thickness of the   
proliferative and hypertrophic zones were measured separately. Importantly, and consistent 
with our in vitro and ex vivo findings, the length of the proliferative zones of both the    
control and celecoxib-treated group did not differ significantly (Figure 5.9B/C). In        
contrast, the hypertrophic zone of the celecoxib-treated group was significantly thinner as 
compared to the control group (113.8 mm vs 148.4 mm, respectively; Figure 5.9B/C). The 
ratio’s of hypertrophic/proliferative zone length of control and celecoxib treated growth 
plates were 0.495 and 0.370, respectively (Figure 5.9D). These ratio’s differ significantly 
from each other and confirms reduced hypertrophic zone length. The difference in total 
growth plate thickness thus resulted from impaired development of the hypertrophic zone. 
Taken together, these in vivo data clearly show that inhibition of COX-2 activity during 
skeletal development affects growth plate development at the chondrocyte hypertrophic 
level and provides further evidence in support of a crucial role of COX-2 activity during 
chondrocyte hypertrophic differentiation in an endochondral ossification context. 
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Figure 5.9: Chondrocyte hypertrophic differentiation in the rabbit growth plate is impaired by inhibition of COX
-2 activity 
Skeletally immature New Zealand white rabbits received Celecoxib (7 animals) on a daily basis. Six control 
animals were used. Rabbits were treated for three weeks. (A). COX-2 inhibition was confirmed by measuring 
PGE2 levels in serum at 3 weeks. Inhibition of PGE2 synthesis was determined as % decrease as compared to pre-
treatment serum samples. (B). Representative examples of growth plate sections of control and celecoxib treated 
rabbits. PZ = proliferative zone, HZ = hypertrophic zone. (C). Quantification of growth plate zones of both 
groups. Normal distribution of the data was confirmed by a Shapiro-Wilk test. White bars: proliferative zone, 
black bars: hypertrophic zones. Average total thickness control group = 451.8 µm; celecoxib group = 421.3 µm 
(Mann-Whitney, p=0.032). PZ control group = 303.4 µm; PZ celecoxib group = 307.5 µm (Mann-Whitney, 
p=0.668). HZ control group = 148.4 µm; HZ celecoxib group = 113.8 µm (Mann-Whitney, p=0.046). (D). Ra-
tio’s between the hypertrophic and proliferative zones of the control and celecoxib groups were determined 
(Mann-Whitney, p=0.013). * indicates p<0.05. 
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4. Discussion 
The involvement of COX-2 in osteogenic differentiation is well documented in literature. 
We here also demonstrate a role for COX-2 in the chondrogenic phase of endochondral 
ossification. Using three independent models we show that late chondrocyte hypertrophy 
in endochondral ossification is, at least in part, determined by COX-2 activity. We provide 
evidence that COX-2 function intersects with BMP-2 and Wnt/β-catenin signalling.      
Importantly, the finding that the effect of COX-2 inhibition appears restricted to          
chondrocyte hypertrophic differentiation has important implications for the clinical      
application of NSAIDs.  
 
4.1 COX-2 in chondrocyte hypertrophy  
We demonstrate that COX-2 is expressed in the growth plate, specifically in the            
prehypertrophic and hypertrophic compartments of the mouse growth plate. Despite      
apparently discrepant COX-2 staining pattern in the rat growth plate18,19, both data sets 
support a role for COX-enzymes in growth plate development. In addition, our in vivo 
findings demonstrate that systemic COX-2 inhibition during skeletal development results 
in abnormal development of the hypertrophic zone of the growth plate. This data is con-
sistent with our observations that in in vitro and ex vivo models COX-2 specific NSAIDs 
decrease chondrocyte hypertrophy. Impaired Wnt/β-catenin signalling was shown to cause 
defective growth plate hypertrophic differentiation28 and postnatal cartilage development29. 
These and our findings predict that the COX-2 -/- mouse13 should display a, most likely, 
subtle skeletal developmental phenotype. Although the presence of functionally redundant 
mechanisms could theoretically explain lack of effects, detailed re-analysis of growth 
plates in COX-2 -/- mice, may reveal a mild phenotype. Conversely, although we could 
detect a significant quantitative difference in hypertrophic zone length between celecoxib 
and non-treated animals, it remains to be determined whether the effects of transient    
COX-2 inhibition results in persistent skeletal abnormalities into adulthood. 
 
4.2 COX-2 – integration into known chondrogenic signalling 
Hypertrophic chondrocyte differentiation can be monitored by expression of several      
important markers like Runx2, Col10a1 and ALP. Direct transcriptional regulation of the 
Col10a1 gene is regulated by Runx222 and transcriptional activity of Runx2 on the 
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Col10a1 promoter is cooperatively controlled by BMP-2-induced Smad’s15. In addition, in 
osteogenic differentiation phosphorylation has been described as an important determinant 
for transcriptional activity of Runx230. Chondrocyte hypertrophic differentiation is, at least 
in part, regulated via Smad1/5/8 signalling26. As we could not detect any difference on 
Smad1/5/8 phosphorylation between control and NS398-treated samples, this suggests that 
COX-2 either acts in parallel to or down-stream of R-Smads. Indeed we found              
experimental evidence that support a down-stream relation. Inhibition of Smad1/5/8    
phosphorylation by dorsomorphin inhibited COX-2 expression and subsequent PGE2    
synthesis (Figure 5.10). Concurrent with decreased detection of PGE2 and reduced Runx2 
and Col10a1 levels, BMP-2 mRNA levels are reduced by NS398 in a dose-dependent  
manner. Hence, the NS398-mediated decrease of Col10a1 expression is consistent with 
reduced Runx2 expression. Upstream of Runx2 we found that b-catenin levels negatively 
respond to inhibition of COX-2 activity. Prostaglandin receptors are G-protein coupled 
receptors that activate protein kinase A (PKA) and in turn control b-catenin levels via    
glycogen synthase kinase 3 (GSK-3) activity31,32. We did not address phosphorylation of  
 
 
Figure 5.10: Smad1/5/8 activity and COX-2 
To determine whether BMP-2 induced Smad1/5/8 activity regulates COX-2 we employed dorsomorphin (10 
mM) on ATDC5 cells in the presence of BMP-2 (30 ng/ml). (A). Differentiating ATDC5 cells were treated with 
BMP-2 and BMP-2 + Dorsomorphin for one day. Protein extracts were analyzed by immunoblotting for phos-
phorylation (= activation) of Smad1/5/8 and expression of COX-2. Lack of detection of p-Smad1/5/8 confirmed 
dorsomorphin functionality. Decreased expression of COX-2 accompanied inhibition of Smad1/5/8 phosphoryla-
tion. (B). To confirm decreased total COX-2 activity, PGE2 levels were determined in culture supernatants. De-
creased PGE2 levels confirm the dorsomorphin-induced COX-2 decrease. (C). To place the above finding in a 
chondrocyte hypertrophic context, ATDC5 cells were differentiated for 14 days in the presence of BMP-2 and 
Dorsomorphin was added from day 7 on (comparable to26). Confirming above data, Inhibition of Smad1/5/8 
phosphorylation resulted in a significantly lower expression of COX-2 mRNA as compared to the BMP-2 con-
trol. 
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Runx2 in this study. However, taking the previously reported involvement of canonical 
Wnt-signalling in the transcriptional regulation of Runx2 expression upon BMP-2 ligand 
binding into account25, this provides, at least in part, a mechanistic explanation for how 
inhibition of COX-2 activity reduces b-catenin levels and leads to reduced chondrocyte 
hypertrophic maturation. 
Combined with data from other groups our findings10,15,33,34 strongly support a functional 
relation between COX-2, PGE2 and BMP-2 in chondrocyte hypertrophy. Chondrocyte   
hypertrophic differentiation is induced by BMP-2 during chondrogenesis33. BMP-2      
induces COX-2 expression and the increased hypertrophic differentiation by exogenous 
BMP-2 supplementation was diminished by inhibition of COX-2 activity. In addition,   
endogenous BMP-2 mRNA levels negatively responded to COX-2 inhibition (10 and this 
study), while endogenous BMP-2 mRNA levels were even further decreased in the       
presence of exogenous BMP-2. Although it remains currently unclear why BMP-2       
treatment increases the NS398 responsiveness of hypertrophic markers, it is possible that a 
negative feedback effect of exogenous BMP-2 on endogenous BMP-2 levels renders     
hypertrophic differentiation more susceptible to COX-2 inhibition. In contrast to the here 
reported anti-hypertrophic effect of COX-2 inhibition, PGE2 has been demonstrated to 
delay (BMP-2 induced) hypertrophic differentiation via PKA and protein kinase C (PKC) 
signalling35,36. These conflicting results may be related to the choice of experimental    
models: whereas we used chondroprogenitors, PKA/PKC involvement was tested in     
mature chondrocyte cultures. In relation to this, differentially regulated COX-2 expression 
during different stages of chondrogenesis was previously suggested37,38. Importantly, as 
COX-2 inhibition leads to an indiscriminate shutdown of prostaglandin synthesis, we   
cannot rule out the possibility that different prostaglandins contribute differently to     
chondrocyte differentiation.  
 
4.3 Clinical use of NSAIDs  
Clinically, NSAIDs are used to block the prostaglandin synthesizing enzymes COX-1 and/
or COX-2. However, the therapeutic application of NSAIDs in the context of bone fracture 
healing is currently under debate as COX-inhibition by NSAIDs is reported to delay      
fracture healing or cause non-union in patients and animal models4-8. COX-2 is reported to 
be expressed in fracture callus13,39 and molecular genetic mouse models showed that    
COX-2 and mPGES-1 activity are critically required for bone fracture union13,14. Although 
there is increasing evidence in support of a role for COX-2 in the chondrogenic phase of 
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endochondral ossification, most studies focused on COX-2 function in the context of the 
osteogenic phase of endochondral ossification (i.e. osteoblast and osteoclast biology). Here 
we identified chondrocyte hypertrophy as another important target of COX-2 activity   
during the proces of endochondral ossification. Recent work by Petit and colleagues     
suggests that expression of COL10A1 mRNA in human bone marrow mesenchymal stem 
cells is decreased by specific inhibition of COX-1 and 5-LOX (5-lypoxygenase)40,        
suggesting similar mechanisms as presented in our present COX-2 study. However,      
experimental cell models differ between studies and whether or how COX-1 and COX-2 
work together or fulfil separate roles in hypertrophic differentiation remains to be         
determined.  
In conclusion, we here show that the hypertrophic action of BMP-2 on endochondral     
differentiating chondrocytes is, at least in part, determined via COX-2 activity. This     
finding may have multiple clinical implications. Firstly, the negative effects of COX-2 
inhibition on growth plate development in skeletally immature animals warrants critical 
reevaluation of the clinical context in which NSAIDs and pharmacological equivalents are 
applied. Secondly, impaired bone fracture healing by NSAIDs may also be explained by 
impaired chondrogenic differentiation, in addition to the currently known impaired osteo-
genic differentiation alone.  
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Abstract 
 
Introduction: NSAIDs are clinically used to relieve pain and decrease inflammation by 
inhibition of cyclooxygenase (COX)-catalyzed prostaglandin (PG) synthesis. As PGs are 
fatty acid mediators involved in bone and cartilage homeostasis, they thereby may provide 
a novel opportunity to influence cartilage regeneration. We hypothesized that COX-1 and 
COX-2 have differential roles in the chondrogenic differentiation process of progenitor 
cells and that their specific inhibition will thereby differently influence the outcome of the 
differentiation process. 
Methodology: ATDC5 cells were differentiated in the presence of different COX-1        
(SC-560, Mofezolac) or COX-2 (NS398, Celecoxib) specific inhibitors. COX-1 or COX-2 
specificity of the NSAIDs and NSAID-specific inhibition of prostaglandin levels were 
determined by colorimetric assays and specific ELISAs. Prostaglandins were added during 
the differentiation process. Gene- and protein expression analyses were employed to     
determine chondrogenic outcome. 
Results: COX-specificity of the NSAIDs was confirmed and for subsequent experiments 
NSAID concentrations were selected that resulted in similar degrees of COX-1 or COX-2 
inhibition. COX-1 specific NSAIDs inhibited Col2a1 and Col10a1 expression. Inhibition 
of COX-2 resulted in substantial decrease of Col10a1 expression, while Col2a1 remained 
unaffected. To explain this difference we determined the expression patterns of both COX 
enzymes as well as specific prostaglandin concentrations during differentiation. COX-1 is 
upregulated during late chondrogenic differentiation, whereas COX-2 is briefly expressed 
early in differentiation and increases again late in differentiation. PGD2 and PGE2 followed 
the COX-2 expression pattern, whereas PGF2α and TXA2 levels remained stably low.    
Furthermore, COX-2 inhibition resulted in decreased levels of all tested PGs, whereas 
COX-1 inhibition decreased the concentration of all PGs, exept for PGD2 and PGF2α, 
which were both increased. Addition of PGE2 and PGF2α resulted in increased expression 
of chondrogenic markers, whereas TXA2 specifically resulted in increased expression of 
hypertrophic markers. 
Conclusions: Our findings point towards a differential role for COX-enzymes and PG-
production in chondrogenic differentiation. Ongoing research is focussing on further      
elucidating the functional partition of cyclooxygenases and specific prostaglandin         
production. 
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1. Introduction 
 
Progenitor cell-based cartilage regeneration is an evolving field and methodologies        
promoting chondrogenic differentiation of mesenchymal progenitor cells towards chondro-
cytes and better understanding of the chondrogenic differentiation process is imperative to 
improve the outcome of cartilage regenerative medicine approaches.  
We have previously shown that COX-2 is transiently expressed during the first hours in 
chondrogenic differentiation of progenitor cells1 and again at later time points, when its 
expression coincidences with chondrocyte extracellular matrix synthesis2. In addition, we 
found that inhibition of COX-2 enzymatic activity results in a reduction of the hypertrophy 
outcome of the differentiation process2. However, whether this observation is specific for 
COX-2 and how this relates to COX-1 activity is largely unknown.  
Cyclooxygenases, also known as prostaglandin H synthases, are enzymes that catalyse the 
rate-limiting step in the generation of prostaglandins3. Specifically, arachidonic acid is 
released from membrane phospholipids by phospholipase A2 and serves as a substrate for 
the cyclooxygenases. Arachidonic acid is oxygenated by COX-activity to form             
prostaglandin G2 (PGG2) and subsequently the peroxidase activity of the COX enzyme 
drives the reduction of PGG2 to hydroperoxy endoperoxide prostaglandin H2 (PGH2)
4
. This 
unstable intermediate is converted by specific synthases to the main prostaglandin        
subgroups PGD2, PGE2, PGI2, PGF2α and TXA2, which can be converted into various other 
intermediates5,6. To date three COX isoforms have been described: COX-1, COX-2 and 
COX-3. The first two are the most prevalent en best described isoforms7. The COX-3    
isoform is a splice variant of COX-1; however there is much debate on the function of 
COX-38-10. Both COX-1 and COX-2 isoforms catalyse the same enzymatic reactions and 
are structurally related11. They have remarkable differences regarding their tissue           
distribution, expression levels and their ability to response to various stimuli7,12,13. COX-1 
is constitutively expressed by most mammalian cells and regarded as the “housekeeping” 
cyclooxygenase. On the other hand, COX-2 expression is low in most tissues but can be 
rapidly induced upon exposure to various stimuli as inflammation, mechanical stress and 
injury3,7 due to inducible enhancer elements in its promoter11. Studies investigating the 
roles of cyclooxygenases and the effects of prostaglandins on (in vitro) chondrogenic dif-
ferentiation have mainly focussed on COX-2 (inhibition) and PGE2
14-20. However, the con-
tribution of COX-1 and other prostaglandins is largely ignored. While, given their different 
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role in cellular prostaglandin synthesis, it is not unlikely that either of the two COX      
enzymes are differently involved in determining the outcomes of the chondrogenic differ-
entiation process. 
We hypothesized that COX-1 and COX-2 have differential roles in the chondrogenic    
differentiation process of progenitor cells and that their specific inhibition will thereby 
differently influence the outcome of the differentiation process. In the present study we 
show that COX-1 and COX-2 have different expression patterns during chondrogenic   
differentiation of progenitor cells and that specific inhibition of the COX-1 enzyme results 
in overall inhibition of chondrogenic differentiation, whereas COX-2 inhibition specifical-
ly decreased the level of chondrocyte hypertrophy. Prostaglandin concentration were found 
to be differentially influenced by COX-1 or COX-2 inhibition and addition of specific 
prostaglandins modulated the chondrogenic outcome unexpectedly different; PGF2α and 
PGE2 increased overall chondrogenic differentiation, whereas TXA2 specifically increased 
chondrocyte hypertrophy. These data provide more insight in the function of the COX-
enzymes and prostaglandins during chondrogenic differentiation.  
 
 
2. Materials and Methods 
 
 
2.1 Mouse growth plates 
The growth plates were isolated from tibias of 6 weeks old C57BL/6 mice (MUMC DEC 
approval 2008-042). The tibia’s were isolated and fixated in formalin. The growth plates 
were separated from the rest of the tibia and decalcified in 0.5 M EDTA pH 7.8 for 2 
weeks. EDTA was refreshed every two days. Growth plates were dehydrated and          
embedded in paraffin. Five micrometer sections were cut and positioned on Superfrost 
Plus slides for IHC. 
 
2.2 ATDC5 cell culture 
ATDC5 cells were cultured in a humidified atmosphere at 37ºC, 5% CO2. Proliferation 
medium (consisting of DMEM/F12 (Invitrogen, Carlsbad, CA, USA), 5% FCS (PAA, 
Pasching, Austria), 1% antibiotic/antimycotic (Invitrogen) and 1% NEAA (Invitrogen)) 
was changed every two days. Differentiation medium comprised proliferation medium 
supplemented with 10 µg/ml insulin (Sigma, St. Louis, MO, USA), 10 µg/ml transferrin 
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(Roche Applied Science, Indianapolis, IN, USA) and 30 nM sodium selenite (Sigma, St. 
Louis, MO, USA). Cells were plated at 6400 cells/cm2 in cell culture dishes, allowed to 
adhere overnight and the following day chondrogenic differentiation was initiated by 
changing the proliferation medium to differentiation medium. Differentiation medium was 
changed every two days (day 0-10) and daily (from day 10 on). To inhibit COX-1 activity 
SC-560 (1 µM)(Cayman Chemical, Ann Arbor, USA) or Mofezolac (5 µM) (Sigma) were 
used and applied during the differentiation process. Similarly, COX-2 activity was        
inhibited by NS398 (20 µM)(Cayman Chemical) or Celecoxib (10 µM) (LC laboratories). 
PGD2, PGE2, PGF2α and U-46619 (a TXA2 receptor agonist, herein referred to as TXA2) 
(Cayman Chemical) were applied daily during the differentiation process at 0, 0.1, 1 or 10 
µM concentrations. These concentrations were selected in the range of the highest         
concentrations reported in the culture supernatants of control differentiated t=14 ATDC5 
cells. PGI2 (from the same manufacturer) was not applied in these experiments as it is   
unstable in culture medium and therefore could be used in a reliable manner. 
 
2.3 Immunohistochemistry 
Growth plate sections of 6-weeks old mice were deparaffinized and antigen retrieval for 
COX-1 sections was performed by digestion with 0.4% hyaluronidase (Sigma) for 30 
minutes at 37°C.  For COX-2 detection, sections were incubated in boiling citrate buffer 
(1.8 mM citric acid and 8.2 mM tri-sodium citrate) for 30 minutes. Endogenous peroxidase 
activity was inactivated and sections were blocked with 10% normal sheep serum. Primary 
antibodies were: anti-COX-1 (Cayman Chemical, Ann Arbor, USA) and anti-COX-2 (BD 
Transduction Laboratories). After washing in PBS-T, bound antibodies were detected with 
HRP-labelled secondary antibodies (Dako, EnVision+ System-HRP labelled Polymer). 
Bound secondary antibodies were visualized by DAB substrate (Dako). Stained sections 
were counterstained with Mayer’s Hematoxylin (Dako), dehydrated and mounted in      
Histomount (Thermo Shandon) for analysis. 
 
2.4 Prostaglandin measurement 
Prostaglandin concentration of PGD2, PGE2, PGF2α and TXB2 (a stable metabolite of 
TXA2, herein referred to as TXA2) was determined in culture supernatants. Culture super-
natants from different chondrogenic time points were stored in aliquots at -80oC until   
analysis. Prostaglandin concentrations were determined by EIA’s according to the manu-
facturers’ protocol (Cayman Chemical).  PGI2 concentrations could not be determined in a     
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reliable manner by the EIA’s from the same manufacturer and was therefore not included 
in these experiments.  
 
2.5 COX specificity assay 
The colorimetrix COX inhibitor screening assay kit (Cayman Chemical) was used accord-
ing to the manufacturers’ protocol to determine COX isoform-specific inhibitory capacity 
for SC-560, Mofezolac, NS398 and Celecoxib. 
 
2.6 RT-qPCR 
For RNA isolation, cells were washed 3 times with 0.9% NaCl w/v and disrupted with 500 
µl Trizol (Invitrogen). RNA isolation, RNA quantification by UV-spectrometry 
(Nanodrop, Thermo Scientific), and cDNA synthesis were performed as described        
before1,2.  Real time quantitative PCR (RT-qPCR) was performed using Mesagreen qPCR 
mastermix plus for SYBR® Green (Eurogentec, Seraing, Belgium). An Applied Biosys-
tems ABI PRISM 7700 Sequence Detection System was used for amplification using the 
following protocol: initial denaturation at 95ºC for 10 minutes, followed by 40 cycles of 
DNA amplification (denaturing for 15 seconds at 95ºC and annealing for 1 minute at 60ºC) 
followed by a dissociation curve. Data were analysed using the standard curve method, 
mRNA expression was normalized to a reference gene (β-actin) and gene expression was 
calculated as fold change as compared to day 0 (t=0 in graphs). Primer sequences are   
depicted in Table 6.1.  
 
2.7 Immunoblotting 
Cells were washed three times with 0.9% NaCl and lysed in RIPA buffer (150 mM NaCl, 
1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5.0 mM EDTA 
pH 8.0, 0.5 mM dithiothreitol and 1 mM phenylmethylsulfonylfluoride). Extracts were 
sonicated on ice using the Soniprep 150 (MSE, London, UK) at amplitude 10 for 14 cycles 
(1 second sonication and 1 second pause). Insoluble material was removed by               
centrifugation (13,000 x g, 4ºC). Protein concentration was determined using the BCA 
protein assay (Sigma). Polypeptides were separated by SDS-PAGE (samples were equally 
loaded) and subsequently transferred to nitrocellulose membranes by electroblotting.    
Primary antibodies for immunodetection were polyclonal goat anti-Col2a1 (Southern Bio-
tech, Birmingham, AL, USA), polyclonal rabbit anti-Col10a1 (Calbiochem, Darmstadt, 
Germany), polyclonal rabbit anti-Sox9 (Abcam), mouse monoclonal anti-Runx2 (MBL, 
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Woburn, USA) and mouse monoclonal anti-α-Tubulin (Sigma, Saint Louis, MO, USA). 
Bound primary antibodies were detected with rabbit anti-goat, swine anti-rabbit or rabbit 
anti-mouse immunoglobulins conjugated with horseradish peroxidase (DakoCytomation, 
Glostrup, Denmark) and visualized by enhanced chemiluminescence. ECL signals were 
quantified using ImageJ 1.46f software, and relative differences, corrected for background 
and housekeeper, were determined as compared to control conditions. 
 
 
Table 6.1: Primer sequences for RT-qPCR 
The 5’ – 3’ forward and reverse oligonucleotide sequences used for RT-qPCR are listed 
 
 
2.8 Cell proliferation 
Cell proliferation was assessed by crystal-violet (Sigma, Saint Louis, MO, USA) staining. 
Cells were washed two times with 0.9% NaCl and subsequently fixed with 4% paraformal-
dehyde in phosphate buffered saline for 10 minutes at room temperature. Fixed cells were 
washed 6 times with water and air dried for storage. Cells were incubated with 0.1%     
crystal-violet for 30 minutes at room temperature. Cells were washed six times with water 
to remove excess crystal-violet and allowed to air-dry in the dark overnight. Crystal-violet 
was extracted from the cells by incubation with 10% acetic acid for 15 minutes under    
continuous agitation. Extracted crystal-violet was determined spectrophotometrically at 
590 nm using a plate reader (Biorad, Hemel Hempstead, UK).  
 
Oligo sets mouse Forward Reverse 
Col2a1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
Col10a1 ‘5-CATGCCTGATGGCTTCATAAA-3’ ‘5-AAGCAGACACGGGCATACCT-3’ 
Sox9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-TACTTGTAGTCCGGGTGGTCTTTC-3’ 
Runx2 ‘5-CGATGAAGACCCCAACCCTAA-3’ ‘5-ACTGGTAATGGCATCAAGGGATA-3’ 
COX-1 ‘5-TCCTCACAGTGCGGTCCAA-3’ ‘5-AAGGCCTCCCAGCTGATGTAG-3’ 
COX-2 ‘5-GGCCATGGAGTGGACTTAAA-3’ ‘5-AAGTGGTAACCGCTCAGGTG-3’ 
β-Actin ‘5-GACAGGATGCAGAAGGAGATTACTG-3’ ‘5-CCACCGATCCACACAGAGTACTT-3’ 
Oligo sets human Forward Reverse 
COL2A1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
COL10A1 ‘5-ATGATGAATACACCAAAGGCTACCT-3’ ‘5-ACGCACACCTGGTCATTTTCTG-3’ 
SOX9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-CGCTTCTCGCTCTCGTTCAG-3’ 
RUNX2 ‘5-TGATGACACTGCCACCTCTTGA-3’ ‘5-GCACCTGCCTGGCTCTTCT-3’ 
COX-1 ‘5-TCCTCACAGTGCGGTCCAA-3’ ‘5-AAGGCCTCCCAGCTGATGTAG-3’ 
COX-2 ‘5-ACCAACATGATGTTTGCATTCTTT-3’ ‘5-GGTCCCCGCTTAAGATCTGTCT-3’ 
28S rRNA ‘5-GCCATGGTAATCCTGCTCAGTAC-3’ ‘5-GCTCCTCAGCCAAGCACATAC-3’ 
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2.9 Alcian blue staining 
GAG deposition was detected by alcian blue staining. Cells were washed two times with 
0.9% NaCl and subsequently fixed with 4% paraformaldehyde in phosphate buffered   
saline for 10 minutes at room temperature. Fixed cells were washed 6 times with water and 
air dried for storage. Fixed cells were incubated overnight with 1% alcian blue (Acros   
Organics, Geel, Belgium) in 0.1 M HCl at room temperature. Cells were washed six times 
with water to remove excess alcian blue and allowed to air-dry in the dark overnight.    
Alcian blue was extracted from the cells by incubation with guanidine-HCl (6 M) for 2 
hours under continuous agitation. Extracted alcian blue was determined spectrophoto-
metrically at 645 nm using a plate reader (Biorad, Hemel Hempstead, UK).  
 
2.10 Statistics 
Statistical significance (p < 0.05) was determined by two-tailed student t-tests using 
Graphpad PRISM 5.0 (La Jolla, CA, USA). To test for normal distribution of the input 
data, D’Agostino-Pearson omnibus normality tests were performed. All quantitative data 
sets presented passed the normality tests. 
 
 
3. Results 
 
3.1 Expression of COX-1 and COX-2 during chondrogenic differentiation 
To examine the involvement of COX-1 and COX-2 during chondrogenic differentiation, 
spatiotemporal expression of these enzymes was determined in murine growth plates. As 
shown in Figure 6.1A, expression of COX-1 was specifically detected in chondrocytes 
located in the hypertrophic zone of the growth plate. COX-2 was expressed in chondro-
cytes in the hypertrophic zone of the growth plate, but also in the resting zone cells. To 
further study COX enzyme expression during chondrogenic differentiation, we analyzed 
expression of COX-1 and COX-2 during chondrogenic differentiation of ATDC5 cells. 
ATDC5 differentiation follows a well-defined chondrogenic program from chondro-
progenitor to a hypertrophic chondrocyte1,21,22. Establishing chondrogenic differentiation 
of these cells, Col2a1 was increasingly expressed from day 7 onwards in ATDC5 differen-
tiation (Figure 6.1B).  Sox9 is expressed early in differentiation (first hours) and its       
expression increases again from day 7 onwards, together with Col2a1 (Figure 6.1B).            
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Expression of chondrocyte hypertrophic genes Runx2 and Col10a1 increased from day 7 
and day 10 onwards, respectively (Figure 6.1B). COX-1 expression was increased in 
ATDC5 differentiation from day 7 onwards (Figure 6.1C/D), correlating with the           
expression timing of Col2a1 and Col10a1 (Figure 6.1B). COX-2 expression was            
transiently upregulated in the first hours of chondrogenic differentiation and increased 
again from day 7 onwards (Figure 6.1C/D). These data correlate with the growth plate   
expression patterns of COX-1 and COX-2 and with our previous findings1,2.                     
To functionally assess COX enzyme activity during chondrogenic differentiation, the    
concentration of the prostaglandins PGD2, PGE2, PGF2α and TXA2 was determined in  
culture supernatants. Figure 6.1E shows that the concentration of PGD2 and PGE2 in the 
culture supernatants differs throughout differentiation and appears to be high in early    
differentiation and seems to increases late in differentiation, resembling the bi-phasic   
expression of COX-2. PGF2α and TXA2 levels remain stably low during chondrogenic   
differentiation.  
 
Figure 6.1: Expression of cyclooxygenases during chondrogenic differentiation from progenitor cells 
Involvement of COX-1 and COX-2 during chondrogenic differentiation was determined by assessing their ex-
pression patterns. (A). Spatiotemporal expression of COX-1 and COX-2 in 6 weeks old mouse growth plates was 
determined by IHC. RZ = resting zone, PZ = proliferative zone, HZ = hypertrophic zone. (B). Col2a1, Col10a1, 
Sox9 and Runx2 mRNA expression during chondrogenic differentiation of ATDC5 cells was determined by RT-
qPCR (relative to t=0 and corrected for β-actin). (C). COX-1 and COX-2 mRNA expression during chondrogenic 
differentiation. In graphs, error bars represent mean ± s.e.m.. * indicates p < 0.05. (D). Protein expression of COX
-1 and COX-2 at 0-24 hours (left panel) and at 0, 7 and 14 days in differentiation (right panel). Molecular weight 
markers (kDa) are depicted on the left of immunoblots and relative quantifications are depicted on top of im-
munoblots. (E). Medium concentrations of PGD2, PGE2, PGF2α and TXA2 during chondrogenic differentiation 
was determined by standard EIA.  
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3.2 COX-1 and COX-2 inhibition have differential effects on chondrogenic outcome and 
specific prostaglandin concentrations 
A colorimetric inhibition assay using isolated ovine COX-1 or COX-2 was used to       
determine inhibitor concentrations at which specificity of the inhibitor for COX-2 over 
COX-1, or COX-1 over COX-2 was highest. This revealed optimal inhibitor                 
concentrations for which similar inhibition capacities between the inhibitors were 
achieved, combined with the highest COX-specificity. For the COX-1 inhibitors these   
optimal concentrations were 1 µM for SC-560 and 5 µM for Mofezolac and for COX-2 
inhibitors 20 µM for NS398 and 10 µM for Celecoxib (Figure 6.2). Using these concentra-
tions, equal inhibition efficiency of COX-1 or COX-2 was achieved with as little as      
possible aspecificity for the other COX enzyme. 
 
 
 
 
 
 
 
 
 
 
To determine how chondrogenic differentiation of progenitor cells responds to COX-1 
versus COX-2 inhibition, the different isoform-specific COX inhibitors were added (in 
concentrations as specified above and Figure 6.2) from 1) the start of differentiation and 2) 
from day 10 onwards (to determine whether a potential effect depends on the                 
differentiation status of the chondrocyte). As compared to control conditions, inhibition of 
COX-1 by SC-560 or Mofezolac from the start of differentiation resulted in decreased 
Col2a1, Col10a1, Sox9 and Runx2 mRNA and protein expression at day 14 in differentia-
Figure 6.2: Specificity of COX-1 and COX-2 inhibitors 
The selectivity of SC-560 and Mofezolac for COX-1 over COX-2 and selectivity of NS398 and Celecoxib for 
COX-2 over COX-1 was determined using a COX-1/COX-2 colorimetric inhibition assay. The inhibitory capaci-
ty was determined as “% inhibition” compared to a maximum activity control condition. Bars represent average 
inhibition percentages of COX-1 and COX-2. Measurements were done in triplicate and error bars represent the 
variances in inhibitory activity. 
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tion (Figure 6.3A/B). Inhibition of COX-1 from day 10 onwards resulted in similar,       
although less pronounced effects on expression of these genes. Inhibition of COX-2, on the 
other hand, did not lead to decreased expression of Col2a1 and Sox9 at day 14 in differen-
tiation and even increased Col2a1 expression (for Celecoxib at both time points and for 
NS398 when added from day 10 onwards in differentiation) (Figure 6.3A/B). A similar 
trend was detected for Sox9, although not significant. Inhibition of COX-2 did however 
affect the expression of chondrocyte hypertrophy genes Runx2 and Col10a1 at day 14 in 
differentiation, when COX-2 was inhibited from the start of the experiment2. Inhibition of 
COX-2 from day 10 onwards resulted in similar although less pronounced effects on these 
chondrocyte hypertrophy genes. COX-specific inhibition from the start of chondrogenic 
differentiation resulted in less increased GAG content for the COX-1 specific inhibitors at 
day 14 in differentiation, whereas COX-2 inhibitors did not affect GAG content (Figure 
6.3C). Furthermore, cell proliferation capacity was assessed in these conditions. Except for 
SC-560, COX inhibitors did not alter cell proliferation capacity (Figure 6.3D).  
In order to confirm successful COX-1 or COX-2 inhibition during chondrogenic            
differentiation and to determine whether both isoforms are equally involved in specific 
prostaglandin synthesis, culture supernatants from experiments shown in Figure 6.3 were 
analyzed for PGE2, PGD2, PGF2α and TXA2 concentrations. As shown in Figure 6.4A 
(upper left panel), inhibition of COX-1 as well as COX-2 from day 0 or day 10 onwards 
caused a significant reduction in the PGE2 concentration at day 14 in differentiation, with 
the most efficient inhibition caused by both COX-1 inhibitors. COX-2 inhibition (both 
from day 0 and day 10 onward) by NS398 or Celecoxib also resulted in reduced PGF2α and 
TXA2 levels, but had no effect on PGD2 levels. Interestingly, COX-1 inhibition from the 
start of differentiation resulted in increased levels of PGD2, PGF2α and TXA2 at day 14 in 
differentiation (Figure 6.4A). In contrast, COX-1 inhibition from day 10 in differentiation 
onwards, did not significantly influence PGD2 levels, but again increased TXA2 levels, 
while PGF2α levels were now decreased as compared to control. Although the inhibitors 
enzymatically interfere with COX-activity, potential feedback mechanisms responding to 
diminished COX-activity might influence the level of COX-1 and COX-2 expression. To 
address this possibility we measured expression of COX-1 and COX-2 mRNAs. Inhibition 
of COX-1 by SC-560 or Mofezolac from the start of differentiation did not influence COX
-1 mRNA expression at day 14 in differentiation, however when COX-1 was inhibited 
from day 10 onwards a slightly decrease in COX-1 mRNA expression was detected.     
Interestingly, COX-2 mRNA expression increased in all tested COX-1 inhibitory           
Prostaglandins and COX-enzymes in Chondrogenic Differentiation 
169 
 
 
 
 
 
Chapter 6 
170 
 
conditions (Figure 6.4B). In cells treated with COX-2 specific inhibitors, COX-2 mRNA 
expression itself was increased as well, whereas COX-1 mRNA expression remained   
unchanged.   
 
3.3 Addition of specific prostaglandins during chondrogenic differentiation  
 
As inhibition of COX-1 or COX-2 has strikingly different consequences on the chondro-
genic outcome and appears to affect downstream specific prostaglandin synthesis different-
ly, we tested whether these prostaglandins differently influence chondrogenic differentia-
tion. To this end, increasing concentrations of prostaglandins PGD2, PGE2, PGF2α and 
TXA2 were added to differentiating ATDC5. Addition of PGE2 and the highest concentra-
tion of PGF2α caused a increased expression of Col2a1, Col10a1, Sox9 and Runx2 mRNA 
and protein at day 14 in differentiation (Figure 6.5A/B). TXA2 addition specifically result-
ed in increased expression of the hypertrophic genes Col10a1 and Runx2 and had almost 
no effects on the expression of chondrogenic genes Col2a1 and Sox9. Expression of Sox9 
and Runx2 was increased by addition of PGD2 but this did only result in an increased trend 
in Col2a1 and Col10a1 expression (Figure 6.5A/B).  Furthermore addition of the individu-
al prostaglandins resulted in increased COX-1 and COX-2 mRNA expression (Figure 
6.5C).  
Together, these data show that the specific prostaglandins have differential effects on 
chondrogenic differentiation of ADTC5 cells. PGE2 and PGF2α showed the most increase 
in chondrogenic potential as determined by Col2a1, Sox9, Col10a1 and Runx2 expression, 
whereas TXA2 specifically resulted in increased Col10a1 and Runx2 expression; markers 
for chondrocyte hypertrophy.  
Figure 6.3: Effects of COX-1 and COX-2 specific inhibitors on chondrogenic differentiation of progenitor cells 
To determine the role the specific cyclooxygenases in chondrogenic differentiation specific COX-1 and COX-2 
inhibitors were added to ATDC5 cells from the start of differentiation or from day 10 onwards. (A). Col2a1, 
Col10a1, Sox9 and Runx2 mRNA expression was determined at day 14 in differentiation by RT-qPCR (relative 
to t=0 and corrected for β-actin). (B). Protein expression of Col2a1, Col10a1, Sox9 and Runx2 at day 14 in differ-
entiation. Molecular weight markers (kDa) are depicted on the left of immunoblots and relative quantifications are 
depicted on top of immunoblots. (C). Glycosaminoglycans (GAGs) were stained by alcian blue and fold change 
of t=14 samples was calculated as compared to t=0 samples. (D). Differences in proliferation speed between 
conditions were determined by crystal-violet staining. Fold change (DNA) from samples from t=14 was calculat-
ed relatively to day 0. In graphs, error bars represent mean ±s.e.m.. * indicates p < 0.05. 
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Figure 6.4: COX-1 and COX-2 specific inhibitors differentially influence prostaglandin levels during chondro-
genic differentiation  
Successful COX-1 or COX-2 inhibition by the inhibitors and possible differences in specific prostaglandin pro-
duction was determined at day 14 in ATDC5 differentiation. NS398, Celecoxib, SC-50 or Mofezolac were added 
from the start of differentiation or from day 10 onwards. (A). PGE2, PGD2, PGF2α and TXA2 medium concentra-
tions were determined at day 14 in differentiation by prostaglandin specific EIA. (B). COX-1 and COX-2 mRNA 
expression at day 14 in differentiation was determined by RT-qPCR (relative to t=0 and corrected for β-actin). In 
graphs, error bars represent mean ± s.e.m.. * indicates p < 0.05. 
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Figure 6.5: Prostaglandins differently regulate chondrogenic differentiation of progenitor cells 
To test whether specific prostaglandins also have differential roles in chondrogenic differentiation, increasing 
concontrations (0, 0.1, 1, 10 µM) of PGE2, PGD2, PGF2α, TXA2 were added to differentiating ATDC5 cells. (A). 
Col2a1, Col10a1, Sox9 and Runx2 mRNA expression was determined at day 14 in differentiation by RT-qPCR 
(relative to t=0 and corrected for β-actin). (B). Protein expression of Col2a1, Col10a1, Sox9 and Runx2 at day 14 
in differentiation. Molecular weight markers (kDa) are depicted on the left of immunoblots and relative quantifi-
cations are depicted on top of immunoblots. (C). In samples from (A) mRNA expression of COX-1 and COX-2 
was determined.In graphs, error bars represent mean ± s.e.m.. * indicates p < 0.05.  
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4. Discussion   
 
The majority of the studies reporting on the function of COX enzymes in cartilage and 
bone tissues focused on the function of COX-2 and PGE2 in mature chondrocytes and  
osteoblasts14-20. This leaves the role of COX-1 and other prostaglandins during             
chondrogenic differentiation from progenitor cells poorly studied.  
In growth plates of 6 weeks-old mice we found that COX-1 and COX-2 presented differen-
tial temporospatial expression patterns; both isoforms were abundantly expressed in the 
hypertrophic chondrocytes of the growth plate, whereas specifically COX-2 was           
additionally found to be expressed in resting zone cells. These findings are in part in      
contrast with previous findings reported by Brochhaussen et al.14, who were the first to 
report COX expression in growth plates, and reported abundant expression of COX-1 
throughout the rat growth plate and increased COX-2 expression in proliferative and    
hypertrophic zone of rat growth plates. Our results from murine growth plates showed   
interesting parallels with our in vitro ATDC5 observations though. Here COX-1 was only 
upregulated late in ATDC5 chondrogenic differentiation whereas COX-2 expression 
showed an initial peak during early differentiation and expression increased again from 
day 7 in differentiation and further. Recently, we and others have shown that NF-κB     
signaling is essential for early chondrogenic differentiation and that early NF-κB activation 
is required for the transient expression of COX-2 during early differentiation1,23. Taken the 
above transient early COX-2 expression into account and the increased presence of COX-2 
in the resting zone cells of murine growth plates, it is tempting to speculate on the role for 
COX-2 early in chondrogenic differentiation. However, based on expression of            
chondrogenic genes, we did not find any differences for COX-2 inhibition between day 0 
and day 10.  
The partially distinct expression patterns for COX-1 and COX-2 may suggest differential 
involvement of the two COX isoforms in chondrogenic differentiation from progenitor 
cells. When COX-1 was specifically inhibited an overall decrease was found in induction 
of chondrogenic and hypertrophic genes as Col2a1, Sox9, Runx2 and Col10a1. Further-
more, chondrogenic gene expression responded similar when COX-1 was specifically  
inhibited late in differentiation, implying that COX-1 activity serves a crucial role during 
various phases of chondrogenic differentiation. These findings are supported by literature 
also showing adverse effects on proteoglycan synthesis and content when COX-1 was  
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inhibited24. Notably, in accordance with the overall chondrogenic inhibitory effect by   
specific COX-1 inhibitors, COX-1 is generally regarded to function as a “housekeeper”, 
although the reason and mechanism behind the increased COX-1 expression  during late/
hypertrophic differentiation remains to be elucidated7.  
Inhibition of COX-2 activity from the start of differentiation specifically decreased       
expression of hypertrophic markers Runx2 and Col10a1, while leaving chondrogenic 
markers Col2a1, Sox9 and GAG content unchanged or even caused increased expression. 
These findings confirm a specific involvement of COX-2 over COX-1 in chondrocyte  
hypertrophy2. An unanswered question however remains how COX-2 can be specifically 
involved in regulating chondrocyte hypertrophy over COX-1, while the sole task of both is 
the synthesis of the PGH2 substrate for the synthesis of specific prostaglandins by         
dedicated downstream enzymes. A possible explanation might be found in the            
housekeeping function of COX-1 and that inhibiting COX-1 causes deleterious effects on 
the chondrocyte’s PGH2 levels, while PGH2 synthesis by COX-2 might occupy only a 
small additional part of the cellular PGH2 pool. Alternatively, a differential involvement of 
COX-1 and COX-2 in the synthesis of specific prostaglandins could well be possible 
though, as we found that specific inhibition of COX-1 or COX-2 differently affected the 
excreted levels of specific prostaglandins in the culture supernatant. COX-1 inhibition 
showed decreased PGE2 concentration but no effects or an even increased concentration 
was seen for the other prostaglandins. COX-2 gene expression was found to be upregulated 
under influence of COX-1 inhibition and might explain the increased prostaglandin levels 
by redundancy mechanisms, although this would still not explain why PGE2 is specifically 
inhibited by COX-1 inhibition as opposed to the other measured prostaglandins.  Inhibition 
of COX-2 resulted in decreased levels of all the prostaglandins but PGD2. Possible cellular 
rescue of COX expression under inhibitory conditions appears not to be mutually         
reciprocal, as opposed to above; COX-1 expression did not increase in the COX-2        
inhibited conditions and would thus not provide an explanation for the inability for COX-2 
inhibitors to down regulate PGD2 levels. Presently we do not have an explanation for this 
observation.  
We demonstrated that PGE2, PGF2α and in lesser extent also PGD2 have positive effects on 
chondrogenic and hypertrophic gene expression, whereas addition of TXA2 resulted in 
increased hypertrophic gene expression only. Some of these observations are in line with 
the report from Jacob et al., who also described a positive effect on chondrogenic outcome 
after addition of PGD2 and PGF2α
25. However, PGE2 did not increase expression of chon-
Prostaglandins and COX-enzymes in Chondrogenic Differentiation 
175 
drogenic markers in this report, whereas in our study it resulted in the most pronounced 
effects from all tested prostaglandins. Differences of culture models; redifferentiating    
mature articular chondrocytes versus differentiating progenitor cells could be responsible 
for this discrepancy. In line with our results, several studies show that the addition of PGE2 
result in increased cAMP levels and PKA signaling15,26 which led to increased mesen-
chymal progenitor cell chondrogenesis. Similarly, addition of PGF2α resulted in an increase 
of chondrogenic marker expression in a rat chondrocyte cell line and mature chondro-
cytes26,27. 
Addition of TXA2, surprisingly, only increased hypertrophic marker expression. This  
nicely correlates with the effects of the COX-2 specific inhibitors, which resulted in     
decreased TXA2 expression and specific decreased hypertrophic gene expression. This 
possibly indicates a role for COX-2 in TXA2 production and chondrocyte hypertrophy, 
which will be subject of further study. Another interesting observation is increased Sox9 
expression after PGD2 treatment, as it was previously described that PGD2 was able to  
induce Sox9 transcriptional activation and subsequent differentiation of sertolli cells via its 
adenylcyclase-coupled DP1 receptor induced cAMP-dependent protein kinase A (PKA) 
signaling, which resulted in phosphorylation and nuclear translocation of Sox928. Although 
we investigated a different cell type in our study, one micromolar PGD2 resulted in a    
similarly increased Sox9 expression, which likely explains the subsequently increased 
Col2a1 expression. However, whether the action of PGD2 in chondrocytes is executed by 
the same signaling cascade needs further investigation. 
The herein presented data clearly show that the various prostaglandins synthesized by  
differentiating progenitor cells may exert very different effects on the chondrogenic      
outcome. This may challenge the use of various non-steroidal anti-inflammatory drugs 
(NSAIDs) for progenitor cell-based cartilage regenerative medicine approaches, as slight 
differences in COX-selectivity between NSAIDs may lead to pronounced and unexpected 
differences in prostaglandin synthesis, which in turn will differentially affect the chondro-
genic outcome of the differentiation process. This study demonstrates that much is yet to 
be learned on how specific prostaglandins influence chondrogenic differentiation and why 
inhibition of COX-1 and COX-2 enzymatic activity selectively influences prostaglandin 
concentrations. Future investigations may include a detailed analysis on the role of TXA2 
in chondrocyte hypertrophy, as well experiments in which COX-1 or COX-2 activity is 
inhibited and in which the inhibition-phenotype is rescued by supplementation of selected 
prostaglandins. In addition, a potential role for prostacyclin (PGI2) will be included in  
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further research. These latter approaches will be particularly interesting as it is expected to 
be able to further elucidate from which prostaglandin(s) a COX-inhibitory phenotype may 
depend. 
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Abstract  
 
Introduction: Three-dimensional (3D) cultures are widely used to redifferentiate chondro-
cytes. However, the rationale behind the choice for 3D above two-dimensional (2D)     
cultures is poorly systematically investigated and mainly based on mRNA expression and 
glycosaminoglycan (GAG) content. The objective was to determine the differential      
redifferentiation characteristics of human articular chondrocytes (HACs) in monolayer, 
alginate beads and pellet culture by investigating mRNA expression, protein expression, 
GAG content and cell proliferation.  
Methodology: Dedifferentiated HACs from six individuals were redifferentiated in       
identical medium conditions for 7 days in monolayer, alginate beads or pellet culture. Read
-out parameters were expression of chondrogenic and hypertrophic mRNAs and proteins, 
GAG content and cell proliferation.  
Results: 3D cultures specifically expressed chondrogenic mRNAs (collagen type II 
(COL2A1), SOX9, aggrecan (ACAN)), whereas 2D cultures did not. Hypertrophic 
mRNAs (collagen type X (COL10A1), RUNX2, MMP13, VEGF-A, osteopontin (OPN), 
ALP) were highly increased in 2D cultures and lower in 3D cultures. Collagen type I 
(COL1A1) mRNA expression was highest in 3D cultures. Protein expression supports 
most of the mRNA data, although an important discrepancy was found between mRNA 
and protein expression of COL2A1 and SOX9 in monolayer culture, stressing on the    
importance of protein expression analysis. GAG content was highest in 3D cultures, 
whereas chondrocyte proliferation was almost specific for 2D cultures.  
Conclusions: For redifferentiation of dedifferentiated HACs, 3D cultures exhibit the most 
potent chondrogenic potential, whereas a hypertrophic phenotype is best achieved in 2D 
cultures. This is the first human study that systematically evaluates the differences between 
proliferation, GAG content, protein expression and mRNA expression of commonly used 
2D and 3D chondrocyte culture techniques.  
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1. Introduction  
 
Articular cartilage basically comprises two fractions: a cellular fraction consisting of     
articular chondrocytes and an extracellular matrix (ECM) that is mainly composed of   
matrix associated water, collagens, glycosaminoglycans (GAGs) and other glycoproteins. 
The ECM determines the articular cartilage-specific functions as tensile strength combined 
with flexibility and resistance to compressive loads1-4.  
Primary human articular chondrocytes (HACs) are enzymatically released from their    
cartilage matrix for autologous cell-based therapeutical interventions (e.g. Autologous 
Chondrocyte Transplantation (ACT)5) as well as for research purposes3,6,7. However, long 
expansion time and multiple passaging, which are generally needed to acquire workable 
amounts of chondrocytes, lead to “dedifferentiation” of the isolated chondrocytes.         
Dedifferentiation of chondrocytes is defined as the gradual loss of molecular markers that 
define a differentiated chondrocyte. As dedifferentiation progresses, expression of ECM 
molecules as GAGs, collagen type II (COL2A1) and aggrecan (ACAN) is lost, whilst at 
the same time the cells acquire an increased fibroblastic phenotype, characterized by     
expression of collagen type I (COL1A1)8-10. In general chondrocytes are considered dedif-
ferentiated after an average of about five monolayer passages8,11,12. Many investigations 
reported ways to decelerate the dedifferentiation process by supplementing the culture  
medium with several different growth factors13-17, varying with cell density18-21 or creating 
more “cartilage-like” culture conditions, such as hypoxic and hypertonic environments22,23. 
Other studies report the “redifferentiation” of dedifferentiated articular chondrocytes by 
specific culture conditions, resulting in regain of a differentiated chondrocyte phenotype 
and re-expression of cartilage marker molecules24-26. Generally, the cellular context is  
regarded as one of the most important contributors to redifferentiate articular                
chondrocytes. Conventional two-dimensional (2D) monolayer cultures are regarded as 
unsuitable, as monolayer expansion of articular chondrocytes does not support the      
chondrogenic phenotype during passaging. Instead, is well accepted that high cell density 
three-dimensional (3D) cultures favor the maintenance of the chondrocyte phenotype and 
support redifferentiation of dedifferentiated articular chondrocytes3. 3D cultures are      
performed by embedding chondrocytes in agarose27-29, fibrin glue27-31, alginate beads32-34, 
synthetic polymer gels or compressing into pellets by centrifugation12,16. Although 3D  
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redifferentiation techniques are almost exclusively used instead of 2D approaches,        
comparative analyses between 2D and 3D redifferentiation approaches, to support the ra-
tionale behind the choice for a specific culture system, are hardly available. Also, although 
protein expression is the most valuable readout for functional gene expression, previous 
studies have hardly determined quantitative protein expression as a read-out parameter to 
compare the chondrogenic properties of different culture systems12,35,36. 
The aim of this study was to compare the chondrogenic characteristics of commonly used 
3D redifferentiation culture techniques for HACs (alginate beads and pellet culture) with a 
conventional 2D monolayer approach with high cell density. The chondrogenic capacities 
of these redifferentiation systems were compared at 7 days in differentiation based on gene 
expression of chondrogenic and hypertrophic/mineralization markers, as well as protein 
expression of a subset of these markers. Finally, GAG content and the proliferative       
capacity of redifferentiating chondrocytes were addressed in the selected culture systems. 
 
 
2. Materials and Methods 
 
2.1 HAC isolation and culture 
Chondrocytes were obtained from the unaffected regions of osteoarthritic (OA) cartilage 
from total knee arthroplasty (MEC approval 08-4-028). Cartilage was separated from the 
subchondral bone and cut into small pieces using a sterile surgical blade. Cartilage pieces 
were digested overnight at 37°C in collagenase type II solution (300 U/ml in HEPES buff-
ered DMEM/F12 (Invitrogen, Carlsbad, CA, USA) supplemented with antibiotics) under 
continuous agitation. The preparation was rinsed with 0.9% NaCl over a 70 µm cell    
strainer and plated in culture flasks. Cells were cultured in a humidified atmosphere at 
37ºC, 5% CO2 and after reaching confluency the cells were continuously passaged 1:2 un-
til passage 5. Culture medium consisted of DMEM/F12 (Invitrogen), 10% FCS (PAA; 
Pasching, Austria), 1% antibiotic/antimycotic (Invitrogen) and 1% non-essential amino 
acids (NEAA; Invitrogen). Chondrogenic redifferentiation was performed with passage 
five cells from six individuals and each isolate was redifferentiated in monolayer, pellet 
and alginate culture. For monolayer the cells were plated 1day prior to start of differentia-
tion at a density close to confluency (30,000 cells/cm2) to mimic the high cell density 
known from 3D cultures. Chondrogenic differentiation was initiated by changing to      
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differentiation medium (DMEM/F12, 1% antibiotic/antimycotic and 1% NEAA            
supplemented with 1% ITS (insulin-transferrin-sodium selenite media supplement,       
Invitrogen), 1% L-ascorbic acid-2-phosphate (Sigma Aldrich, St. Louis, MO, USA) and 10 
ng/ml TGF-β3 (R&D, Minneapolis, MN, USA)) 13,14,37 For pellet culture redifferentiation, 
300,000 cells per pellet were centrifuged at 120xg in conical tubes in differentiation     
medium (see above). The tubes were placed in a humidified atmosphere at 37ºC, 5% CO2 
with the lid opened, after two days the pellets were transferred (three pellets per well) to 
uncoated 25-wells plates (Corning, Corning, NY, USA) and further allowed to               
differentiate. For alginate culture the cells were suspended in a sterile alginate solution 
(1.2% alginate in 0.9% NaCl; 4,000,000 cells/ml) and drops of this solution were carefully 
dispensed in a cold CaCl2 solution (102 mM) using a 21 gauge needle. After ten minutes 
the alginate beads were washed in 0.9% NaCl and transferred to standard six well culture 
dishes (10 beads per well) and cultured in differentiation medium. Differentiation medium 
was changed every two days for all three culture methods. Cells were harvested for RNA 
and protein analysis at day 7 in redifferentiation (see below). 
 
2.2 RT-qPCR 
For RNA isolation, monolayer cells and pellets were washed 3 times with 0.9% NaCl and 
disrupted with 500 µl Trizol. Alginate beads were first dissolved in ice cold citrate buffer, 
centrifuged and the cell pellet was then dissolved in Trizol (Invitrogen). RNA isolation, 
RNA quantification by UV-spectrometry (Nanodrop, Thermo Scientific), and cDNA    
synthesis were performed  as described before 38.  Real time quantitative PCR (RT-qPCR) 
was performed using Mesagreen qPCR mastermix plus for SYBR® Green (Eurogentec, 
Seraing, Belgium). An Applied Biosystems ABI PRISM 7700 Sequence Detection System 
was used for amplification using the following protocol: initial denaturation at 95ºC for 10 
minutes, followed by 40 cycles of DNA amplification (denaturing for 15 seconds at 95ºC 
and annealing for 1 minute at 60ºC) followed by a dissociation curve. Data were analyzed 
using the standard curve method, mRNA expression was normalized to 28S rRNA as a 
housekeeping gene and gene expression was calculated as fold increase as compared to 
day 0 (t=0 in graphs). Primer sequences are depicted in Table 7.1.  
 
2.3 Immunoblotting  
Cells or pellets were washed three times with 0.9% NaCl and lysed in RIPA buffer (150 
mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5.0 
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mM EDTA pH 8.0, 0.5 mM dithiothreitol and 1 mM phenylmethylsulfonylfluoride).    
Alginate beads were first dissolved in ice cold citrate buffer, centrifuged and the cell pellet 
was then lysed in RIPA buffer. For all samples the same volume of RIPA buffer was used. 
Extracts were sonicated on ice using the Soniprep 150 (MSE, London, UK) at amplitude 
10 for 14 cycles (1 second sonication and 1 second pause). Insoluble material was removed 
by centrifugation (13,000g, 4ºC). Protein concentration was determined using the BCA 
protein assay (Sigma Aldrich). Polypeptides were separated by SDS-PAGE (samples were 
equally loaded) and subsequently transferred to nitrocellulose membranes by                 
electroblotting. Primary antibodies for immunodetection were polyclonal goat anti-
COL2A1 and  polyclonal goat anti-COL1A1 (Southern Biotech, Birmingham, AL, USA), 
polyclonal rabbit anti-COL10A1 (Calbiochem, Darmstadt, Germany), polyclonal goat anti-
SOX9 (Abcam, Cambridge, UK), mouse monoclonal anti-RUNX2 (MBL, Woburn, MA, 
USA) and mouse monoclonal anti-α-Tubulin (Sigma Aldrich, Saint Louis, MO, USA). 
Bound primary antibodies were detected with rabbit anti-goat, swine anti-rabbit or rabbit 
anti-mouse immunoglobulins conjugated with horseradish peroxidase (DakoCytomation, 
Glostrup, Denmark) and visualized by enhanced chemiluminescence (ECL). ECL signals 
were quantified using ImageJ 1.46f software.  
 
2.4 DNA quantification 
DNA concentration in RIPA samples from day 0 and day 7 was determined using SYBR® 
Green I Nucleic Acid stain (Invitrogen). A serially diluted standard curve of genomic    
control DNA (calf thymus, Invitrogen) in TE buffer (10mM Tris/HCl pH 8.0, 1mM 
EDTA) was included to quantify the DNA concentration in the samples. Before           
measurement, RIPA samples were diluted in TE buffer (1 µl RIPA sample and 99 µl TE 
buffer) and standards were prepared (99 µl standard in TE and 1 µl RIPA buffer). SYBR® 
Green was diluted 10,000 times in TE buffer and 100 µl of this solution was added to 100 
µl of the above prepared samples or standards. Fluorescence was determined in standard 
96 wells ELISA plates in a Spectramax M2 microplate reader (Molecular Devices):      
excitation 488 nm and emission 522 nm. DNA concentration was determined using the 
standard curve and fold increase of the DNA content was calculated relatively to the     
average concentration value at day 0 in differentiation.  
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Table 7.1: Primer sequences for RT-qPCR 
The 5’ – 3’ forward and reverse oligonucleotide sequences used for RT-qPCR are listed 
 
2.5 Total GAG quantification 
Total sulfated GAG content was determined in RIPA samples from day 0 and day 7      
cultures by using 1,9-dimethylmethylene blue (DMB; Polysciences). A standard curve of 
chondroitin sulfate (Sigma Aldrich) in PBS-EDTA (0.1 M Na2HPO4, 0.01 M Na2EDTA, 
pH 6.5) was included to determine the GAG concentration in the samples. One hundred 
microliter diluted RIPA sample (5 µl RIPA sample and 95 µl PBS-EDTA) or standard (95 
µl standard and 5 µl RIPA) was added to 200 µl DMB solution (46 µM DMB in 40 mM 
NaCl, 0.4 M glycine pH 3.0), and the extinctions were determined spectrophotometrically 
at both 595 nm and 540 nm 39,40. GAG content was determined using the generated     
standard curve, corrected for DNA content (see above) and expressed as µg GAG/ng 
DNA.  
 
2.6 Statistics 
Statistical significance (p < 0.05) was determined by two-tailed student t-tests (paired for 
Figures 7.1 and 7.3, unpaired with Welch’s correction for Figure 7.2D) using Graphpad 
PRISM 5.0 (La Jolla, CA, USA). To test for normal distribution of the input data, D’Ago-
stino Pearson omnibus normality tests were performed. All quantitative data sets presented 
here passed the normality tests. Error bars in graphs represent mean ± 95% confidence 
interval. In the dot plots p-values are presented for every statistical calculation. 
Oligo sets human Forward Reverse 
COL1A1 ‘5-TGTGCCACTCTGACTGGAAGA-3’ ‘5-AGACTTTGATGGCATCCAGGTT-3’ 
COL2A1 ‘5-TGGGTGTTCTATTTATTTATTGTCTTCCT-3’ ‘5-GCGTTGGACTCACACCAGTTAGT-3’ 
COL10A1 ‘5-ATGATGAATACACCAAAGGCTACCT-3’ ‘5-ACGCACACCTGGTCATTTTCTG-3’ 
ACAN ‘5-GCAGCTGGGCGTTGTCA-3’ ‘5-TGAGTACAGGAGGCTTGAGGACT-3’ 
SOX9 ‘5-AGTACCCGCACCTGCACAAC-3’ ‘5-CGCTTCTCGCTCTCGTTCAG-3’ 
RUNX2 ‘5-TGATGACACTGCCACCTCTTGA-3’ ‘5-GCACCTGCCTGGCTCTTCT-3’ 
MMP13 ‘5-CTTCACGATGGCATTGCTGAC-3’ ‘5-CGCCATGCTCCTTAATTCCA-3’ 
ALP ‘5-GGGCTCCAGAAGCTCAACAC-3’ ‘5-GTGGAGCTGACCCTTGAGCAT-3’ 
VEGF-A ‘5-ACGAAGTGGTGAAGTTCATGGAA-3’ ‘5-AAGATGTCCACCAAGGTCTCGAT-3’ 
OPN ‘5-CGGTGCCTGACCCATCTC-3’ ‘5-TTTCTTCAGAGGACACAGCATTC-3’ 
28S rRNA ‘5-GCCATGGTAATCCTGCTCAGTAC-3’ ‘5-GCTCCTCAGCCAAGCACATAC-3’ 
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3. Results  
 
3.1 Gene expression during chondrogenic redifferentiation in 2D and 3D culture 
Dedifferentiated HACs were redifferentiated in 2D monolayer (n=6 individuals) or in 3D 
alginate beads (n=6 individuals) or pellet cultures (n=6 individuals) for 7 days under    
identical medium conditions. To assess the level of chondrogenic redifferentiation,       
induction of COL2A1, ACAN and SOX9 mRNA expression was determined compared to 
t=0 (Figure 7.1A)41. Gene expression data reveal the induction of COL2A1 and ACAN 
mRNAs in both 3D systems. In monolayer redifferentiation however, the expression of 
these markers was not induced as compared to t=0. Although not significantly different, 
induction of COL2A1 and ACAN was slightly higher in alginate beads than in pellets. In 
line with the data above, no SOX9 mRNA induction was detected in monolayer-
redifferentiated chondrocytes. In contrast, alginate beads and pellet culture supported the 
induction of SOX9, although the alginate beads supported a much higher induction of 
SOX9 compared to pellet culture redifferentiation. 
Redifferentiation of HACs might induce expression of hypertrophic and mineralization 
markers41. As shown in Figure 7.1B, COL10A1, RUNX2 and ALP mRNAs were highly 
induced in monolayer cultures after 7 days. Although significantly lower than in           
monolayer, COL10A1 and RUNX2 induction was also found in both 3D cultures.          
Expression of MMP13, VEGF-A and osteopontin (OPN) differed from the other above 
hypertrophic/mineralization markers. MMP13 induction was found in monolayer and    
pellet culture, but was hardly induced in alginate beads. In contrast, induction of VEGF-A 
was found to be the highest in pellet culture and for OPN similar induction characteristics 
were found. In 2D cultures COL1A1 is only marginally induced as was the case for pellet 
cultures (Figure 7.1C). COL1A1 expression was substantially higher in alginate beads, 
indicating fibrocartilaginous redifferentiation in this culture system. 
Overall the gene expression data indicate that redifferentiation of dedifferentiated HACs in 
2D and 3D culture systems results in different redifferentiated chondrocyte phenotypes 
from which the 3D systems support chondrogenic differentiation the best, whereas the 2D 
monolayer system gives rise to induction of hypertrophic/mineralization markers. 
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Figure 7.1: RT-qPCR analysis of dedifferentiated HACs after redifferentiation in 2D and 3D culture systems 
Dedifferentiated HACs (n=6 individuals) were redifferentiated in 2D monolayer or 3D alginate beads or pellet 
culture using identical medium conditions. Relative induction of gene expression was determined at day 7 in 
redifferentiation as compared to day 0. (A). Induction of mRNAs of the chondrogenic genes COL2A1, SOX9 and 
ACAN was determined. (B). Similar to A. but here relative induction of hypertrophic/mineralization markers 
COL10A1, RUNX2, MMP13, VEGF-A, OPN and ALP was determined. (C). Similar to A. but now the fibrotic 
marker COL1A1 was determined. In all graphs dots represent the average value of three individual samples per 
HAC isolate (n=6 individual donors) and error bars represent mean ± 95% confidence interval. Statistical signifi-
cant p-values (p < 0.05) are shown by an *, ns = not statistical significant.  
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3.2 Protein expression during chondrogenic redifferentiation in 2D and 3D culture 
In general, the majority of previously published work on redifferentiation of                  
dedifferentiated chondrocytes uses mRNA expression and GAG content as the major    
determinant to investigate chondrogenic redifferentiation of HACs. However, it is well 
known that protein expression not always faithfully follows mRNA expression. Taking this 
fact into account we concluded that investigating mRNA expression alone does not      
provide enough information to truly compare the characteristics of the herein tested 2D 
and 3D culture systems for chondrogenic redifferentiation of HACs. Therefore, COL2A1, 
SOX9, COL1A1, COL10A1 and RUNX2 protein expression was measured in similar   
samples as described above. The results of the immunoblot analyses are shown in Figure 
7.2A (monolayer), Figure 7.2B (alginate beads) and Figure 7.2C (pellets). Quantitative 
data of immunoblots are presented in Figure 7.2D. 
In remarkable contrast to the mRNA expression data (see above), COL2A1 protein       
expression was found to be induced in all three culture systems. Interestingly, induction of 
COL2A1 protein expression in monolayer culture was found to be equally high as in     
alginate beads and higher as in pellet cultures. Induction of SOX9 protein expression was 
also found in all three culture systems with no significant differences between the different 
redifferentiation protocols, which is again in sharp contrast with mRNA expression data. In 
line with the gene expression analyses of hypertrophic markers above, COL10A1 and 
RUNX2 protein expression was induced in all systems, with monolayer presenting a    
significantly higher induction of COL10A1 and RUNX2 protein expression as compared 
to the 3D culture systems. Finally, induction of COL1A1 protein expression was also 
found in all three systems, revealing significantly higher COL1A1 expression levels in 
alginate beads and pellet cultures as compared to monolayer. Generally these protein    
expression data confirm the gene expression data that were derived from the different    
redifferentiation methods, albeit 2D redifferentiation provided some interesting             
contradictions when gene expression was compared to protein expression. 
 
3.3 Total GAG content and cell proliferation during chondrogenic redifferentiation in 2D 
and 3D cultures 
Besides expression of chondrogenic transcription factors and extracellular proteins, GAG 
synthesis is an important hallmark of chondrogenic differentiation. As can be seen in    
Figure 7.3A, monolayer redifferentiation did not support the synthesis of GAGs more than 
was already synthesized by the dedifferentiated chondrocytes at t=0. Both 3D systems 
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however allowed increased GAG content per cell as a result of the redifferentiation      
process. Notably, although seeded at close to 100% confluency, the monolayer             
redifferentiation culture allowed an almost 4-fold increase in cell numbers (determined by 
DNA content; Figure 7.3B), whereas cell numbers did hardly (alginate) or not (pellet)  
increase in both 3D systems. Taken together, these data show that not all culture systems 
supported the synthesis of GAGs and differentially allow cell proliferation. 
Figure 7.2: Immunoblot analysis of dedifferentiated HACs after redifferentiation in 2D and 3D culture systems 
HACs (n=6 individuals) were redifferentiated in monolayer, alginate beads or pellet culture. Protein expression 
of a subset of the genes from Fig. 7.1 (COL2A1, COL10A1, COL1A1, SOX9, RUNX2) was determined at day 7 
in redifferentiation as compared to day 0. (A). Protein expression of HACs redifferentiated in 2D monolayer 
culture. (B). Protein expression of HACs redifferentiated in 3D alginate beads. (C). Protein expression of HACs 
redifferentiated in 3D pellet cultures. α-Tubulin was used as housekeeper. Quantifications of ECL signals 
(corrected for the complementary α-Tubulin signals and relatively to t=0) are depicted on top of all immunoblots. 
In immunoblots COL2A1 runs at 120 kDa; COL10A1 at 180 kDa; COL1A1 at 130 kDa; SOX9 at 60 kDa; 
RUNX2 at 66 kDa (lower band). (D). Graphs of immunoblot quantifications from (A) to (C). Each dots represent 
the determined value for each of the individual HAC isolates (n = 6) and error bars represent mean ± 95% confi-
dence interval. Statistical significant p-values (p < 0.05) are shown by an *, ns = not statistical significant.  
Figure 7.3: GAG content and DNA induction in redifferentiated HACs  
Dedifferentiated HACs (n=6 individuals) were redifferentiated in monolayer, alginate beads or pellet culture, 
using identical medium conditions. (A). Total GAG content was determined in day 0 and day 7 samples. To cor-
rect for cells numbers, GAG content was normalized to total DNA. (B). The DNA content used in (A). to correct 
GAG content is shown to determine cell proliferation. DNA induction was calculated relative to DNA content in 
day 0 samples. In all graphs dots represent the average value of three individual samples per HAC isolate (n=6 
individual donors). Statistics were calculated for these n=6 and error bars represent mean ± 95% confidence 
interval. Statistical significant p-values (p < 0.05) are shown by an *, ns = not statistical significant. 
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4. Discussion 
 
It is well established that expansion of isolated articular chondrocytes using conventional 
monolayer passaging leads to loss of the chondrogenic phenotype and results in an overall 
fibroblast-like phenotype3,8-10. This phenomenon is called dedifferentiation and for       
cartilage regenerative applications and chondrocyte studies this adverse phenomenon is 
avoided by using the isolated chondrocytes in relatively early passages (when cells are not 
(fully) dedifferentiated yet) or induce redifferentiation by means of selected medium    
supplements (e.g. ascorbic acid, TGF-β isoforms, insulin, transferrin, selenite13,14,37,42 and 
others). Both methods are generally combined with 3D culture approaches that mimic the 
cartilage environment3. As 2D monolayer passaging does not support maintenance of the 
chondrogenic phenotype, this culture method is generally regarded as unsuitable for      
redifferentiation. Bernstein and colleagues compared the redifferentiation characteristics of 
dedifferentiated porcine chondrocytes in different culture models43. However, to the best of 
our knowledge no study reported on the comparison between 2D and 3D culture methods 
for the redifferentiation of human dedifferentiated chondrocytes. Thereby our study      
contributes to the understanding how these culture methods differentially determine the 
outcome of in vitro chondrogenic redifferentiation and may provide a rational behind the 
choice for one or the other culture system when addressing different research questions. As 
strikingly little evidence is available in the literature supporting human chondrocyte     
redifferentiation on the protein level35, an important additional aspect of our study is the 
inclusion of immunoblot detection to determine expression of important chondrogenic 
marker molecules. Overall these protein expression data support the results from mRNA 
expression analyses, however show some remarkable contradicting results specifically for 
the monolayer redifferentiation cultures.  
In general, 3D chondrocyte culture methods allow the cells to differentiate for a very long 
time (generally between 14 and 28 days). Our primary focus was to address the 
chondrogenic capacity of the three herein selected culture methods. As terminal 
chondrocyte differentiation is more likely to progress at late timepoints in differentiation 
we decided to allow differentiation for 7 days only. Indeed, both 3D culture methods 
showed mRNA induction of chondrogenic markers such as COL2A1, ACAN and SOX9, 
whereas gene induction of hypertrophic markers (COL10A1, ALP, RUNX2) remained 
relatively low. This is in sharp contrast with monolayer redifferentiation in which we 
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found a very high induction of the above mentioned hypertrophic markers, associated with 
little chondrogenic capacity as concluded from COL2A1, ACAN and SOX9 mRNA 
induction. Also, in time points between t=0 and t=7 did these chondrogenic markers not 
increase in expression, excluding the possibility of “missing” a potential expression peak 
of these chondrogenic genes (Figure 7.4). The chondrocyte hypertrophic genes COL10A1 
and RUNX2 did increase in expression over time. These finding suggests that monolayer 
redifferentiation supports a more chondrocyte hypertrophic phenotype as compared to 3D 
culture conditions.  
 
 
Protein expression analysis of hypertrophic markers COL10A1 and RUNX2 supports the 
gene expression data from all three culture methods. For chondrogenic markers, protein 
expression data from alginate and pellet culture support the results of their respective gene 
expression analyses. However, monolayer-redifferentiated chondrocytes show               
contradicting results between mRNA and protein expression specifically for COL2A1 and 
SOX9 induction. A similar observation has previously been described for COL2A136. 
Figure 7.4: RT-qPCR analysis of dedifferentiated HACs after redifferentiation in monolayer over time 
Dedifferentiated HACs (n=3 individuals) were redifferentiated in 2D monolayer. Relative induction of gene 
expression of COL2A1, SOX9, ACAN, COL10A1, RUNX2 and COL1A1 was determined at day 2, 4, 6 and 8 in 
redifferentiation as compared to day 0. In all graphs bars represent the average value of three individual samples 
per HAC isolate (n=3 individual donors) and error bars represent mean ± 95% confidence interval. 
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Whereas COL2A1 and SOX9 mRNA expression is not or hardly induced in monolayer, 
COL2A1 and SOX9 proteins are expressed in monolayer culture. Notably, the magnitude 
of COL2A1 and SOX9 protein induction in monolayer was not significantly different from 
alginate or pellet culture. In general, discrepancies between mRNA and protein expression 
can be the result of posttranscriptional regulation of the mRNA, as well as differences in 
mRNA and protein turnover rates44. Mechanistically, induction of protein expression can 
be the result of two different pathways. Firstly, induction of mRNA expression and      
subsequently translation of this mRNA into functional protein. The other mechanism omits 
the induction of mRNA expression, but instead only translates the cellular pool of the    
given mRNA into protein. This latter mechanism might be dominant in the monolayer  
redifferentiation cultures. A possible explanation why this was specifically observed in 
monolayer might be found in the high hypertrophic nature of monolayer redifferentiation, 
which is not likely to support (SOX9 dependent) chondrogenic redifferentiation. Under 
these hypertrophic conditions, SOX9 and COL2A1 mRNA may not be transcribed de   
novo, but a remainder pool of SOX9 and COL2A1 mRNAs in the dedifferentiated HACs 
could still be translated. Indeed we found that SOX9 and COL2A1 mRNAs are still      
detectable in dedifferentiated HACs (data not shown). However, currently we cannot    
explain how the induction of SOX9 protein in monolayer does not lead to induction of 
COL2A1 mRNA. A dysfunctional nuclear translocation of SOX9 could explain this     
phenomenon45,46. 
Nevertheless, although COL2A1 and SOX9 proteins were equally induced in all three   
culture models, the alginate and pellet cultures showed the lowest levels of COL10A1 and 
RUNX2 protein induction and at the same time the highest induction of total GAG        
synthesis. This supports the conclusions drawn from the mRNA expression data discussed 
above and of previous work47, indicating that 3D chondrocyte culture displays a high   
chondrogenic potential, whereas we here additionally show that monolayer is inducing a 
more chondrocyte hypertrophic phenotype in these cells. A mechanism behind the        
predominantly monolayer-associated hypertrophic phenotype remains to be determined. 
Reoxygenation of hypoxic proliferating growth plate chondrocytes from the subchondral 
compartment is one of the mechanisms partaking in growth plate chondrocyte hypertrophic 
differentiation48,49. Also in vitro there is ample evidence that oxygen tension is a major 
determining factor in chondrocyte hypertrophic differentiation48,50. 3D chondrocyte cul-
tures may have limited oxygen availability due to limitations in oxygen transport/diffusion 
throughout the 3D structure, whereas monolayer cultures may have the highest oxygen 
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availability of the three herein tested culture systems. Consequently, this might provide an 
explanation for the monolayer-associated hypertrophic phenotype. 
With regard to the other hypertrophy-associated markers (MMP13, VEGF-A and OPN41) 
some interesting observations were made that are not completely in line with the above 
hypertrophic COL10A1, RUNX2 and ALP mRNA expression data. MMP13, OPN and 
VEGFA mRNAs are not only expressed in monolayer but are also remarkably high      
induced in pellet cultures, which in contrast with the almost absence of COL10A1, 
RUNX2 and ALP mRNA induction in pellet cultures. The pellet cultures induced 
COL2A1, SOX9 and ACAN mRNAs to a lesser extent than alginate; this could possibly 
relate to the relative high induction of MMP13, VEGF-A and OPN mRNAs in this culture 
system. 
Another interesting finding is that the induction of COL1A1 mRNA and protein,           
associated with a more fibrocartilaginous phenotype, was the highest in alginate cultures. 
In contrast, monolayer-redifferentiated chondrocytes were found to be the lowest inducers 
of COL1A1 mRNA and protein. This is in contrast with the findings by Bernstein and   
colleagues43, who found that redifferentiation of dedifferentiated porcine chondrocytes in 
monolayer resulted in relatively high COL1A1 mRNA levels as compared to other culture 
systems. Possibly the osteoarthritic nature of our cell source may be a factor in the fibrotic 
outcome of our alginate cultures51. It remains however a remarkable observation that this 
was specifically found for the alginate cultures that, in general, seem to support the highest 
chondrogenic capacity during redifferentiation. It is therefore likely that differences in 
technical procedures between our study and previous work43 may provide a basis for the 
observed differences in experimental results; different alginate types were used as well as 
different compositions of the chondrogenic culture medium. 
As a crucial component of the redifferentiation medium we supplemented our cultures with 
10 ng/ml TGF-β3. Previous research reported that the use of one or the other TGF-β      
isoform (TGF-β1, -2, -3) has no differential influence on the outcome of the chondrogenic 
differentiation of human mesenchymal progenitor cells52,53. However Cals et al. reported 
that in the presence of mineralizing medium supplements (e.g. β-glycerophosphate),     
TGF-β3 gives rise to a more mineralized cartilage phenotype, as compared to other TGF-β 
isoforms53. Although we did not add such mineralizing components, the specific use of 
TGF-β3 could explain the relative high induction of mineralization markers in all three 
culture systems. However, it remains unclear why monolayer culture specifically provokes 
the highest expression of these markers. 
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In agreement with previous studies34, we found that cell numbers increased the highest in 
the 2D monolayer redifferentiation cultures, even though the differentiation medium was 
deprived from serum and the cells were seeded at close to 100% confluency. Both 3D  
cultures showed no such high increase in cell numbers. Physical limitations of the 3D   
cultures to support cell proliferation could explain the absence of increase in DNA content, 
as opposed to monolayer culture. Interestingly, as the appearance of clonal populations of 
proliferating chondrocytes is a hallmark of early osteoarthritis54-56, this predominantly 
monolayer-specific property might add to preferable characteristics for a cell culture model 
to investigate osteoarthritis-associated processes. 
In summary, we compared the redifferentiation characteristics of dedifferentiated HACs in 
three different cell models (monolayer, alginate beads and pellet culture). In addition to 
commonly used mRNA expression analysis, for the first time we herein report protein  
expression analyses to compare the redifferentiation characteristics of chondrocytes.   
Overall these protein data support gene expression data, although an important discrepancy 
was found between mRNA and protein expression of COL2A1 and SOX9 in monolayer 
culture, stressing on the importance of protein expression analyses in this culture system. 
Furthermore, both 3D cultures were found to exhibit the highest chondrogenic capacity, 
whereas monolayer redifferentiation appears to result in expression of hypertrophic and 
mineralization markers and as such this model might be used for complementary studies 
addressing hypertrophic differentiation of chondrocytes. 
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Repair of articular cartilage is challenging due to the complex biomechanical function of 
cartilage and the biochemical composition of its extracellular matrix. Furthermore, its  
intrinsic self-repair capacity is limited due to lack of vascularization and limited source of 
progenitor cells. Understanding mechanisms of (progenitor) cell commitment into the 
chondrogenic lineage and prevention of chondrocyte hypertrophy are of importance to 
optimize cartilage repair strategies. Chondrogenic differentiation is a tightly regulated   
process in which many factors regulate the discrete stages of the differentiation program 
(Chapter 1). The work described in this thesis aimed to explore novel perspectives to   
increase the chondrogenic differentiation capacity of progenitor cells and modulate their 
chondrogenic outcome. 
 
 
1. Stimulating chondrogenic differentiation of progenitor cells  
 
Progenitor cells as a source for therapeutic strategies have various beneficial properties; 
such as their multipotency and ability to secrete paracrine factors to modulate their micro-
environment and own cellular (differentiation) processes. This makes progenitor cells at-
tractive candidates for cell-based cartilage regenerative approaches and it is crucial to   
better understand the regulatory mechanisms of their differentiation into cartilaginous   
tissues. 
Several approaches were explored to enhance the chondrogenic differentiation capacity of 
progenitor cells. First, we explored if inflammatory mediators as NF-κB/p65 (nuclear   
factor kappa-light-chain-enhancer of activated B-cells/subunit p65) and cyclooxygenase 
(COX)-2 have a role in the onset of chondrogenic differentiation, as they are both         
described to be essential for early bone fracture healing. The aforementioned inflammatory 
factors are able to induce expression of growth factors, and we determined which of a   
subset of BMPs (bone morphogenic proteins) would be most optimal for increasing the 
chondrogenic potential of progenitor cells. Furthermore, as an alternative approach to   
influence the magnitude of chondrogenic differentiation we studied if increasing culture 
medium osmolarity to mature articular cartilage physiological levels was beneficial for the 
chondrogenic outcome, and if the NF-κB family member Nfat5 (nuclear factor of activated 
T-cells 5) is involved in this process.  
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1.1 Role for inflammatory mediators in early chondrogenic differentiation  
The general understanding on the role of inflammatory molecules and articular cartilage is 
a katabolic one. Inflammatory mediators (mainly originating from the synovium1) initiate 
and/or maintain cartilage breakdown processes seen in osteoarthritis (OA) and rheumatoid 
arthritis (RA), resulting in decreased cartilage functioning and chondrocyte viability2.   
Important inflammatory molecules in progression of OA are e.g. NF-ĸB/p65, tumor     
necrosis factor alpha (TNFα), interleukins, cyclooxygenases and prostaglandins2,3.        
Interestingly, despite the overall inflammatory environment in an OA joint, osteoarthritis 
often induces osteophyte formation. Basically, these are ossifying and isolated ectopic   
cartilaginous tissues near the synovial membrane, which are committed to follow the     
process of endochondral ossification4,5. Moreover, endochondral bone fracture healing 
depends on an inflammatory haematoma formation6-8, where early chondrogenic            
differentiation also takes place in an inflammatory environment. These are two examples 
where initiation of chondrogenic differentiation is permitted in an inflammatory             
environment; we therefore hypothesized that inflammatory mediators are a valuable tool to 
influence in vitro chondrogenic differentiation of progenitor cells. In Chapter 2 we showed 
that indeed chondrogenic differentiation of chondroprogenitor cells is, at least in part,    
determined by early activation of NF-κB/p659. These results are supported by several other 
studies showing that factors secreted by OA chondrocytes are able to induce chondrogenic 
differentiation of mesenchymal progenitor cells10,11 Chondrogenic differentiation in vivo 
during skeletal development is not yet reported to be associated with inflammatory factors. 
We found expression of COX-2, inducible nitric oxide synthase (iNOS) and p65 in the 
resting zone of the growth plate. However it remains elusive at this time if and how these 
factors are in vivo stimulated by inflammatory signaling molecules as TNFα or interleukins 
and contribute to growth plate development. Inflammatory signaling in this context could 
arise from paracrine signaling from neighboring chondrocytes or even bone marrow.     
Alternatively, growth factors might induce the expression of these inflammatory           
mediators; it is known that transforming growth factor (TGF)-β-receptor (TGFR), insulin-
like growth factor (IGF)-receptor (IGFR) and BMP signaling activate NF-κB and expres-
sion of chondrogenic markers12-14. In addition, an important regulator of chondrogenic 
progenitor cells; Bapx1/Nkx3.2 (Bagpipe homeobox homolog 1/ NK3 homeobox 2), is 
also described to activate the NF-κB pathway and subsequent chondrocyte viability15.  
Furthermore, this Bapx1/Nkx3.2 activity can be maintained by BMP signals16.  
Progenitor cells produce several growth factors (BMP-2, BMP-4, TGF-β1, IGF-1, fibro-
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blast growth factor (FGF)-2, FGF-3, vascular endothelial growth factor (VEGF),  hepato-
cyte growth factor (HGF), and others) after stimulation with lipopolysaccharide (LPS) or 
TNFα in a NF-κB dependent manner which might initiate/maintain the chondrogenic   
differentiation process9,17. We have also shown that activated p65 was found to be a crucial 
factor in driving an early transient induction of Sox9 (SRY (sex determining region Y) box 
9), a key event in early chondrogenic differentiation. This early transient Sox9 induction at 
the start of chondrogenic differentiation is accompanied by a similar early transient      
expression of COX-2, iNOS, interleukin 6 (Il-6) and TNFα. Although these factors are 
described to be involved in endochondral ossification processes18,19, their function in early 
chondrogenic differentiation is currently unknown. Gain- and loss-of-function experiments 
are needed to acquire more insight in their early chondrogenic function (The influence of 
COX-2 on chondrogenic differentiation is discussed in paragraph 2.2).  
Further research is needed to unravel how inflammatory processes influence important key 
chondrogenic pathways and how this can be deployed for cartilage regenerative medicine. 
As TNFα or LPS might be counterintuitive (non-physiological) inducers of inflammatory 
(NF-κB) signaling for progenitor-based cartilage strategies, using alternative approaches as 
dedicated biological (growth factors)/pharmacological agents targeting inflammatory   
pathways are expected to provide the right tools for cartilage regenerative medicine      
approaches.  
We determined (Chapter 4) that both BMP-2 and BMP-7 in equimolar concentrations were 
able to enhance chondrogenic differentiation from progenitor cells, with a more             
pronounced effect for BMP-7. Moreover, BMP-2 is able to increase the early Sox9       
expression levels in a NF-κB/p65 dependent way9 (Chapter 1). It would therefore be 
tempting to determine if BMP-7 (Chapter 4) is also able to execute this effect via increased 
NF-κB/p65 signaling (maybe even more than BMP-2), which results in the increased early 
Sox9 expression and ensuing collagen type II (Col2a1)expression. Interestingly, BMP-7 
(but not BMP-2) was able to prevent induction of chondrocyte hypertrophy. This will be 
discussed in paragraph 2.1. 
Based on the above and previous literature, growth factors and inflammatory mediators are 
in a tight interplay in regulating early chondrogenic differentiation. The use of               
anti-inflammatory agents might therefore contribute to poor self-repair capacity of the car-
tilage as the few progenitor cells residing in the tissue20 are now prevented from the poten-
tial to repair the damaged cartilage. This potentially poses a stalemate in the use of         
anti-inflammatory agents for the treatment of OA.  
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1.2 Changing the micro-environment of progenitor cells to the physiological environment 
of cartilage  
The extracellular matrix (ECM) of articular cartilage is normally hypoxic due to the     
absence of blood vessels21. It is generally known that hypoxia is essential for chondrocyte 
survival in vivo; it inhibits chondrocyte proliferation in the growth plate allowing increased 
extracellular matrix accumulation22. Consequently, mature chondrocyte cultures (passaging 
and redifferentiation) benefit from culturing under low oxygen levels. In addition, several 
studies also showed increased chondrogenic potential from progenitor cells when cultured 
under hypoxia17,22-24. Specifically, hypoxia-induced Hif-1α (hypoxia-inducible factor 1, 
alpha subunit) expression is able to transcriptionally activate Sox9 expression in prechon-
drogenic cells23. Furthermore, hypoxic conditions also increase growth factor expression in 
human mesenchymal stem cells via a NF-κB dependent manner17. It would be tempting to 
determine whether and how hypoxia or Hif-1α are involved in the above described       
induction of early chondrogenic differentiation by inflammatory mediators. The above 
suggests that chondrogenic differentiation from progenitor cells can benefit from natural 
environmental characteristics of the cartilage ECM. Another important hallmark of the 
cartilage ECM is increased osmolarity (ranging from 350 – 480 mOsm) as compared to 
plasma levels (~280 mOsm)25,26. Sulphated glycosaminoglycan (GAG) chains on the     
proteoglycans are responsible for a high fixed negative charge density, which attracts   
mobile cations and water from the ECM-environment27,28. Together with the quality of the 
collagen network, this determines the osmolarity of the cartilage extracellular fluid and 
provides compressive strength and flexibility to the cartilage tissue. Several studies have 
shown that culturing mature human articular chondrocytes in vitro under chondrocyte 
physiological osmolarity results in increased ECM synthesis26,29-31. In Chapter 3 we     
describe that also chondrocyte progenitor cells are osmolarity-responsive and their       
chondrogenic potential is increased when cultured in medium with increased osmolarity 
(+100 mOsm). As we used sodium chloride to increase the medium osmolarity, the effects 
on chondrogenic differentiation might also arise from sodium of chloride ion specific    
effects. However, in a previous study30 using human articular chondrocytes, we used    
sucrose or N-methyl-D-glucamine (NMDG-CL; a bulky substitute for small cations that 
are impermeable to almost all known channels) to adjust the medium to +100 mOsm and 
found similar results as with sodium chloride. This indicates that the effects of increased 
osmolarity on chondrogenic outcome were mainly caused by hypertonic stress rather than 
sodium of chloride ion specific effects. As increasing the osmolarity of a cellular environ-
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ment in vitro or in vivo is relatively simple and safe, this holds a promise for future       
optimization of progenitor cell-based cartilage repair approaches. Increasing the osmolarity 
on sites where in vivo progenitor cells reside (periosteum, synovium, superficial layer of 
cartilage) might induce or support chondrogenic differentiation which can repair damaged 
cartilage. Combining cells with biomaterials (gells) which have an increased osmolarity is 
a tempting possibility. During cartilage degeneration (OA), GAG content is decreased and 
as a result also the osmolarity of the cartilage ECM32,33. Increasing osmolartiy in these  
conditions back to normal physiological conditions might stimulate cartilage repair      
mechanisms in the OA joint.  
Nfat5 is an important regulator in the cellular reaction to hypertonic stress, and indeed, our 
results showed that increased osmolarity correlates with increased Nfat5 expression and 
knockdown of Nfat5 under increased osmolarity (+100 mOsm) conditions resulted in 
downregulation of chondrogenic markers back to control levels. Overexpression of Nfat5 
will reveal whether Nfat5 is enough to increase chondrogenic differentiation from         
progenitor cells independent of increased osmolarity. In addition, we found an osmolarity-
independent function of Nfat5 during chondrogenic differentiation, as Nfat5 is already 
expressed during in vitro chondrogenic differentiation and knockdown under control     
plasma osmolarity levels (~280 mOsm)  resulted in reduced expression of Col2a1,         
aggrecan (Acan), Sox9, collagen type X (Col10a1) and runt-related transcription factor 2 
(Runx2). This is in line with a growing body of evidence indicating that Nfat5 has diverse 
osmolarity-independent functions34-36. Further analysis will reveal how Nfat5 influences 
chondrogenic differentiation from progenitor cells. One of the possibilities we explored is 
a transcriptional interaction between Nfat5 and the early expression of Sox9. ChIP 
(chromatin immuno-precipitation) experiments would be able to elucidate a direct         
transcriptional interaction between these two. 
 
1.3 Importance of activation of Sox9 during early and late chondrogenic differentiation  
We identified two potential activators of the first Sox9 expression peak during early    
chondrogenic differentiation; both NF-κB/p65 and Nfat5 were able to regulate its         
expression. However, we know little of the early transient Sox9 function; how it is       
regulated and what it regulates. It became clear is that specific interference with early Sox9 
function abrogates the complete downstream chondrogenic differentiation program. This 
indicates that very early in differentiation crucial decisions are being made that impact the 
result of the differentiation process. Instant hypertrophic differentiation (data not shown) is 
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one of the possible explanations for the chondrogenic failure upon early Sox9 interference, 
as well as Sox9-dependent epigenetic priming of chondrogenic loci. The second, late Sox9 
peak co-incidences with ECM synthesis and is thus expected to transcriptionally serve 
ECM synthesis. We expect that early Sox9 expression is transcriptionally regulated via 
different mechanisms as compared to late Sox9 induction. Transcription of Sox9 has been 
reported to involve binding of general transcriptional enhancers and factors including 
CCAAT-binding factor, CREB (cAMP response element-binding), NF-κB/p65, Hif-1α and 
Sp1(specificity protein 1)23,37,38 to the proximal promoter. In this light it would therefore be 
intriguing to determine whether these Sox9 transcriptional activators act in driving early 
Sox9 expression, or are specific to late Sox9 expression. A yeast one-hybrid screening 
approach would be able to identify novel transcription factors for Sox9 in an unbiased 
way, providing the opportunity to dissect mechanisms that specifically regulate early     
versus late Sox9 expression. On the other hand, this bi-phasic Sox9 expression might also 
indicate differential regulation of target genes. Sox9 is described to be essential for       
transcription of important chondrogenic genes as Col2a1, Acan, collagen type IX (Col9a1), 
collagen type XXVII (Col27a1) and matrilin 1 (Matn1)39-47, however these reports did not 
discriminate if these involved transcription by early or late Sox9 activation. Gain- and loss-
of-function studies concerning Sox9 early and late in differentiation will contribute to the 
understanding of the role of both Sox9 expression peaks.  
Taken together, novel findings have been made on understanding the role of Sox9 in 
(early) chondrogenic differentiation, however, in general, little knowledge is transferred to 
the cartilage regenerative medicine field. As Sox9 is a key transcription factor for        
chondrogenic lineage commitment and maintenance, activation of Sox9 is essential for 
progenitor cell-based cartilage regenerative techniques. Stimulating Sox9 activation by 
inflammatory mediators, increased osmolarity, hypoxia or other approaches are promising 
tools for augmenting progenitor cell-based cartilage regeneration.  
 
 
2. Modulating cartilage hypertrophic differentiation 
 
Equally important for obtaining an optimal chondrogenic phenotype is not only to       
stimulate progenitor cells towards chondrocytes but also prevent them from hypertrophy. 
Unfortunately, when stimulating progenitor cells towards the chondrogenic lineage they 
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almost inevitable become hypertrophic, as they express typical hypertrophic molecules as 
Runx2, Col10a, alkaline phosphatase (Alp) and myocyte-specific enhancer 2c (Mef2c). 
This was also observed in our studies where progenitor cells were stimulated with        
inflammatory mediators (Chapter 2), increased osmolarity conditions (Chapter 3) and 
BMP-2 supplementation (Chapter 4). These factors not only induced chondrogenic genes 
as Sox9, Col2a1 and Acan but this was followed by an increase in expression of the above 
mentioned hypertrophic genes. As chondrogenic differentiation from progenitor cells is an 
essential part of the endochondral ossification pathway, it might not be surprising that   
hypertrophy occurs. However, for cartilage regenerative approaches this is of course not 
desirable and needs to be addressed with great care. 
Although it is a possibility that the cartilage micro-environment (increased osmolarity, 
hypoxia, ECM structure, parathyroid hormone related peptide (PTHrP)) guides 
(differentiating) progenitor cells towards functional cartilage and prevents the unwanted 
hypertrophy, it could still be advantageous for ex vivo induced cartilage regenerative    
medicine approaches to combine this with an anti-hypertrophic strategy. We found several   
novel leads in suppressing the chondrocyte hypertrophy during chondrogenic                 
differentiation of progenitor cells. Firstly, to determine hypertrophy suppressing effects 
one needs a chondrogenic culture model that becomes hypertrophic by nature. Both our 
frequently used in vitro cell models; ATDC5 and monolayer-differentiated human bone 
marrow stem cells (hBMSCs) do so. Chapter 4 and 5 show that the hypertrophic          
phenotype can be enhanced after BMP-2 stimulation. Interestingly, we found that BMP-7 
was able to suppress the chondrocyte hypertrophy. In addition, we identified a role for 
COX-2 in hypertrophy as inhibition of COX-2 resulted in suppressed hypertrophy while 
leaving chondrogenic differentiation unaltered48. Moreover, we determined how this might 
be explained by differential prostaglandin synthesis under COX-2 and COX-1 specific 
inhibition.  
Chondrocyte hypertrophy is not only an unwanted phenomenon in chondrogenic            
differentiation from progenitor cells but is also a hallmark of early OA in mature mature 
chondrocytes and hampers the outcome of chondrocyte-based cartilage repair approaches. 
A cell culture system displaying a chondrocyte hypertrophic phenotype can be of           
importance when studying this process on a molecular basis. To determine differences in 
chondrogenic and hypertrophic marker expression we compared different culture models 
for human articular chondrocytes (HACs)49. Potential chondrogenic-stimulating and hyper-
trophic-suppressing agents identified in our previous studies could also be applied for   
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mature articular chondrocytes. 
 
2.1 Differential effects of BMP-2 and BMP-7 on chondrogenic outcome  
As described above both BMP-2 and BMP-7 stimulation during chondrogenic                
differentiation of progenitor cells resulted in an increased chondrogenic marker expression. 
Runx2 was differentially influenced by the BMPs; increased after BMP-2 stimulation and 
suppressed after BMP-7 stimulation, which might explain the suppressed hypertrophy in 
these cultures. Studies into the possible underlying mechanism revealed the Runx2       
transcriptional repressor Bapx1/Nkx3.2 as a potential candidate50-53. Bapx1/Nkx3.2 is an 
important mediator in early (somitic) chondrogenic differentiation as it directly inhibits the 
expression of Runx2 and increases the expression of Sox9 allowing chondrogenic         
induction16,54. Sox9 in turn increases the expression of Bapx1/Nkx3.2 establishing a      
positive feedbackloop for chondrogenic differentiation and maintenance. During the course 
of chondrogenic differentiation the expression of Bapx1/Nkx3.2 is lost and expression of 
Runx2 increases again, tipping the balance towards chondrocyte hypertrophy50,51,55. In   
support of this hypothesis we found that the decreased hypertrophy in the BMP-7         
condition could be attributed to increased Bapx1/Nkx3.2 expression in these cells, and that 
the hypertrophy-suppressing action of BMP-7 was reversed after knock-down of Bapx1/
Nkx3.2. As BMP signals play an essential role in induction of Sox9 induced early        
chondrogenic differentiation, it is unknown if BMP-2 and BMP-7 are able to induce this 
effect on the same magnitude. Our preliminary data show that also the early Sox9          
expression levels can be enhanced by both BMPs, with a more pronounced effect evoked 
by BMP-7 (Figure 8.1). In addition, Bapx1/Nkx3.2 also activates NF-κB/p65                 
signalling15,56, and it would be interesting to determine if BMP-7 is able to signal through 
the NF-κB/p65 pathway during early chondrogenic differentiation. This might be an     
explanation on how BMP-7 is able to induce or sustain Bapx1/Nkx3.2 signalling which 
results in suppressed hypertrophy at later stages in chondrogenic differentiation. Why 
BMP-2 does not result in similar increase in Bapx1/Nkx3.2 expression as BMP-7 is       
currently unknown. BMP-2 is described in literature to induce Bapx1/Nkx3.2-mediated 
Sox9 expression early in (somitic) chondrogenic differentiation16,54, and also induces early 
Sox9 expression in our experiments however, it does not cause increased Bapx1/Nkx3.2 
levels at later time points in differentiation. This might be a concentration-dependent    
effect, as BMP-7 in the same concentration is more potent in inducing Sox9 expression 
and perhaps a higher concentration of BMP-2 is needed to obtain similar results. BMP-2 
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might also signal at other time points in differentiation via alternative molecular pathways 
resulting in chondrocyte hypertrophy. BMP-2 and BMP-7 are described to differentially 
bind to the BMP receptors; BMP-2 preferentially binds to BMP receptor type IA (BMPR-
IA; Activin receptor like kinase (ALK) 3) and BMPR-IB (ALK6), whereas BMP-7 binds 
with higher affinity to ALK2 and BMPR-IB 57-60 which could result in differential down-
stream signalling. In addition, specific Smad-signaling has been linked to the chondrogenic 
fate (Smad1/5/8 with chondrocyte hypertrophy and Smad2/3 with chondrogenic        
maintenance61), it is interesting to determine whether the differential action of BMP-2 and 
BMP-7 can be explained by specific Smad activation, potentially even at different time 
points in differentiation.  More research is needed to define the role of both BMP-2 and 
BMP-7 during different phases of chondrogenic differentiation. Importantly, BMP-7 as 
opposed to BMP-2 appears to be a better candidate for optimization for cartilage            
regenerative strategies.  
 
 
 
 
 
 
 
 
 
 
 
 
2.2 A role for cell stress and COX-enzymes in chondrocyte hypertrophy 
For the articular cartilage component, osteoarthritis is in many ways similar to                
endochondral ossification, as in OA articular chondrocytes start to differentiate into hyper-
Figure 8.1: Differential effects of BMP-2 and BMP-7 on the chondrogenic outcome of ATDC5 cells 
Equimolar concentrations (1 nM) of BMP-2 or BMP-7 were added from the start of chondrogenic differentiation 
of ATDC5. Sox9 mRNA expression was determined at 2 hours in differntiation. White bars represent control 
condition (set at 1.0), grey bars the BMP-2 condition and black bars the BMP-7 condition. In graphs, error bars 
represent mean ± s.e.m. * indicates p < 0.05 and is determined with respect to the control condition and between 
BMP-2 and BMP-7 conditions.  
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trophic chondrocytes for reasons that are not yet completely understood62-65. Notably, the 
OA-associated inflammatory factors and accompanying cell stress are known to be        
involved in chondrocyte hypertrophic differentiation in the growth plate and may explain 
why articular cartilage is terminally differentiating in OA65,66. Stress-related pathways that 
are activated in growth plate chondrocyte hypertrophic differentiation involve ER 
(endoplasmic reticulum)-stress/unfolded protein response, oxidative stress67-69, advanced 
glycation end product-formation (AGEs)70-74, DNA damage and others 66. In the growth 
plate these pathways are probably activated due to the rapid cell proliferation in the       
proliferative zone, reoxygenation of hypertrophic chondrocytes from the subchondral bone 
marrow, vast extra cellular matrix protein synthesis, etc.66. Moreover, correlating with   
hypertrophic differentiation, (pre-)hypertrophic cells also start to (re)express inflammatory 
molecules (COX-1, COX-248, iNOS75-77, p6513,78,79 and others (our unpublished data), 
which we think enhance the intrinsic cellular capacity for hypertrophic differentiation. The 
message that should be taken from these observations is that failure of cartilage            
regenerative techniques due to formation of interlesional osteophytes, hypertrophic        
differentiation and calcification of cartilage grafts, may originate from similar processes. 
The pathways and processes stated above are therefore expected to be promising targets 
for avoiding failure due to terminal differentiation of the cartilage graft in the clinic. 
Other authors have identified anti-oxidative components that decrease inflammatory     
signaling or chondrocyte hypertrophic differentiation. These components include N-acetyl 
cysteine (NAC)80-82, resveratrol83-85, and even mechanical loading is described to lower the 
concentration of inflammatory mediators secreted during OA66,86. Similarly, parathyroid 
hormone related peptide (PTHrP) is known for its capacity to keep proliferating articular 
chondrocytes in their chondrocyte state and prevent them for further developing into    
hypertrophic chondrocytes87,88. Chapter 5 shows that pharmacological inhibition of the 
inflammatory enzyme cyclooxygenase-2 by e.g. NS398 and/or Celecoxib decreases the 
level of chondrocyte hypertrophic differentiation, even in BMP-2 induced chondrocyte 
hypertrophy48. This may provide a potential pharmacological approach to prevent or      
decrease chondrocyte hypertrophic differentiation in cartilage repair techniques. Indeed, 
preliminary data also show a delayed bone fracture healing and delayed calcification of the 
tissue generated by the in vivo bioreactor (IVB) when animals were treated with Celecoxib 
(Figure 8.2). In addition, our data show that systemic inhibition of COX-2 results in     
aberrant growth plate development due to a smaller hypertrophic zone48.  
Remarkably, for COX-2 knockout (KO) mice a skeletal phenotype has not been described  
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Figure 8.2: Different endochondral read-outs after systemic celecoxib treatment.  
In a study using new-zealand white (NZW) rabbits (1.8 kg) celecoxib (10 mg/kg/day) was orally admitted for 21 
days and the study consisted of three groups of six animals each (1 control group, 1 group with Celecoxib from 
day 0, 1 group with Celecoxib from day 7 on. Endochondral study points per animal were non-critical ulna-
fracture of 0.5 cm and two in vivo bioreactors (IVB’s) on tibial bones. A. The IVB: the periosteum is detached 
from the underlying bone using a tailor made periosteal elevator. The resulting subperiosteal space is filled with 
an agarose gel and after 3 weeks a cartilage callus is formed90. B. Induction of bone fracture: from the right ulna 
0.5 cm bone was removed and the defect was measured to confirm the size of the defect. C. PGE2 plasma levels. 
Serum from day 21-animals was measured for PGE2 to confirm Celecoxib efficacy. D. Representative examples 
of X-rays of fracture healing of the three groups. The arrows indicate the site of the original fracture. E. Same for 
the IVB’s. Calcified IVB’s are visible on X-ray images. The arrows indicate the site where the IVB was created. 
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but they do have problems with bone fracture healing89. It would be intriguing to              
re-evaluate if the COX-2 KO mice truly has no abnormalities in skeletal development and 
if so, how and why this differs from post-natal skeletal repair mechanisms. In addition, as 
COX-2 KO mice have no COX-2 protein and COX-2 inhibitors are not able to completely 
block total COX-2 function, a potential explanation for the discrepancies between the KO 
mice and COX-2-inhibitor treated animals might also be derived from here. Alternatively, 
there might also be differential rescue effects from COX-1 activity or differential           
prostaglandin synthesis between both situations  
In vitro, COX-2 also shows two peak-expression patterns; one early in differentiation and 
one from day 7 in differentiation onwards. Until so far, we have inhibited COX-2 activity 
during the complete course of differentiation and future loss- and gain-of-function        
experiments at different time points and time spans in differentiation will reveal if these 
two COX-2 peaks have a different function in regulating chondrogenic differentiation from 
progenitor cells. It is thus important to realise that the same mediators might have          
differential effects on different phases during chondrogenic differentiation of progenitor 
cells via potential signalling through different molecular pathways. In addition to     
Celecoxib, other non-steroidal anti-inflammatory drugs (NSAIDs) are also described to 
influence the endochondral ossification process. Systemic NSAID treatment delays spinal 
fusion in patients and animal models 91 and fracture healing of the long bones92-95. This 
property of NSAIDs is, however, exploited in the clinic to prevent periprosthetic            
heterotopic calcification after hip surgery96. However, as different NSAIDs have a         
different specificity on COX-enzyme inhibition it is possible that the other COX enzyme, 
COX-1, is also involved in mediating these effects. Indeed, as described in Chapter 6 COX
-1 specific inhibition resulted in decreased chondrogenic differentiation in vitro and our 
results also point towards a different regulation of the COX-enzymes in prostaglandin   
synthesis during different phases of chondrogenic differentiation. To use NSAIDs for    
successful progenitor cell-based cartilage regenerative medicine approaches it is necessary 
to determine if the COX-enzymes differentially regulate different phases of chondrogenic 
differentiation and if this is executed via COX-specific prostaglandin production.  
For each prostaglandin (PG) subtype several PG receptors have been reported97; EP1-4 are 
four receptor subtypes that can bind PGE2, DP1 can bind PGD2, and receptors of the I-type 
(IP) and F-type (FP) bind PGI2 and PGF2α respectively. All of these receptors signal via    
G-proteins; however the intracellular signalling consequences differ97. EP(4) and IP signal 
via Gs-mediated increases in cAMP, and FP signals via Gq-mediated increases in          
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intracellular calcium97, which might explain the differential effects of the different PGs on 
chondrogenic outcome. Elucidating how the specific prostaglandins influence regulatory 
molecular mechanisms in chondrogenic differentiation via potential differential receptor 
activation will provide more insight in how the prostaglandins affect the differentiation 
process and makes them a target for optimizing cartilage regeneration approaches as well. 
 
2.3 Culture methods for chondrocytes 
Progenitor cells are not the only source of cells which can be used for cartilage             
regenerative medicine, mature chondrocytes are another important cell-target. In Chapter 7 
we compared different 2D and 3D culture methods for redifferentiation of HACs49. Both 
three-dimensional cultures were found to exhibit the highest chondrogenic capacity, suited 
for studies in chondrocyte-biology/maintenance. However, monolayer redifferentiation 
appears to result in expression of hypertrophic and mineralization markers and as such this 
model might be used for complementary studies addressing hypertrophic differentiation of 
chondrocytes. This study contributes to the understanding how these culture methods     
differentially determine the outcome of in vitro chondrogenic redifferentiation and may 
provide a rational behind the choice for one or the other culture system when addressing 
different research questions. For studying chondrocyte biology primary chondrocyte     
cultures in various 3D models are currently the primary choice and cell lines as SW135398, 
T/C28a2/499 or C28/I2100 are also described as reliable in vitro cell systems to investigate 
chondrocyte homeostasis. For studying the whole chondrogenic differentiation process 
from progenitor cells the ATDC5101, C3H10T1/2102,103, or USAC104,105 cell lines are     
available, or primary mesenchymal stem cells can be used which can be isolated from  
various tissues. However, for studying chondrocyte hypertrophy not many standardized 
cell culture models are available. MCT cells106 are an example of a cell line which        
becomes hypertrophic within one day and ATDC5 cells can also be induced to become 
hypertrophic over long culturing period107. Using monolayer culture with primary (OA or 
healthy) chondrocytes might thus be an interesting option for studies into chondrocyte   
hypertrophy.  
Importantly, a major discrepancy was found between mRNA and protein expression of 
COL2A1 and SOX9 in monolayer culture. Whereas COL2A1 and SOX9 mRNA          
expression is not or hardly induced in monolayer, COL2A1 and SOX9 proteins are       
expressed in monolayer culture. Notably, the magnitude of COL2A1 and SOX9 protein 
induction in monolayer was not significantly different from alginate or pellet culture.   
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Including (quantitative) protein expression analysis is thus of importance when studying 
chondrocyte (re)differentiation and relying on frequently used gene expression analysis or 
GAG content alone is not sufficient and may lead to misinterpretation of the experimental 
data. 
 
3. Conclusions 
 
If progenitor cells are used for cartilage regenerative medicine approaches it is essential to 
realize that these cells differentiate via the endochondral ossification pathway towards 
chondrocytes and cartilage and that hypertrophy may be inevitable.  
Manipulating the endochondral ossification processes can be used for optimizing cartilage 
repair techniques. The work described in this thesis aimed to find novel perspectives to 
increase the chondrogenic differentiation capacity from progenitor cells and modulate the 
chondrogenic outcome. Especially for progenitor cell based repair technologies, our novel 
insights could be employed to increase the differentiation potential of progenitor cells   
toward engineered cartilaginous tissue in vitro and in vivo.  
An overview of the chondrogenic regulators which are studied in this thesis and their   
interactions in the context of chondrogenic differentiation from progenitor cells is depicted 
in Figure 8.3. Several approaches were explored to enhance the chondrogenic                
differentiation capacity of progenitor cells. First we determined that inflammatory        
mediators as NF-κB/p65 have a role in the onset of chondrogenic differentiation, by     
increasesing expression of Sox9 and important chondrogenic growth factors. We found 
that the use of a defined subset of growth factors, BMP-2 and BMP-7, were able to        
contribute to increasing the chondrogenic potential of progenitor cells as well. Moreover, 
BMP-2 enables the generation of hypertrophic cartilage whereas BMP-7 prevented      
chondrocyte hypertrophy. Furthermore, as an alternative approach to optimize              
chondrogenic differentiation we found that increasing the osmolarity of the culture       
medium to physiological levels found in mature articular cartilage was beneficial, and that 
a Nfat5 - Sox9 genetic interaction is involved in this process.  
Equally important for optimal chondrogenic differentiation is not only to stimulate the 
progenitor cells towards chondrocytes but also keeping them chondrocytes and prevent 
them from hypertrophy. In this manuscript we found several novel approaches in           
suppressing chondrocyte hypertrophy during chondrogenic differentiation of progenitor 
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cells. Interestingly, we found that BMP-7 was able to suppress the chondrocyte             
hypertrophy via regulation of Bapx1/Nkx3.2. We identified a role for COX-2 in             
hypertrophy as inhibition of COX-2 resulted in suppressed hypertrophy while leaving 
chondrogenic differentiation unaltered. Also, we determined how the prostaglandin      
synthesizing enzyme COX-2 might influence chondrogenic differentiation and how this 
relates to the other prostaglandin synthesizing enzyme COX-1. 
For cartilage regenerative approaches one could envision a procedure where progenitor 
cells are per-operatively isolated and pre-treated for a short period of time with LPS/TNFα/
growth factors to induce inflammatory signaling, priming the cells for chondrogenic     
differentiation before transplanting using a selected cartilage repair technique. Part of the 
failure of current cartilage repair techniques originates from calcification or hypertrophic 
differentiation of the cartilage graft, as well due to the development of interlesional       
osteophytes. These adverse effects might be avoided when joint homeostasis is taken into 
account as an important factor in the post-operative treatment strategy after cartilage    
repair. A synovial fluid environment supplemented with the aforementioned factors 
(increased osmolarity, COX-inhibitors, BMP-7) might contribute to the success rate on an 
anti-hypertrophic basis. To be able to test the above candidates on human articular       
chondrocytes in a hypertrophic differentiation context in the future, we set up a human in 
vitro culture system suitable of displaying hypertrophic potential. Using this 2D model 
requires protein analysis as an important read out parameter and once again stresses on the 
mutual analysis of mRNA and protein in chondrocyte molecular biology.  
Creating cartilage or bone by triggering endochondral ossification in an ectopical site and 
using the body as its own “in situ incubator” also has many advantages. The cells provide 
their own matrix and complex and costly isolation; selection and culturing procedures are 
bypassed. Optimization of the by our group described in vivo bioreactor technique90 might 
also benefit from the aforementioned approaches in both stimulating progenitor cell       
differentiation (treatment with LPS/TNFα/growth factors or increasing osmolarity) and 
prevention of hypertrophy (COX-2 inhibition/BMP-7 supplementation).  
Taken together, our findings described in this thesis on molecular pathways involved in 
regulating the chondrogenic phase of endochondral ossification may not only be a logical 
way to stimulate cartilage (and endochondral bone) (re)generation, but is also expected to 
provide useful information how to keep differentiating progenitors or mature chondrocytes 
in the desired phase and will contribute to our understanding of skeletal developmental 
processes, fracture healing and diseases like OA.   
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Fig 8.3 Overview of regulators studied in this thesis during chondrogenic differentiation. 
During endochondral ossification mesenchymal progenitor cells differentiate towards chondrocytes which even-
tually become hypertrophic chondrocytes. These phases can be marked by specific genes; Sox9 for early chon-
drogenic differentiation, Col2a1 and Acan for mature chondrocytes and Runx2, Mef2c, Col10a1 and Alp for 
hypertrophic differentiation. In Chapter 2 we have shown that (mild) inflammatory stimuli can activate the NF-
κB/p65 signalling and subsequent induction of Sox9 transcription which results in increased chondrogenic out-
come. In Chapter 3 we determined that a similar pathway was activated by Nfat5 when the progenitor cells were 
exposed to increased osmolarity of the cellular environment. NF-κB/p65 signalling not only resulted in increased 
Sox9 expression but also in increased COX-2 enzyme activity. The role for COX-2 in chondrogenic differentia-
tion was determined in Chapter 5 and 6 and revealed a COX-2 specific role in hypertrophic differentiation possi-
bly signalling via β-Catenin. As COX-2 is a prostaglandin synthesizing enzyme a start was also made by deter-
mining the specific effect of each prostaglandin subclass on chondrogenic outcome and the possible underlying 
molecular mechanisms (Chapter 6). COX-2 inhibition might thus be an interesting pharmaceutical approach in 
inhibiting chondrocyte hypertrophy. In Chapter 4 a differential effect of BMP-2 and BMP-7 on chondrogenic 
outcome was described, with a more pronounced stimulating effect on hypertrophic differentiation for BMP-2 
whereas BMP-7 stimulation had a chondrocyte hypertrophy suppressing effect. For BMP-7 a potential underlying 
mechanism was found in Bapx1/Nkx3.2 signalling which could be driven via early Sox9 transcriptional activation 
and which results in a suppression of Runx2 and subsequent hypertropic differentiation. BMP-2 resulted in a 
decreased Bapx1/Nkx3.2 signalling which could explain the increased hypertrophic differentiation in this context. 
It remains elusive if BMP-2 signals via COX-2 in regulating hypertrophic differentiation, directly via Bapx1/
Nkx3.2 or via alternative pathways (e.g. β-Catenin directly).  Taken together, our findings described in this thesis 
on molecular pathways involved in regulating the chondrogenic phase of endochondral ossification is expected to 
provide useful information on how to differentiate progenitor cells and to keep differentiating progenitors or 
mature chondrocytes in the desired phase.  
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Chondrogenic differentiation is a tightly regulated process in which many factors regulate 
the discrete stages of the differentiation program. Understanding the mechanisms of cell 
commitment and further differentiation into the chondrogenic lineage is of great           
importance to optimize (progenitor) cell-based cartilage repair techniques. The work     
described in this thesis aimed to find novel perspectives to increase the chondrogenic    
differentiation capacity from progenitor cells and modulate their chondrogenic outcome.    
Several approaches were explored to enhance the chondrogenic differentiation capacity of 
progenitor cells. First it was found that inflammatory mediators as NF-κB/p65 have a role 
in the onset of chondrogenic differentiation from progenitor cells. Modulating the activity 
of NF-κB/p65 alters the chondrogenic outcome via signalling through key chondrogenic 
transcription factor Sox9. In addition, expression of several growth factors, including BMP
-2, is co-regulated in differentiating chondrocytes by NF-κB/p65 and in turn BMP-2 is able 
to regulate NF-κB/p65 signalling which could, at least in part, explain the pro-
chondrogenic effect of BMP-2. As an alternative approach to optimize chondrogenic     
differentiation from progenitor cells we found that chondrogenic marker expression of 
differentiating chondroprogenitor cells in vitro can be enhanced by increasing the         
osmolarity levels of culture medium by 100 mOsm. The osmolarity responsive gene Nfat5 
is part of the mechanism that underlies this effect and might directly influence               
chondrogenic differentiation via controlling the expression of key chondrogenic            
transcription factor Sox9. 
Equally important for optimal chondrogenic differentiation is not only to stimulate the 
progenitor cells towards chondrocytes but also keeping them chondrocytes and prevent 
them from hypertrophy. Several new leads were found to suppress chondrocyte             
hypertrophy during chondrogenic differentiation of progenitor cells. We found that BMP-2 
and BMP-7 have differential effects on the chondrogenic outcome of differentiating     
chondroprogenitor cells: BMP-2 not only induced chondrogenic differentiation but even 
more chondrocyte hypertrophy, while BMP-7 appears to increase or maintain               
chondrogenic potential and prevent chondrocyte hypertrophy. Studies into the possible 
underlying mechanism explaining this discrepancy revealed Bapx1/Nkx3.2 signalling as a 
potential candidate in regulating chondrocyte hypertrophy. Next to BMP-7, we identified a 
role for COX-2 in chondrocyte hypertrophy. COX-2 is one of the main transcriptional   
targets of the NF-κB/p65 complex and we found that inhibition of COX-2 activity by COX
-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) specifically decreases the 
level of chondrocyte hypertrophic differentiation in different progenitor-based             
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chondrogenic differentiation models, while leaving chondrogenic differentiation unaltered. 
Also, systemic inhibition of COX-2 activity in vivo resulted in significantly impaired    
chondrocyte hypertrophic differentiation in rabbit growth plates. Next to COX-2-specific 
NSAIDs, other NSAIDs specifically inhibit COX-1 or both COX-enzymes. It was        
determined that, as opposed to COX-2 inhibition, COX-1-specific NSAIDs inhibit        
extracellular matrix production during chondrogenic differentiation from progenitor cells. 
A possible explanation for the discrepancy in the chondrogenic outcome influenced by 
COX-1- and COX-2- specific inhibitors might lie in differential prostaglandin synthesis 
under these circumstances.  
Especially for progenitor cell-based cartilage repair technologies, our novel insights could 
be employed to increase the differentiation potential of progenitor cells toward engineered 
cartilaginous tissue in vitro and in vivo. To also be able to test the above candidates on 
human articular chondrocytes in an hypertrophic differentiation context in the future, we 
set up a human in vitro culture system suitable of displaying hypertrophic potential. Using 
this 2D model requires protein analysis as an important read out parameter and once again 
stresses on the mutual analysis of mRNA and protein in chondrocyte molecular biology.  
Taken together, the findings described in this thesis on molecular pathways involved in 
regulating the chondrogenic phase of endochondral ossification may not only be a logical 
way to stimulate cartilage (and endochondral bone) (re)generation, but is also expected to 
provide valuable information how to keep differentiating progenitor cells or mature     
chondrocytes in the desired differentiation phase and will contribute to our understanding 
of skeletal developmental processes, fracture healing and diseases like OA.   
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Kraakbeen differentiatie is een strak gereguleerd proces waarbij vele factoren betrokken 
zijn die de afzonderlijke fasen van het differentiatie programma reguleren. Het begrijpen 
van de moleculaire mechanismen die betrokken zijn bij de differentiatie in de chondrogene 
lijn zijn van groot belang voor de optimalisatie van op (voorloper/stam) cellen gebaseerde 
kraakbeen herstel technieken. Het werk beschreven in dit proefschrift is gericht op het 
vinden van nieuwe perspectieven om de chondrogene differentiatie capaciteit van 
kraakbeen voorloper cellen te verhogen en de chondrogene uitkomst te moduleren. 
Verschillende benaderingen werden bestudeerd om de chondrogene differentiatie 
capaciteit van voorlopercellen te verbeteren. Allereerst hebben we vastgesteld dat 
ontstekings-mediatoren als NF-κB/p65 een rol spelen bij de initiatie van chondrogene dif-
ferentiatie van voorlopercellen cellen. Moduleren van de activiteit van het NF-κB/p65 
complex resulteert in een veranderde chondrogene differentiatie via signalering via een 
van de belangrijkste chondrogene transcriptiefactoren: Sox9. Daarnaast is de expressie van 
verschillende groeifactoren, waaronder BMP-2,  tijdens differentiatie mede gereguleerd 
door NF-κB/p65, en op zijn beurt kan BMP-2 NF-κB/p65 signalering reguleren waardoor, 
althans gedeeltelijk, het pro-chondrogene effect van BMP-2 kan worden verklaard. Als een 
alternatieve benadering voor de optimalisatie van chondrogene differentiatie vanuit  kraak-
been voorloper cellen hebben we gevonden dat kraakbeen gen-expressie in vitro kan 
worden verbeterd door de osmolariteit van het kweekmedium te verhogen met 100 mOsm. 
Nfat5, het gen dat gevoelig is voor osmolariteit,  maakt deel uit van het mechanisme dat 
ten grondslag ligt dit effect en kan mogelijk chondrogene differentiatie direct beinvloeden 
via de het reguleren van de expressie van Sox9. 
Even belangrijk voor optimale chondrogene differentiatie is niet alleen de stimulatie van 
kraakbeen voorloper cellen naar chondrocyten, maar ook om vervolgens het chondrocyt 
fenotype te behouden en kraakbeen hypertrofie te voorkomen. Verschillende nieuwe leads 
bleken chondrocyt hypertrofie te onderdrukken tijdens de chondrogene differentiatie van 
voorlopercellen. We vonden dat BMP-2 en BMP-7 differentiële effecten hebben op de 
uitkomst van chondrogene differentiatie chondroprogenitor cellen: BMP-2 induceerde niet 
alleen chondrogene differentiatie maar ook chondrocyte hypertrofie, terwijl BMP-7 het 
chondrogene vermogen lijkt te verhogen of handhaven en tevens chondrocyt hypertrofie te 
voorkomen. In de studies naar een mogelijke onderliggend mechanisme ter verklaring van 
deze discrepantie kwam Bapx1/Nkx3.2 signalering naar voren als een potentiële kandidaat 
in het reguleren van chondrocyten hypertrofie. Naast BMP-7 identificeerden we ook een 
rol voor COX-2 in chondrocyte hypertrofie. COX-2 is een van de belangrijkste 
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transcriptionele targets van het NF-κB/p65 complex, en het bleek dat remming van COX-2 
activiteit van door COX-2 selectieve niet-steroïdale anti-inflammatoire geneesmiddelen 
(NSAIDs) specifiek de hoogte van chondrocyte hypertrofie kon voorkomen in verschillen-
de voorlopercel-gebaseerde chondrogene differentiatie modellen, terwijl chondrogene  
differentiatie ongewijzigd bleef. Ook systemische remming van COX-2 activiteit in vivo 
leidde tot een significante vermindering van chondrocyt hypertrofe differentiatie in     
groeischijven van jonge konijnen. Naast de COX-2-specifieke NSAIDs, zijn er ook andere 
NSAIDs die specifiek COX-1 of beide COX-enzymen remmen. Er werd vastgesteld dat, in 
tegenstelling tot COX-2 specifieke NSAIDs, COX-1-specifieke NSAIDs de kraakbeen 
extracellulaire matrix productie remmen tijdens chondrogene differentiatie van kraakbeen 
voorloper cellen. Een mogelijke verklaring voor deze discrepantie in de chondrogene 
uitkomst kan liggen in differentiële prostaglandinesynthese onder deze omstandigheden. 
Speciaal voor voorlopercel-gebaseerde kraakbeenherstel technologieën kunnen onze 
nieuwe inzichten worden gebruikt om zo het differentiatiepotentieel van voorlopercellen te 
verhogen voor ge-engineered kraakbeenweefsel in vitro en in vivo. Om ook de 
bovengenoemde kandidaten te testen op humane articulaire chondrocyten in een hypertrofe 
context hebben we een in vitro differentiatie systeem opgezet voor het induceren van 
chondrocyt hypertrofie in humane adulte chondrocyten. Dit 2D-model vereist wel eiwit 
analyse als een belangrijke parameter en benadrukt zo nogmaals op het analyseren van 
zowel eiwit als RNA in de moleculaire chondrocyt biologie.  
Tezamen kunnen de bevindingen beschreven in dit proefschrift de moleculaire pathways 
die betrokken zijn bij het reguleren van de chondrogene fase van endochondrale ossificatie 
niet alleen op een logische manier gebruikt worden om kraakbeen (en endochondrale bot) 
(re) generatie te stimuleren, maar zal ook naar verwachting  waardevolle informatie  
verstrekken over hoe differentiërende stamcellen of volwassen chondrocyten in de 
gewenste differentiatie fase te houden en zal daarnaast bijdragen aan ons begrip van 
skeletaire ontwikkelingsprocessen, fractuurgenezing en ziekten zoals artrose. 
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Daar is het dan, mijn proefschrift. Eindelijk! Ik denk dat dit proefschrift een mooie 
weerspiegeling is van wat ik de afgelopen jaren heb geleerd en hoe we samen met het 
laboratorium zijn gegroeid tot wat het nu is. Van een lab met alleen een centrifuge in de 
koelkast (‘gekoeld’), een zwartgallige vortex en een golfslagbad naar een volledig 
ingericht laboratorium met alle proffesionele apparatuur, technieken en protocollen die we 
maar kunnen wensen binnen handbereik. Hopelijk gaan we zo door!     
Natuurlijk heb ik dit onderzoek niet allemaal alleen gedaan en heb ik tijdens de afgelopen 
vier jaar hulp en sturing gehad van anderen die ik graag wil bedanken voor dit mooie 
resultaat.  
 
Als allereerste mijn promotie-team: Prof. Dr. L.W. van Rhijn, Dr. T.J.M. Welting en Dr. 
P.J. Emans. Beste Lodewijk, als eerste wil ik je bedanken voor de kans om op deze 
afdeling te promoveren en voor al de adviezen en steun die je me hebt gegeven tijdens 
deze periode. Ik vergeet nooit meer de grote repen chocolade als troost nadat een van onze 
eerste ‘grote’ experimenten mis was gegaan.  
Beste Tim, ontzettend bedankt! Als co-promotor stond je zeer dicht bij mijn onderzoek, je 
steeds weer nieuwe ideeen en kritische blik tijdens alle fasen van het onderzoek hebben me 
enorm geholpen. Ik ben erg dankbaar voor de kans die je me hebt gegeven om zelf 
experimenten en onderzoek te doen, technieken op te zetten, te discussieren, te presenteren 
op congressen over de hele wereld, onderwijs te geven en manuscripten te schrijven, 
kortom om een goede wetenschapp(st)er te worden. Ondanks je protocollen uit Nijmegen 
en je voorliefde voor RNA ;-) kunnen we het toch goed vinden met elkaar, en ik hoop dat 
we nog lang ‘good science’ kunnen doen.  
Beste Pieter, ook zonder jou was dit proefschrift niet geworden wat het nu is. Ik wil je 
bedanken voor je bijdrage, de geboden mogelijkheden, en het laten inzien dat klinische 
relevantie ook erg belangrijk is bij het onderzoek doen (ook al vind Tim van niet ;-) ). Ik 
heb veel van je geleerd tijdens het opzetten en uitvoeren onze dierproef. Je enthousiasme 
en ambitie voor onderzoek werken aanstekelijk en ik hoop dat we nog lang samen 
onderzoek kunnen doen. Nu heb ik dadelijk eindelijk tijd om ‘ons geheime inflammatie-
proefje’ in te zetten.       
 
I would also gratefully acknowledge the members of the assessment committee; Prof. Dr. 
Ir. L.H. Koole, Dr. F.A. van Nieuwenhoven, Prof. Dr. G.J.V.M. van Osch, Dr. M. Poeze 
and Prof. Dr. B. Zabel for their time and effort to critically judge this thesis.  
 238 
Don en Andy, ik wil jullie ook graag bedanken voor alle hulp bij de experimenten. Jullie 
staan altijd meteen voor iedereen klaar om te helpen, zorgen dat alles altijd op voorraad is 
en het lab geen grote chaos wordt ook al doen we daar zo ons best voor. Don, ik wil jou 
ook bedanken voor alle Don-koffietjes en momenten om te ventileren of gewoon lekker te 
kletsen. We gaan snel nog een keer eten en een ravanche doen met bowlen, deze keer heb 
ik geen pols-blessure...  Andy,  ik je ook bedanken voor zo strak opgeruimd houden van 
het lab en de -80°C (stiekem werkt het toch best goed), het gewillig in mijn grapjes trappen 
en voor het regelen van de cup-a-soup carroussel! We kunnen nu al niet meer zonder.      
Jim, Laura, Guus, Shennah, Alex, Maarten, Mandy, Ilona, Marielle, Michiel en Pieter ook 
jullie wil ik bedanken voor alle wetenschappelijke en minder wetenschappelijke discussies, 
jullie hulp en steun, voor het bijkletsen en de ontspannende momenten tijdens de cake-van-
de-week en bier-van-de-maand! Ook wil ik jullie bedanken voor alle uitstapjes tijdens de 
congressen, ze hebben al een hoop sterke verhalen opgeleverd.  Who’s next ?? .... 
Chris en Liesbeth wil ik ook graag bedanken voor hun bijdrage aan dit proefschrift. Chris, 
als mede-brabander wil ik je bedanken voor de gezellige momenten tijdens alle 
congressen, voor je je kritische commentaar over mijn ‘peppie-en-kokkie’ onderzoekjes en 
het uitvinden ‘de vork’- statement. Liesbeth, dankjewel dat je vaak een luisterend oor 
wilde zijn en voor alle gezellige momenten tijdens de afgelopen 4,5 jaar.        
Ook wil ik hier Peter, Daan, Kathleen, Monique, Matheus, Fay en Olaf bedanken voor hun 
bijdrage aan de verschillende onderzoeken. Ik heb het erg leuk en leerzaam gevonden om 
jullie te begeleiden en hoop dat ik jullie heb kunnen helpen tijdens de stageperiodes.   
Natuurlijk wil ik ook alle andere medewerkers van de afdeling Orthopedie bedanken, ik 
heb me altijd erg thuis gevoeld in deze groep.   
Het Nfat5/osmolariteits onderzoek was niet mogelijk geweest dankzij de samenwerking 
met Dr. Holger Jahr en Drs. Anna van der Windt van het Erasmus MC in Rotterdam. 
Dankjewel voor deze mooie samenwerking en ik hoop dat we het in de toekomst voort 
kunnen zetten!  
Ik ben ook zeer erkentelijk aan alle deelnemers en in het speicaal Jan-Willen Voncken van 
de WORK /Maastro/Bone meetings voor hun constructieve kritische blik en goede ideeen 
voor ons onderzoek.  
 
Hier wil ik ook graag de research schools GROW en CAPHRI bedanken voor hun support 
tijdens dit promotie-traject. 
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 A.   
A (in DNA or RNA sequence) Adenine 
Acan/ ACAN Aggrecan (mouse/human) 
ACT Autologous Chondrocyte Transplantation 
β-Actin Beta form of Actin 
ADAMTS A destintegrin and metalloproteinase with thrombospondin motifs 
AGE Advanced glycation endproduct 
ALK2 Activin receptor like kinase 2 
ALK3 Activin receptor like kinase 3 
ALK6 Activin receptor like kinase 6 
Alp/ ALP Alkaline phosphatase (mouse/human) 
(c)AMP (cyclic) Adenosine monophosphate 
ATDC5 
Chondrogenic cell-line derived from a differentiating culture of 
AT8085 teratocarcinoma cells 
ATF Activating transcription factor 
Atf-2 Activating transcription factor-2 
  
B.  
Bapx1  Bagpipe homeobox homolog 1 
BCA Bicinchoninic acid 
Bgn Biglycan 
BMP Bone morphogenic protein 
BMP-2 Bone morphogenic protein 2 
BMP-4 Bone morphogenic protein 4 
BMP-7 Bone morphogenic protein 7 
BMPR-IA BMP receptor type IA 
BMPR-IB BMP receptor type IB 
BMSCs Bone marrow derived stem cells 
BSA Bovine serum albumin 
Bsp1 Bone sialoprotein 1 
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 C.   
°C Degrees Celsius 
C (in DNA or RNA sequence) Cytosine 
C (in figures) Cytoplasmic extract 
CaCl2 Calciumchloride 
C28/I2 Immortalized chondrocyte cell line 
C3H10T1/2 Murine (fibroblastic) multipotent mesenchymal cells 
Cbfa1 Core-binding factor subunit alpha-1 
β-catenin Cadherin-associated protein beta 
cDNA Complementary DNA 
ChIP Chromatin Immunoprecipitation 
CI Confidence interval 
cm2 Centimeter squared 
CO2 Carbon dioxide 
Col1a1/COL1A1 Collagen type I (mouse/human) 
Col2a1/COL2A1 Collagen type II (mouse/human) 
Col6a1 Collagen type VI 
Col9a1 Collagen type IX 
Col10a1/COL10A1 Collagen type X (mouse/human) 
Col11a1 Collagen type XI 
Col12a1 Collagen type XII 
Col14a1 Collagen type XIV 
Col27a1 Collagen type XXVII 
COMP Cartilage oligomeric protein 
COX Cyclooxygenase 
COX-1 Cyclooxygenase 1 
COX-2 Cyclooxygenase 2 
COX-3 Cyclooxygenase 3 
cPAC Chicken periosteum agarose culture 
CREB cAMP response element-binding 
Crtm Cartilage matrix protein / Matrilin1 (Matn1) 
Cyclin D1 Cell cycle G1/S transition specific cyclin D1 
Cyclophilin A Peptidylprolyl isomerase A 
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 D.   
2D   Two-dimensional 
3D Three-dimensional 
d (in figures) Days 
DAB 3,3’-diaminobenzidine 
Dcn Decorin 
DEC Animal ethical committee (Dier ethische commissie) 
DEPC Diethylpyrocarbonate 
DMB Dimethylmethylene blue 
DMEM  Dulbecco’s modified Eagle medium 
DMEM/F12  Dulbecco’s modified Eagle medium with nutrient mixture F12 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
DNase I  Deoxyribonuclease 1 
dNTPs  Desoxynucleotide triphosphates 
DP1  PGD2 receptor 
DTT  Dithiothreitol 
  
E.  
ECL  Enhanced chemo-luminescence 
ECM  Extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid 
e.g.  exempli gratia /  for example 
EIA  Enzyme immuno assay 
ELISA  Enzyme-linked immunosorbent assay 
EP1-4  PGE2 receptors 1-4 
ER-stress  Endoplasmic reticulum stress 
ES  Embryonic stem cells 
Etc.  et  cetera/ and so forth 
  
F.    
FCS  Fetal calf serum 
FGF  Fibroblast growth factor 
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 FGF-2  Fibroblast growth factor 2 
FGF-3  Fibroblast growth factor 3 
FGFR-3  FGF receptor 3 
Fmod  Fibromodulin 
FP  PGF2α receptor 
  
G..  
G (in DNA or RNA sequence) Guanine 
g  Gravitational  force 
G-protein  Guanine nucleotide-binding protein 
GAG  Glycosaminoglycan 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GSK-3β  Glycogen synthase kinase 3 beta 
  
H.    
h (in figures)  Hours 
H3  Histone 3 
HAC  Human articular chondrocyte 
hBMSCs  Human bone marrow stem cells 
HCl  Hydrochloric acid 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF  Hepatocyte growth factor 
Hif-1α  Hypoxia-inducible factor 1, alpha subunit 
HMG  High mobility group 
HRP  Horseradish peroxidase 
hrs  Hours 
Hspg2  Heparan  sulphate proteoglycan 2 / perlecan 
HZ  Hypertrophic zone of the growth plate 
  
I.  
ID  Identification 
IGF  Insulin-like growth factor 
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 IGF-1  Insulin-like growth factor 1 
IGFR  IGF receptor 
IgG  Immunoglobulin G 
IgG1  Immunoglobulin G1 
IgG2a  Immunoglobulin G2a 
IHC  Immunohistochemistry 
Ihh  Indian hedgehog 
Il  Interleukin 
Il-1  Interleukin 1 
Il-1β  Interleukin 1 beta 
Il-6 / IL-6  Interleukin 6 (mouse/human) 
iNOS  Inducible nitric oxide synthase 
IP  PGI2 receptor 
iPS  Induced pluripotent stem cells 
ITS  Insulin-transferrin-sodium selenite media supplement 
IVB  In vivo bioreactor 
  
K.  
KCl  Potassium chloride 
Kd  Knockdown 
kDa  Kilodalton 
KO  Knockout 
  
L.   
5-LOX  5-lypoxygenase 
LPS  Lipopolysaccharide 
  
M,  
M  Molar 
MACT  Matrix-assisted chondrocyte transplantation 
MAPK  Mitogen-activated protein kinase 
MCT  
Mouse chondrocytes immortalized by SV40 temperature-sensitive 
large T antigen 
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 Matn1  Matrilin 1/ Crtm 
MEC  Medical ethical committee 
Mef2c  Myocyte-specific enhancer 2c 
MgCl2  Magnesium chloride 
ml  Milliliter 
mm  Millimeter 
mM  Millimolar 
M-MLV  Moloney murine leukemia virus 
MMPs  Matrix metalloproteinases 
Mmp13/ MMP13 Matrix metalloproteinase 13 (mouse/human) 
mOsm    Milliosmolair 
mPGES  Microsomal prostaglandin E synthase 
mRNA  Messenger RNA 
MSC  Mesenchymal stem cells 
MUMC  Maastricht university medical center 
  
N.   
n  Number 
N (in figures)  Nuclear extract 
N (in DNA sequence)  Any nucleotide 
NAC  N-acetylcysteine 
NaAc  Sodium acetate 
NaCl  Sodium chloride 
Na2HPO4  Disodium hydrogen phosphate 
Na2EDTA  Disodium EDTA 
Ncad  N-cadherin 
Ncam  Neural cell-adhesion molecule 
N.E.A.A.   Non-essential amino acids 
Nfat5/NFAT5 Nuclear factor of activated T-cells 5 (mouse/human) 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B-cells 
ng Nanogram 
Nkx3.2  NK3 homeobox 2 
nm  Nanometer 
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 nM  Nanomolar 
NMDG-Cl  N-methyl-d-glucamine chloride 
NO  Nitric oxide 
NP-40  Nonyl phenoxypolyethoxyethanol-40 
NRS  Normal rabbit serum 
NS398  
N-[2-(Cyclohexyloxy)-4-nitrophenyl]methane-sulfonamide; a 
selective COX-2 inhibitor 
NSAIDs  Non-steroidal anti-inflammatory drugs 
NZW  New-Zealand white rabbit 
  
O.  
OA  Osteoarthritis 
OATS  Osteochondral autograft transfer system 
OP-1  Osteogenic protein 1 / BMP-7 
Opn/OPN  Osteopontin (mouse/human) 
  
P.  
p38  MAPK p38 
p50  p50 subunit of the NF-κB complex 
p52  p52 subunit of the NF-κB complex 
p65  p65 subunit of the NF-κB complex 
p-value  Probability value 
PAC  Periosteum agarose culture 
PBS  Phosphate buffered saline 
PBS-T  Phosphate buffered saline with Tween-20 (polysorbate 20) 
PCR  Polymerase chain reaction 
PDGF  Platelet derived growth factor 
PG  Prostaglandin 
PGD2  Prostaglandin D2 
PGE2  Prostaglandin E2 
PGF2α  Prostaglandin F2α 
PGG2  Prostaglandin G2 
PGH2  Prostaglandin H2 
 258 
 PGI2  Prostaglandin I2 / prostacyclin 
PGs  Proteoglycans 
pH  Potential hydrogenii / Hydrogen ion concentration 
PKA  Protein kinase A 
PKC  Protein kinase C 
PLA2s  Phospholipase A2 
PMSF  phenylmethanesulfonylfluoride 
PPARγ  Peroxisome proliferator-activated receptor gamma 
pSmad1/5/8  Phosphorylated Smad 1/5/8 
PTHrP  Parathyroid hormone related peptide 
PZ  Proliferative zone of the growth plate 
  
Q.  
qPCR  Qualitative PCR 
  
R.   
R  Purine 
RA  Rheumatoid arthritis 
Rel  V-rel reticuloendotheliosis viral oncogene homolog 
RelA  V-rel reticuloendotheliosis viral oncogene homolog A 
RIPA  Radio immunoprecipitation assay 
RM  Regenerative medicine 
RNA  Ribonucleic acid 
RNAi  Interfering RNA 
RNAsin  Ribonuclease inhibitor 
28S rRNA  28S ribosomal RNA 
R-Smad  Receptor regulated Smad 
RT-buffer  Reverse transcriptase buffer 
RT-qPCR  Real time quantitative PCR 
Runx2/RUNX2  Runt-related transcription factor 2 (mouse/human) 
RZ  Resting zone of the growth plate 
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259 
 S.   
 S100A4 S100 calcium binding protein 4 
SC-560  
5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-
pyrazole, a selective COX-1 inhibitor 
Sdc3  Syndecan 3 
SDS  Sodium dodecyl sulphate 
SDS-PAGE  Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
s.e.m.  Standard error of mean 
siRNA  Small-interfering RNA 
Slc5a3  Solute carrier 5 (sodium/myoinositol cotransporter) member 3 
Smad  
Homolog of Drosophila MAD (mothers against decapentaplegic) 
and C. elegans SMA (small) 
Sox  SRY box 
L-Sox5  SRY (sex determining region Y) box 5, long form 
Sox6  SRY (sex determining region Y) box 6 
Sox9/SOX9  SRY (sex determining region Y) box 9 (mouse/human) 
Sp1  Specificity Protein 1 
SRY  Sex determining region Y 
SW1353    Human humerus chondrosarcoma cell line 
  
T..  
t  Time point 
T (in DNA sequence)  Thymine 
T (in figures)  Total extract 
T/C28a2 Immortalized human chondrocyte cell line 
T/C28a4 Immortalized human chondrocyte cell line 
TBD  Triazabicyclodecene 
TBS-T  Tris buffered saline with Tween 20 (polysorbate 20) 
TBS-BSA  Tris buffered saline with Bovine serum albumin 
TCF/LEF  Transcription factor/lymphoid enhancer-binding factor 
TE  Tissue Engineering 
TE buffer  Tris/EDTA buffer 
TGF-β  Transforming growth factor beta 
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 TGF-β1  Transforming growth factor beta 1 
TGF-β2  Transforming growth factor beta 2 
TGF-β3  Transforming growth factor beta 3 
TGFR  TGF-β receptor 
TLCK  
N-alpha-p-tosyl-l-lysinechloromethyl ketone hydrochloride, 
inhibitor of NF-κB 
TLR-2  Toll-like receptor 2 
TLR-4  Toll-like receptor 4 
Tnc   Tenascin C 
TNFα  Tumor necrosis factor alpha 
TNFR  TNFα receptor 
TonEBP  Tonicity responsive enhancer binding protein 
α-Tubulin  Tubulin; alpha chain 
TXA2  Thomboxane A2 
TXB2  Thomboxane B2 
  
U.   
U (in RNA sequence)  Uracil 
U  Units 
USAC  Human chondrogenic osteosarcoma cell-line 
UV  Ultraviolet 
  
V.   
Vcan  Versican 
VEGF  Vascular endothelial growth factor 
VEGF-A  Vascular endothelial growth factor A 
  
W.  
w/v  Weight/volume 
Wnt  Wingless-type MMTV integration-site family 
  
X.    
XY  X and Y chromosome 
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Y.   
Y     Pyrimidine 
  
Z..  
ZnCl2  Zinc chloride 
  
Other.    
µg  Microgram 
µl  Microliter 
µm  Micrometer 
µM  Micromolar 

